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ABSTRACT 
 
This report describes the results of a pilot study of the reliability of the biokinetic and 
dosimetric models currently used by the U.S. Nuclear Regulatory Commission (NRC) as 
predictors of dose per unit internal or external exposure to radionuclides. The study 
examines the feasibility of critically evaluating the accuracy of these models for a 
comprehensive set of radionuclides of concern to the NRC.  Each critical evaluation 
would include: identification of discrepancies between the models and current databases; 
characterization of uncertainties in model predictions of dose per unit intake or unit 
external exposure; characterization of variability in dose per unit intake or unit external 
exposure; and evaluation of prospects for development of more accurate models. 
Uncertainty refers here to the level of knowledge of a central value for a population, and 
variability refers to quantitative differences between different members of a population. 
This pilot study provides a critical assessment of models for selected radionuclides 
representing different levels of knowledge of dose per unit exposure.  The main 
conclusions of this study are as follows: 
 
(1) To optimize the use of available NRC resources, the full study should focus on 
radionuclides most frequently encountered in the workplace or environment. A list of 50 
radionuclides is proposed. 
 
(2) The reliability of a dose coefficient for inhalation or ingestion of a radionuclide (i.e., 
an estimate of dose per unit intake) may depend strongly on the specific application. 
Multiple characterizations of the uncertainty in a dose coefficient for inhalation or 
ingestion of a radionuclide may be needed for different forms of the radionuclide and 
different levels of information of that form available to the dose analyst. 
 
(3) A meaningful characterization of variability in dose per unit intake of a radionuclide 
requires detailed information on the biokinetics of the radionuclide and hence is not 
feasible for many infrequently studied radionuclides. 
 
(4) The biokinetics of a radionuclide in the human body typically represents the greatest 
source of uncertainty or variability in dose per unit intake. 
 
(5) Characterization of uncertainty in dose per unit exposure is generally a more 
straightforward problem for external exposure than for intake of a radionuclide. 
 
(6) For many radionuclides the most important outcome of a large-scale critical 
evaluation of databases and biokinetic models for radionuclides is expected to be the 
improvement of current models. Many of the current models do not fully or accurately 
reflect available radiobiological or physiological information, either because the models 
are outdated or because they were based on selective or uncritical use of data or 
inadequate model structures. In such cases the models should be replaced with 
physiologically realistic models that incorporate a wider spectrum of information.
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1.0. INTRODUCTION 
 
This report describes the results of a pilot study of the reliability of the biokinetic and 
dosimetric models currently used by the U.S. Nuclear Regulatory Commission (NRC) as 
predictors of dose per unit internal or external exposure to radionuclides. The study 
examines the feasibility of critically evaluating the accuracy of these models for a 
comprehensive set of radionuclides of concern to the NRC. Each critical evaluation 
would include: identification of discrepancies between the models and current databases; 
characterization of uncertainties in model predictions of dose per unit intake or unit 
external exposure; characterization of variability in dose per unit intake or unit external 
exposure; and evaluation of prospects for development of more accurate models. 
Uncertainty refers here to the level of knowledge of a central value for a population, and 
variability refers to quantitative differences between different members of a population. 
 
This pilot study provides a critical assessment of biokinetic and dosimetric models for 
selected radionuclides representing different levels of knowledge of dose per unit 
exposure.  Estimates are made of the resources needed to implement a large-scale 
analysis. 
 
The main body of the report is divided as follows.  Section 2 gives definitions and 
background information used in subsequent discussions of different data types, 
uncertainties, variability, and different approaches to uncertainty analysis. Sections 3 and 
4 provide extensive illustrations of the type and quality of data underlying the two main 
“generic” models used by the International Commission on Radiological Protection 
(ICRP) in dose calculations for internal emitters: the respiratory tract model (Section 3), 
and the gastrointestinal tract model (Section 4).  The respiratory and gastrointestinal 
models are referred to as generic models because the bases, features, and predictions of 
these models are in many respects independent of the radionuclide. The basis for generic 
features of each of these two models is discussed at length due to the importance of these 
two regions as interfaces between the environment and interior of the human body, and 
because estimated doses to tissues in these two regions based on current models often 
dominate the effective dose or projected risk from intake of radionuclides.  Section 5 
demonstrates different levels of information of the biokinetics in humans and dose per 
unit intake for specific radionuclides, summarizes information on the variability of 
biokinetics and dose per unit intake or per unit exposure in each case, and critically 
evaluates uncertainty assessments on those cases previously addressed in the literature.  
Five main radionuclides are considered in Section 5.  These are listed below in order of 
decreasing direct knowledge of their behavior in humans. 
 
137Cs:  Level 1 – The database contains extensive, high quality data on the behavior 
of cesium in human subjects, supported by numerous observations on the behavior of 
cesium in laboratory animals. There is also extensive information on the biokinetics 
of physiological analogues of cesium in humans and laboratory animals.  A revised 
model described in Section 5 based on physiological considerations provides a good 
fit to the data. 
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90Sr:  Level 2 – Extensive data are available for human subjects and laboratory 
animals, but data for strontium are more variable and less easily interpreted overall 
than data for cesium.  For 90Sr there is increased reliance on indirect information, 
particularly data for physiological analogues.  Conversion from activity to dose 
involves only small errors for most tissues but somewhat larger errors for the most 
highly irradiated tissues, bone surfaces and red marrow.   
 
60Co:  Level 3 – Human data include external measurements of retention and also 
excretion data from a few controlled studies. The internal distribution of cobalt has 
been studied in laboratory animals but extrapolation to humans is complicated by 
apparent differences between species and the chemical form administered.  Cobalt 
has no close physiological analogues.  Conversion from activity to dose is 
straightforward for 60Co. 
 
106Ru:  Level 4 – Modeling of ruthenium biokinetics is based on data for laboratory 
animals, supplemented with limited information for man. Suspected physiological 
analogues of ruthenium also have sparse databases. Conversion from activity to dose 
appears to introduce relatively small errors. 
 
252Cf:  Level 5 – The biokinetics of californium must be modeled on the basis of 
animal data, including information on the comparative behavior of californium and 
other transuranic elements. There are also important potential errors associated with 
the dosimetric model used to convert from 252Cf activity to equivalent dose to 
tissues.  These potential errors arise in part from a simplistic and somewhat uncertain 
representation of dose due to spontaneous fission and in part from uncertainties 
regarding the radiobiological effectiveness (RBE) of alpha particles and neutrons 
arising from decay of 252Cf. 
 
Section 6 discusses the basis for external dose coefficients and potential errors associated 
with applications of those coefficients for selected radionuclides.  The nuclear decay data 
used in the development of dosimetric models are discussed briefly in Sections 3-6 and 
are addressed in more detail in Section 7.  Although nuclear decay data generally 
represent only a minor source of error in dose estimates, examples are given in Section 7 
to illustrate that these data can be an important source of error in dose estimates for some 
infrequently studied radionuclides.  Section 8 proposes a general approach for assessing 
and in many cases reducing potential errors in dose estimates for a selected set of 
important radionuclides.  A list of 50 radionuclides is proposed for consideration, based 
on their importance as indicated by past experience or the potential for elevated 
exposures in the future. Estimates of the time, funds, and other resources required to 
implement a larger project are provided. 
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2.  DEFINITIONS AND BACKGROUND INFORMATION 
 
This section defines the “current dosimetric tools” addressed in this report, the term “dose 
coefficient” for intake of a radionuclide or external exposure to a radionuclide in a given 
medium, and the terms “ uncertainty and variability” as used in this report.  Examples are 
given to show that the commonly used term, “uncertainty in a dose coefficient”, is 
ambiguous for the case of ingestion or inhalation of a radionuclide, without specific 
information or assumptions concerning the form of the radionuclide taken into the body.  
A measure of uncertainty in biokinetic or dosimetric quantities is described.  Different 
categories of biokinetic data are defined and assigned abbreviated names for use in later 
sections.  
 
2.1. Current dosimetric tools 
 
Unless otherwise indicated, the current dosimetric tools referred to in this report are the 
tools for internal dosimetry currently recommended by the ICRP, including biokinetic 
and dosimetric models as well as dose coefficients, and the external dose coefficients 
given in Federal Guidance Report No. 12 (FGR12) (EPA, 1993). 
 
2.2. Definition of a dose coefficient 
 
To place all ionizing radiations on a common scale with regard to their potential health 
detriment, the ICRP uses quantities called the equivalent dose and the effective dose.  
The equivalent dose is the absorbed dose averaged over an organ or tissue and multiplied 
by a radiation weighting factor, WR, that reflects the relative biological effectiveness of 
the type and energy of radiation causing the dose.  The effective dose takes into account 
that the relationship between equivalent dose and the probability of radiogenic effects 
depends on the organ or tissue irradiated.  The effective dose is a weighted sum of 
equivalent doses to radiosensitive tissues, with the tissue weighting factors, wT, 
representing the relative contribution of the different tissues to the total detriment for the 
case of uniform irradiation of the whole body. 
 
For an internally deposited radionuclide, the time integral of the equivalent-dose rate, 
beginning at intake, is called the committed equivalent dose.  If not otherwise specified, 
the integration period is 50 y for intake by adults and to age 70 y for intake by children.  
The committed effective dose is the weighted sum of the committed equivalent doses to 
radiosensitive tissues.  A committed tissue equivalent dose per unit intake or a committed 
effective dose per unit intake for a specified radionuclide, exposure mode, and population 
(e.g., a certain age group) is referred to as a dose coefficient. 
 
The steps involved in the calculation of dose coefficients for inhalation or ingestion of 
radionuclides are indicated in the flow chart in Figure 2.1.  The estimation of absorbed 
dose to radiosensitive tissues involves application of models, commonly referred to as 
biokinetic models, that describe the biological behavior of activity entering the body and 
a second set of models, referred to in this report as “dosimetric models”, that describe 
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radiation transport from the point of decay of radionuclides and resulting deposition of 
ionizing energy in tissues.  Once the absorbed doses have been calculated, the effective 
dose is computed as an arithmetic combination of the absorbed doses, radiation-
weighting factors (wR) that represent the radiobiological effectiveness (RBE) of alpha 
particles, fission fragments, or neutrons relative to gamma or beta radiation, and tissue-
weighting factors (wT) that represent relative detriment to different tissues from uniform 
whole-body irradiation. 
 
 
 
 
Figure 2.1.  Schematic of ICRP methodology for calculation of dose coefficients for 
inhalation or ingestion of radionuclides  
 
 
An external dose coefficient is a reference value for dose rate to a tissue or effective dose 
rate per unit concentration of the radionuclide in an environmental medium.  The external 
dose coefficients given in FGR12 (EPA, 1993) are based on idealized exposure 
geometries and a mathematical phantom representing a reference adult male standing in 
an upright position at the air-ground interface.  In FGR 12, dose coefficients are provided 
for radionuclides in different environmental media including: air submersion; exposure to 
contaminated ground surface; and exposure to soil contaminated to a depth of 1 cm, 5 
cm, 15 cm, or infinite depth. 
  
2.3. Definitions of uncertainty and variability 
 
The biokinetic and dosimetric models used in ICRP publications and the dose coefficients 
derived from those models are intended to represent typical or “reference” members of 
the population.  The biological behavior of some radionuclides is reasonably well 
established but in other cases must be predicted on the basis of sparse or inconsistent 
data.  Additionally, some components of the ICRP's dosimetric models involve 
considerably simplified anatomical structures and assumptions concerning energy 
deposition, leading to an uncertain characterization of the absorbed dose to the tissues at 
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risk.  Thus, there is some uncertainty as to whether the components of the biokinetic and 
dosimetric models and the dose coefficients derived from those models accurately 
represent typical members of the population, and the level of uncertainty varies from one 
radionuclide to another. 
 
In this report, “uncertainty” refers to the level of confidence that can be placed in a given 
biokinetic or dosimetric quantity as an estimate of the central value.  Usually, the central 
value is taken to be an arithmetic or geometric mean for the population. 
 
The uncertainty in the central value of a quantity in the population should not be 
confused with the “variability” of that feature in the population.  Variability refers to 
quantitative differences between different members of a population under similar 
conditions (inter-individual variability) or within an individual under different conditions 
(intra-individual variability).  For example, the transit time of material through the colon 
may differ between two persons of the same size, race, age, and gender and having 
identical diets (inter-individual variability) or may differ in the same person at different 
times due to changes in diet, state of health, or other conditions (intra-individual 
variability). 
 
2.4. Ambiguity of the term “uncertainty in a dose coefficient” for internal emitters 
 
It is common to refer to “the uncertainty in a dose coefficient”, and a number of 
investigators have addressed this topic for specific radionuclides and intake modes.  The 
published papers generally do not clearly define what is meant by “uncertainty”.  In many 
cases, it appears from the analytical methods that the reference may be to an unknown 
individual. 
 
Whether the reference is to a central estimate or an individual, the problem arises that 
“the uncertainty in a dose coefficient” is not a well defined concept for internal emitters. 
The difficulty is that the level of confidence that can be placed in a dose coefficient may 
vary considerably from one application to another, depending on the form of the 
radionuclide and the level of knowledge concerning that form.  Suppose, for example, 
that an inhalation dose coefficient for 90Sr, Type F, is used to estimate tissue doses to a 
worker exposed for a known period to a known concentration of 90Sr in air.  Uncertainties 
in the derived doses would be relatively small if the physical and chemical form of 
airborne 90Sr are known and indicated by the literature to be consistent with the ICRP’s 
model for Type F.  The uncertainties would be larger if available information is weak but 
suggestive of Type F material and still larger if Type F is applied as a typical absorption 
type for 90Sr in the absence of any specific information on the form of inhaled material. 
 
One could define the uncertainty in a dose coefficient in terms of a confidence level for 
arbitrary use of that value, but that would substantially overstate the uncertainties 
associated with dose estimates in many cases.  For example, a later section discusses the 
relatively high level of confidence that can be placed in ingestion dose coefficients for 
137Cs in most situations but not all situations.  Most forms of 137Cs are readily absorbed 
from the gastrointestinal tract to blood, and high confidence can be placed in the dose 
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coefficients when applied to these forms.  It seems misleading to assign a large 
uncertainty to the dose coefficient for ingested 137Cs simply because that coefficient may 
occasionally be applied to a form of 137Cs for which the level of absorption to blood is 
highly uncertain. 
 
A more workable solution would be to provide uncertainty statements for a few different 
levels of knowledge of the form of the radionuclide.  For example, an uncertainty 
statement could be provided for an ingestion dose coefficient for 137Cs under the 
assumption that the radionuclide is incorporated in food or ingested in soluble inorganic 
form, and an alternate uncertainty statement could be derived for arbitrary use of the dose 
coefficient. 
 
2.5. Uncertainty in an external dose coefficient 
 
The “uncertainty in a dose coefficient” is easier to define for an external dose coefficient 
than for an inhalation or ingestion dose coefficient, because the physical or chemical 
form of the radionuclide generally is not relevant to the case of external exposure. The 
problem of estimating external dose rates from contaminated air, soil, or ground surfaces 
was divided into two steps:  (1) the calculation of the radiation field incident on the 
surface of the body and (2) calculation of organ dose rates due to a body surface source.  
The total uncertainty in an external dose coefficient for a specific radionuclide, exposure 
scenario (e.g., standing on a contaminated ground surface), and tissue would reflect the 
uncertainty in the radiation field incident upon the body and uncertainties in dose rates to 
specific tissues due to a body surface source.  
 
2.6. A convenient measure of uncertainty 
 
It is often convenient to use a shorthand description to summarize conclusions concerning 
the current level of knowledge of specific biokinetic and dosimetric quantities.  The 
approach used here is consistent with a method used in Federal Guidance Report No. 13 
(FGR13) (EPA, 1999).  That is, judgments concerning uncertainties in quantities are 
sometimes summarized in terms of a subjective confidence interval [A,B] or an 
associated uncertainty factor (UF).  The uncertainty in a given quantity is expressed in 
terms of a subjective confidence interval, that is, an interval of positive values, [A,B], 
such that the true but unknown value is judged with reasonable confidence to lie between 
A and B.  Here, “reasonable confidence” is defined as a subjective confidence level of 
90%.  That is, it is judged that there is only a small probability (about 5%) that the true 
value is less than A and only a small probability (about 5%) that it is greater than B.  For 
purposes of comparing levels of uncertainty of model components that are expressed in 
different terms or have different orders of magnitude, it is sometimes convenient to apply 
the concept of an uncertainty factor (UF).  An uncertainty factor for a quantity with 
subjective confidence interval [A,B] is defined as (B/A)1/2.  The quantity is considered to 
be known within a factor of (B/A)1/2 in the sense that all values in the interval are within 
a factor of (B/A)1/2 of the geometric mean of A and B.   
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The description of uncertainties in terms of uncertainty factors is a convenient way of 
summarizing conclusions regarding uncertainties in model components.  It has no 
implications with regard to the central value or the distribution of possible values of a 
model component.   
 
2.7. Categories of biokinetic information 
 
Throughout, the following abbreviations are used for different types of biokinetic data 
used in the construction of biokinetic models for an element or compound.  The 
“substance of interest” referred to in these abbreviations is usually but not always a 
specific element or compound. For example, for studies of fractional deposition of 
inhaled particulates in the respiratory tract, the “substance of interest” is essentially any 
particulate of specified dimensions, such as AMAD. 
• H1:  direct information on humans, i.e., quantitative measurements of the 
substance of interest in human subjects. 
• H2:  observations of the behavior of chemically similar or physiologically related 
substances in human subjects. 
• A1:  observations of the behavior of the substance of interest in non-human 
species. 
• A2:  observations of the behavior of chemically similar or physiologically related 
substances in non-human species. 
• P:  Physiological or anatomical information, e.g., the turnover rate of water in the 
body as one estimate of the retention time of tritium taken into the body as 
tritiated water, or the turnover rate of cortical or trabecular bone as an estimate of 
the retention time of plutonium in bone of that type. 
• in vitro data 
 
Although H1 is the preferred type of information for construction of biokinetic models 
for man, direct observations of an element in human subjects often has one or more of the 
following limitations:  small study groups, coupled with potentially large inter-subject 
variability in the biokinetics of an element; short observation periods, coupled with 
potentially large intra-subject variability; use of unhealthy subjects whose diseases may 
alter the biokinetics of the element; paucity of observations for women and children; 
collection of small, potentially non-representative samples of tissue; inaccuracies in 
measurement techniques; uncertainty in the pattern or level of intake of the element; 
atypical study conditions; and inconsistency in reported values.  For such reasons, 
development of biokinetic models for many elements relies heavily and sometimes 
completely on indirect sources of information (H2, A1, A2, P, and in vitro).  Information 
on chemical families as a whole (H2 or A2) is particularly important for purposes of 
building a model structure, because we rely heavily on collective information from a set 
of physiological analogues as well as comparisons with essential elements. 
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3.  RESPIRATORY TRACT MODEL:  UNDERLYING DATA AND 
INITIAL ASSESSMENTS OF VARIABILITY AND UNCERTAINTY 
 
This section describes the structure of the ICRP’s Human Respiratory Tract Model 
(HRTM) and the basis for default parameter values of the model.  Several examples of 
potential errors or uncertainties in HRTM predictions are given. The examples address: 
o uncertainties in components of the HRTM as assessed by its developers 
o uncertainties in predictions of the HRTM as assessed in an expert elicitation study 
o uncertainties in predictions of the HRTM for three cases ( inhaled 222Rn 
daughters, PuO2, or UO2/U3O8) as assessed by standard parameter uncertainty 
analysis  
o uncertainties in HRTM default values for 24-hour average ventilation rate as 
revealed by comparison with an alternate model 
o uncertainties in predictions of the HRTM as indicated by comparison with 
predictions of an alternate respiratory model developed by a committee of the 
National Council on Radiation Protection and Measurements (NCRP) 
o reduction in potential errors of the HRTM for specific materials through critical 
evaluations of the database as illustrated by a recently published review of 
information on inhaled mercury vapor 
o reduction in potential errors of the HRTM for specific materials by use of site-
specific information as illustrated by a recently published case study of inhalation 
of UAlx by workers 
 
3.1. The respiratory model 
 
Current understanding of the behavior of inhaled radionuclides in the human respiratory 
tract and of resulting radiation doses to the tissues of the tract is discussed here within the 
framework of the ICRP’s HRTM.  The information used to develop the HTRM is 
described at length in ICRP Publication 66 (1994a). Guidance on application of the 
HRTM is given in Publication 66 and in more recent open literature publications and an 
ICRP guidance document (ICRP, 2002a).   
 
The database underlying the HRTM is large, and a prohibitive amount of time and effort 
would be required to provide a reasonably complete bibliography in a letter report.  The 
reader is referred to the bibliographies given in ICRP documents (1994a, 2002a) and in 
papers by Bailey and coworkers (1994, 2003).  Original references are listed in this 
section only when not cited in those reports and papers or when very specific information 
from a given study is used here. 
 
The structure of the HRTM is shown in Figure 3.1.  The HRTM Task Group that 
developed this model incorporated as many anatomically and physiologically realistic 
features as feasible.  Nevertheless, the model includes some empirically based 
components. For example, the alveolar region is arbitrarily divided into three 
compartments to describe different phases of clearance from this region. Thus, 
 9
 
compartments within the AI region are defined on a kinetic basis rather than an 
anatomical or physiological basis.  
 
The HRTM divides the respiratory system into extrathoracic (ET) and thoracic tissues.  
The airways of the ET region are further divided into the anterior nasal passages in which 
deposits are removed by extrinsic means such as nose blowing and the posterior nasal 
passages (nasopharynx, oropharynx, and the larynx) from which deposits are swallowed 
or absorbed to blood.  The airways of the thorax include the bronchi (BB), bronchioles 
(bb), and alveolar interstitium (AI).  Material deposited in the thoracic airways is cleared 
into blood by absorption, to the gastrointestinal tract by mechanical processes (i.e., 
transported upward and swallowed), and to the regional lymph nodes via lymphatic 
channels.  In Figure 3.1, reference values for particle transport rate constants are shown 
beside the arrows and are in units of d-1. 
 
For an inhaled compound, the mechanical clearances of particles indicated in Figure 3.1 
are in competition with dissolution rates and absorption to blood, which depend on the 
element and the chemical and physical form in which it is inhaled.  Material-specific 
dissolution rates have been developed for some radionuclides, usually on the basis of in 
vitro dissolution studies or interpretation of measured clearance times from the lungs in 
laboratory animals (ICRP, 2002a).  
 
In most applications of the HRTM, a radionuclide inhaled as a particulate is assigned to 
one of three default absorption types:  Type F (fast dissolution and a high level of 
absorption to blood), Type M (an intermediate rate of dissolution and an intermediate 
level of absorption to blood), and Type S (slow dissolution and a low level of absorption 
to blood).  The user selects Type F, M, or S based on ICRP recommendations or 
independent interpretation of available element-specific information.  Sufficient 
information often is available in the literature to associate one of the three default 
absorption types to a given form of a radionuclide, but information usually is not 
sufficient to develop material-specific parameter values. 
 
A time-dependent dissolution rate in the respiratory tract is modeled by using one set of 
compartments representing an initial dissolution rate and a parallel set (not shown in 
Figure 3.1) representing a final dissolution rate.  As indicated in Figure 3.2, material 
deposited in a compartment representing the initial state dissolves and is absorbed to 
blood at a constant rate sp but is simultaneously transferred at a rate spt to a corresponding 
compartment representing a transformed state.  Particles in the transformed state have a 
dissolution rate st.  With this system, the initial dissolution rate is approximately sp and 
the final dissolution rate is approximately st.   
 
It is assumed that transformed particles are cleared from a compartment at the same rate 
as the particles in initial state.  More generally, all of the particle transport rates indicated 
in Figure 3.1 (e.g., 0.0001 d-1 from AI3 to bb1) are assumed to be independent of the 
material, although the structure of the model enables particle transport rates to be 
modified when information is available. As discussed later, the assumption of material-
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independent mechanical transport rates has a physiological basis or empirical support for 
some but not all regions of the respiratory tract. 
 
 
 
 
Figure 3.1.  Structure of the ICRP’s respiratory tract model (ICRP, 1994a) (numbers beside 
or above the arrows indicate particle transport rates (d-1); AI = alveolar interstitium, BB = 
bronchi, bb = bronchioles, ET = extrathoracic, LN = lymph nodes, SEQ = sequestered, TH 
= thoracic) 
 
 
 
The system indicated in Figure 3.2 can be used to depict an increasing rate of dissolution 
but generally has been used to describe a decreasing dissolution rate with a rapid phase of 
dissolution immediately after intake.  The latter pattern is predicted by the ICRP’s default 
parameter values for fast (F), moderate (M), and slow (S) dissolution. 
 
Deposition of inhaled material in the respiratory tract is defined as the portion of inhaled 
material remaining after exhalation, including any that is instantaneously absorbed to 
blood.  For radionuclides inhaled as solid or liquid particles, regional deposition is 
assumed to be determined only by the size distribution of the aerosol particles. For 
inhaled gases and vapors, deposition in the respiratory tract is assumed to depend entirely 
on the chemical form, which is consistent with results of studies indicating that regional 
deposition of a gas or vapor depends on its solubility and reactivity. 
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Figure 3.2.  Schematic of treatment of time-dependent dissolution of inhaled particles in the 
HRTM (material deposited in a compartment is absorbed to blood at a rate sp and 
simultaneously transferred at a rate spt to a parallel compartment representing a 
transformed state; transformed particles are absorbed to blood at a rate st) 
 
As a default approach, the HRTM assigns gases and vapors to one of three solubility-
reactivity (SR) classes on the basis of the initial pattern of deposition in the respiratory 
tract.  Class SR-0 represents insoluble and non-reactive gases or vapors, with deposition 
assumed to be negligible.  Class SR-1 represents soluble or reactive gases or vapors, with 
deposition potentially occurring throughout the respiratory tract; the default assumption is 
100% deposition, with 10% assigned to ET1, 20% to ET2, 10% to BB, 20% to bb, and 
40% to AI.  Class SR-2 represents highly soluble or reactive gases; in this case, 100% of 
inhaled activity is assumed to deposit in the extrathoracic airways (ET2).  If specific 
information is available for a gas or vapor, that information is used either to assign the 
material to one of the three solubility-reactivity classes or to develop material-specific 
parameter values.  
 
3.2. Basis for generic parameter values of the HRTM 
 
3.2.1. Main types of information 
 
Except where otherwise indicated, the summaries of information on various parameter 
values are based on material given in ICRP Publication 66 or a recent ICRP (2002a) 
guidance document.  However, the critical evaluations of the merits of the data are 
largely those of the authors of the present report. 
 
Generic parameter values for the HRTM are based largely on data for human subjects 
(H1), either from controlled studies or follow-up studies of exposed workers.  In some 
cases, gaps in the information are filled with data for laboratory animals (A1).  H1 data 
underlying most parameter values of the HRTM are mainly for adult males.  For some 
parameter values such as the ventilation rate, however, available information provides 
insight into variability among adult males and differences with age, gender, state of 
health, and other factors. 
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3.2.2. Ventilation rates 
 
There is considerable age- and gender-specific information on breathing rate and tidal 
volume (volume of inspired air) in individuals at rest or performing selected tasks of 
varying physical intensity.  For any given age, gender, and level of activity, there is 
reasonable agreement in ventilation rates (tidal volume times breathing frequency) 
determined in different studies.  While ethnic variability exists in lung volumes, flow 
rates, and tidal volume, minute ventilation at rest and at various levels of exercise does 
not appear to be very different between the ethnic groups that have been studied. 
 
The average ventilation rate was estimated in ICRP Publication 66 (1994a) as a 
time-weighted average of ventilation rates for rest periods and periods of light and heavy 
activity.  The least certain aspect of the calculation may be the characterization of a 
normal daily mix of activities.  A normal mix of daily activities is more difficult to define 
for young children than for adults.  The "time budgets" used in Publication 66 were based 
mainly on surveys conducted in the 1970s and 1980s and involving thousands of men, 
women, and children from a few different countries.  Estimated average ventilation rates 
for adult males based on time budgets usually fall in the range 13-17 L min-1. 
 
Layton (1993) proposed a considerably different approach for estimating average 
ventilation rates based on the body's oxygen requirements.  The rationale is that total air 
intake must be metabolically consistent with reasonably well established age- and 
gender-specific energy expenditure.  Variability with age and gender as estimated by 
Layton is indicated in Figure 3.3.  Layton's method yields 24-h average ventilation rates 
of about 10 (5.5-13) L min-1 for adult males and 7 (5-9) L min-1 for adult females, 
compared with the ICRP’s values of 15.4 L min-1 and 12.6 L min-1, respectively.  The 
HRTM method and the Layton method yield more consistent results for infants, children, 
and adolescents.  For example, Layton derived the value 5.5 (3.5-7.5) L min-1 for age 5 y, 
compared with the ICRP’s value of 6.1 L min-1.  The values in parentheses after Layton’s 
central estimates indicate differences between relatively inactive and relative active 
subgroups of the population, rather than uncertainty in the central value. 
 
 
3.2.3. Total deposition in the respiratory tract 
 
Total deposition of inspired material in the respiratory tract has been studied extensively 
in human subjects.  Most studies have involved adult Caucasian males and particle sizes 
of 1-10 μm aerodynamic diameter.  While the sparseness of age- and gender specific data 
introduces some uncertainty into estimates for the general population, these uncertainties 
do not appear to be large for three reasons:  (1) age- and gender-specific deposition can 
be estimated using a sophisticated theoretical deposition model based on well established 
physical principles; (2) there are some scattered age- and gender-specific data that allow 
spot checks of this model; and (3) the adult male respiratory tract appears to be a 
reasonably good surrogate in most respects for respiratory tracts in women and children.  
Gaps in human data on deposition of particles of aerodynamic diameter <1 μm have also 
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been filled to some extent with theoretical models and with experiments involving 
physical models, particularly anatomically realistic hollow casts of nasal passages, 
naso-oropharynx, and larynx. 
 
 
Figure 3.3.  Variation with age and gender in 24-h average air intake, as estimated by 
Layton (1993) on the basis of the body’s energy requirements 
 
 
Because the filtration efficiencies of the nose and mouth are different, a subject's 
breathing habit, defined as the ratio of nose breathing to mouth breathing, affects the 
amount of inhaled material that deposits in the lungs.  There is considerable variability in 
breathing habits, even among healthy persons of the same age and gender.  Estimates of 
total deposition of inhaled particles generally are made by combining experimental data 
for mouth breathing with separately derived information for deposition in the 
extrathoracic regions. 
 
3.2.4. Initial division between the thoracic and extrathoracic regions 
 
Deposition in the extrathoracic region is generally estimated in parts, that is, as the sum 
of deposition fractions determined separately for the nose and oropharyngeal-laryngeal 
regions.  Because processes that govern deposition of particles in the extrathoracic region 
depend strongly on particle size, different measurement techniques have been developed 
to measure different ranges of particle size.  Particles with an aerodynamic diameter 
larger than about 0.5 μm are deposited primarily by aerodynamic transport processes of 
inertial motion (impaction) and gravitational settling.  For very large particles and fibers, 
interception with surfaces in the extrathoracic airways also contributes to deposition.  
Particles with an equivalent physical diameter less than a few tenths of a micrometer are 
deposited primarily by the thermodynamic transport process of Brownian diffusion. 
 
Aerodynamic deposition in the nose is much better documented than aerodynamic 
deposition in other parts of the respiratory tract because this is the most easily observed 
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portion of the tract.  Measurement techniques include determination of the change in 
particle concentration when an aerosol is drawn in through the nose and out through the 
mouth during breath holding, external detection of deposited radioactivity after inhalation 
of labeled particles, and unfolding of the efficiencies of nasal deposition after 
measurement of the total respiratory tract deposition under different breathing maneuvers 
(nose breathing, pure mouth breathing, nose-in mouth-out, and mouth-in nose-out 
breathing).  Most measurements have been for particle sizes of 1 μm or greater. Perhaps 
the best available information on nasal deposition of smaller particles comes from 
measurements of deposition in anatomically accurate hollow casts of nasal passages, 
naso-oropharynx, and larynx.  The casts were made from MRI scans of two adult males 
(one postmortem) and a 1.5-y-old child. 
 
Most experimental studies of aerodynamic deposition in the oropharyngeal-laryngeal 
region have been performed with mouth breathing through a tube, since this is a 
convenient method for aerosol administration.  Oral deposition is measured by repeated 
mouth washings directly after inhalation.  The remainder of the extrathoracic deposition 
(oropharynx and larynx) is measured by external gamma counting.  In some cases, 
activity in the stomach has also been measured within a short time of deposition and 
assumed to represent transfer of material from extrathoracic airways to stomach.  The 
results of the studies are weakened by their apparent dependency on the structure and 
positioning of the mouthpiece and evidence that normal mouth breathing gives higher 
extrathoracic deposition than breathing through a mouthpiece.  Also, determination of 
typical deposition in the oropharyngeal-laryngeal region is complicated by a large 
intersubject variability in extrathoracic deposition.  This variability may be due mainly to 
differences in the morphology and physiology of the region, especially the larynx and 
vocal cords.  Thus, the experimental results are not sufficient to model aerodynamic 
deposition in the mouth and lower extrathoracic regions with much accuracy.  However, 
there is enough information to conclude that for particles less than about 10 μm 
aerodynamic diameter, the bulk of the extrathoracic deposition during mouth breathing 
occurs in the larynx. 
 
Deposition of submicron particles in the oropharyngeal-laryngeal airways has not been 
studied systematically in vivo in human subjects.  As is the case for nasal deposition of 
small particles, reliance must be placed on particle deposition in hollow airway casts.  
Limited experiments using hollow casts indicate slightly higher deposition in the 
oropharyngeal-laryngeal airways than in the nasal passageway of the same individual, but 
there is some question concerning the anatomical realism in the hollow casts. For 
example, the positioning of the tongue during open-mouth breathing could influence 
deposition in ways not revealed by the hollow casts. 
 
3.2.5. Regional deposition in the lungs 
 
Although there have been several studies of regional deposition of material in the lungs 
of human subjects, the experimental data are not sufficiently complete or consistent to 
define the division between the tracheobronchial and alveolar regions in the adult male or 
the effects of different airway size in other groups.  Estimates of regional deposition as a 
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function of age and gender must be based mainly on theoretical models of the lungs.  The 
theoretical model used in ICRP Publication 66 (1994a) evaluates the combined effects of 
convective and diffusive gas transport and aerosol loss processes within the airways of 
the lungs.  Predictions of the theoretical model do not differ substantially from measured 
values of total lung deposition over a wide range of particle sizes. 
 
The published experimental determinations of regional deposition in the respiratory tract 
are generally interpreted in terms of assumptions or models that may not be entirely 
correct.  For example, the data as presented in the literature generally rely on the premise 
that particles deposited in distinct anatomical regions (e.g., the ciliated tracheobronchial 
airways or the respiratory airways of the alveolar interstitium) are cleared with distinctly 
different rates.  In experimental studies involving human subjects, two distinct phases of 
particle clearance from the lungs are usually observed:  an initial rapid phase succeeded 
by a slow phase with a fitted half-time of several tens of days.  Results of some studies 
indicate, however, that a substantial fraction of particles deposited in the tracheobronchial 
region may have been cleared at a slow rate that was indistinguishable from clearance 
from the alveolar-interstitial airways.  Thus, the fundamental premise of uniformly rapid 
ciliary clearance may not be valid. 
 
There does not appear to be any information on regional lung deposition in children, but   
total thoracic deposition was measured in a group of children of average age about 10 y 
and in another group of average age about 5 y.  The data agree reasonably well with the 
theoretical deposition model, but only a small range of particle sizes was tested.  Thus, 
total lung deposition is less well determined in children than in adults. 
 
Variability of total or regional deposition of inhaled material in the respiratory tract in the 
population is not established.  Predictions of the HRTM indicate little variation with age 
in deposition (Table 3.1), but in the case of regional deposition these predictions are 
based on assumptions and models rather than data. 
 
 
Table 3.1. Variation with age in total and regional deposition fractions as a function of age, 
as predicted by HRTM for inhalation of 1-μm particles (AMAD) 
Age  
 
Region 
 
100 d 
 
1 y 
 
5 y 
 
10 y 
 
15 y 
Adult male 
member of 
public 
Adult 
male 
(worker) 
AI 0.0856 0.0964 0.0985 0.0951 0.107 0.115 0.107 
Bbe 0.0204 0.0171 0.0185  0.017   0.020 0.0195 0.0165 
BBi 0.0104 0.0104 0.0104 0.0117 0.0169 0.0129 0.0124 
ET 0.482 0.484 0.397 0.406 0.320 0.339 0.376 
Total 0.598 0.608 0.524 0.530 0.464 0.486 0.512 
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3.2.6. Clearance of material from the lungs 
 
Particle clearance from the tracheobronchial region has been studied extensively.  There 
is general agreement that mucociliary transport is the principal mechanism of particle 
removal from this region, the main flow is towards the pharynx, and mucous velocities 
decrease distally.  There is much less agreement about the rate at which the decrease 
occurs or the precise pattern of mucous flow.  Central values for tracheal mucociliary 
transport rates reported for different studies vary from about 4 to about 25 mm min-1.  
Measurements indicate that mucociliary clearance associated with deposition in the upper 
8-10 airway generations is complete in a few hours.  For the bronchioles, large 
discrepancies (factor of 40 or more) are seen in reported mucous velocities.  Also, a 
relatively slow phase of clearance from the tracheobronchial region is indicated, but the 
fraction of the deposited amount associated with this phase and the rate of clearance are 
poorly understood. 
 
There appears to be some retention in the airway walls in portions of the tracheobronchial 
region, based on studies of several species, including humans (ICRP, 1994a).  Retention 
has been best quantified for the rat trachea, where about 0.7% of the deposit remained 
and was cleared with an estimated half-time of 88 d.  These results form the basis of the 
reference values describing retention in the tracheobronchial airway walls.  Studies 
completed since the appearance of ICRP Publication 66 (1994a) and involving other 
animal species indicate that the HRTM may overestimate retention in the airway walls 
(M. Bailey, private communication). 
 
Effects of different host factors or personal habits on lung mucociliary clearance have 
been investigated in a number of studies.  Some permanent factors that can have a 
significant effect on lung mucociliary clearance are age (older persons may have slower 
clearance), possibly gender (women could have faster clearance), and cigarette smoking 
(slower clearance).  There is no information on factors affecting either the magnitude or 
duration of slow tracheobronchial clearance, or of particle retention in the airways of 
humans. 
 
Retention of insoluble particles in the alveolar region has been reasonably well 
characterized in controlled experimental studies covering periods up to 300 d after intake, 
at least in healthy adult males.  Estimates of subsequent retention must be based on data 
for accidental intakes by human subjects or experimental intakes by laboratory animals.  
The data for accidental intakes by humans fall into two categories:  in vivo 
measurements, usually of radioactive materials, over the thoracic region; and postmortem 
measurements of the amount of material in the lungs, which in some cases have been 
compared with the estimated intakes. 
 
The experimental studies involving human subjects indicate that about 80% (range of 
central estimates, 56-93%) of the initial alveolar deposit remains at 50 d after intake, 70% 
(34-83%) at 100 d, and 50% (11-64%) at 300 d.  This conclusion is based mainly on 
results of 10 experimental studies on human subjects.  In four studies, both smokers and 
non-smokers were involved and were studied separately.  The studies involve five 
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different materials of differing solubility that would have tended to increase the 
variability compared to uniformly soluble materials. 
 
Measurements of accidentally exposed persons at times remote from the primary 
exposure(s) indicate that 10% or more of deposited material may be retained in the lungs 
at 3000-10,000 d after exposure.  The data are generally based on external measurements 
over the chest and, depending on the energy of the photon emission and knowledge of the 
biokinetics, may not clearly distinguish between activity in the lungs, lymph nodes, and 
thoracic bone.  These external measurements serve mainly as upper-bound estimates on 
lung retention.  
 
More direct evidence of very long-term retention of material in the lungs comes from 
postmortem measurements on occupationally exposed persons.  For example, the 
distribution of actinides in former workers has been estimated on the basis of 
concentrations in tissues taken at autopsy, 30 years or more after exposure.  The 
measurements have revealed that lung tissues may contain up to half of total-body 
activity, indicating a long retention time for a substantial portion of the inhaled material 
in the lungs.  Much additional information on long-term retention of radioactivity in the 
lungs of workers, particularly plutonium workers in the U.S. and at the Mayak plant in 
Russia, has become available since the completion of the HRTM (e.g., Khokhryakov et 
al., 2005).  
 
Evidence of long-term retention of inhaled material in the lungs also comes from studies 
on laboratory animals.  For example, studies of inhaled PuO2 in dogs and baboons 
indicate that the half-time of particle clearance increases with time for years after intake 
and that several percent of the initial alveolar deposit may be retained in the lungs for 
many years after exposure. 
 
3.2.7. Retention in the lymph nodes 
 
Much information has been collected on retention of inhaled material in human lymph 
nodes.  Interpretation of the data is complicated by uncertainties in the time-course and 
composition of the intakes, the high variability among lymph nodes of the same person, 
and the small portion of lymph nodes generally sampled.  Nevertheless, the collective 
data provide an indication of the typical relative contents of lungs and lymph nodes at 
times remote from intake.  Material is consistently found in both tissues, even many years 
after exposure has ceased. 
 
Information on retention of inhaled material in human lymph nodes can be divided into 
four main categories:  environmental exposure to nuclear weapons fallout, particularly 
plutonium and cerium; environmental exposure to natural long-lived radionuclides, 
particularly thorium; occupational exposure to actinides, particularly plutonium; and 
occupational exposure to mine dusts.  Concentration ratios for tracheobronchial lymph 
nodes to lungs were 24 for cerium in non-occupationally exposed persons (one study); 
1.9-15.0 (median 6.5) for plutonium in non-occupationally exposed persons (several 
studies); 1.5-20 (median 10.4) for thorium and uranium in non-occupationally exposed 
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persons (several studies); 1.3-34.4 (median 9.7) for plutonium, thorium, uranium, and 
americium in occupationally exposed persons (several studies); 0.1-2.5 (median 1.8) for 
uranium in lungs of occupationally exposed persons (several studies). Relatively low 
concentrations were determined for dust concentrations in hilar lymph nodes of coal 
miners (two studies). 
 
3.2.8. Absorption to blood 
 
Absorption of inhaled material from the respiratory tract to blood is viewed as a 
two-stage process:  (1) dissociation of the particles, and (2) uptake of the dissociated 
material.  Absorption rates tend to change with time because the process of dissociation 
changes the physicochemical form of the material.  There is insufficient information to 
model the factors involved in dissolution and uptake, in order to predict the rate of 
absorption into blood for specific materials. 
 
Theoretically, absorption to blood can be estimated as the difference between lung 
retention and particle transport from the lungs.  This method assumes that particle 
transport is not the dominant mechanism of removal from lungs.  Particle transport is 
often the observed dominant mechanism for very insoluble particles.  It is also often the 
dominant mechanism in studies with small rodents (rats, hamsters, mice), which have 
relatively high particle transport rates from the alveolar region. 
 
In practice, estimates of absorption into blood are usually based on observations of 
urinary excretion or accumulation of material in systemic organs.  This approach requires 
a reasonably good systemic biokinetic model and information on gastrointestinal uptake. 
If such observations are not available for human subjects, it is preferable to use data for 
medium to large animal species, such as baboons or dogs.  
 
The absorption rate of a given compound may vary with such factors as particle size, 
method and temperature of formation, isotopic composition, and presence of other 
metals.  Particles encountered in practice may be complex mixtures of ill-defined 
compounds, and the radionuclide of concern may be present as a minor constituent of the 
material.  The first stage in absorption, particle dissolution, is assumed to be determined 
by the particle matrix, rather than by the radionuclide itself. 
 
Uptake of dissolved material to blood is thought to be rapid for most elements.  In some 
cases, however, a significant fraction of the dissociated material is absorbed slowly as a 
result of binding to respiratory tract components.  For example, such binding has been 
observed for cadmium. 
 
Even with relatively insoluble materials, a rapid phase of uptake to blood is often 
observed immediately after inhalation.  This may be due to some combination of the 
following factors:  a soluble component of the inhaled material, an unstable particle 
surface, presence of a portion of the activity in small particles with a relatively high 
specific surface area, particles small enough to pass directly to blood, and transformation 
of the deposited material into a form that is less readily absorbed.  As discussed in a later 
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section, however, the rapid phase of absorption may be absent for some materials, and the 
default absorption types used with the HRTM do not take this possibility into account. 
 
Dissolution rates in the respiratory tract may differ according to whether the particles are 
in the liquid lining the epithelium, or phagocytosed by macrophages.  The phagosomes 
have a relatively low pH (4-5), but pH alone is not sufficient to account for observed 
differences in dissolution rates in alveolar macrophages and saline. 
 
Several simplifying assumptions were made in the development of the HRTM to model 
clearance kinetics for the wide range of materials considered by the ICRP: 
 
(1) It is assumed that clearance kinetics may be expressed in terms of fractional 
clearance rates.  This same assumption is made in most biokinetic models used by 
the ICRP. 
 
(2) Clearance rates due to particle transport and absorption are assumed to be 
independent.  The limited supporting evidence for this assumption includes two 
interspecies comparisons involving inhalation of monodisperse 57Co-labeled cobaltic 
oxide.  The first study involved human volunteers, baboons, dogs, guinea pigs, 
hamsters, and three strains of rats.  The second study involved baboons, dogs, and 
one strain of rats.  Particle sizes were 0.8-1.7 μm.  The pattern of particle transport 
rates over time in the various species was qualitatively different from that of the 
absorption rates.  Initial absorption rates for the 0.8 μm particles were higher than 
those of 0.9 and 1.7 μm particle sizes in each species, whereas there was no apparent 
effect of particle size on particle transport rates.  During the first three months, the 
absorption rate remained constant or initially increased with time in each group, 
while the particle transport rate decreased monotonically.  There was no correlation 
between the interspecies differences in absorption and particle transport rates.  Both 
rates were high in rats and low in humans and baboons.  Dogs showed rapid 
absorption of cobalt to blood but very slow particle transport. 
 
(3) Particle transport rates are assumed to be the same for all materials.  This 
assumption is not strongly supported by available data but seems reasonable in lieu 
of material-specific data, at least for mucociliary transport. Less is known about 
factors influencing particle transport from the AI region to the bb region.  
  
(4) The rate of absorption of a material to blood is assumed to be the same in all 
regions of the respiratory tract, including the regional lymph nodes.  This is an 
assumption of convenience that may be particularly inaccurate for the time 
immediately after deposition, when the rate of absorption of dissolved material might 
be higher than average in the alveolar region where the air-blood barrier is thinnest.  
In a study involving 12 different drugs with widely varying properties such as 
molecular size, lipid solubility, degree of ionization, and chemical structure, 
absorption to blood was about twice as rapid following administration by inhalation 
than following intratracheal injection (Schanker et al., 1986).  It is possible that 
absorption was substantially more rapid from the alveolar region than from the 
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tracheobronchial region.  The assumption of a uniform absorption rate in the 
respiratory tract may be more reasonable at times later than a few hours after 
inhalation, when most particles are likely to be within macrophages in all regions of 
the lungs, and dissolution in macrophages might be the rate-determining step in the 
absorption of activity into blood. 
 
(5) It is assumed that material deposited in the anterior nasal passage is not absorbed 
to blood.  This is based on the structure of the epithelium; the structure is much like 
that of skin, which shows low (but not zero) permeability by most materials.  
 
3.2.9. Definition of lung dose 
 
Lung dose is defined in ICRP Publication 66 as a weighted average of the calculated 
doses to three radiosensitive regions of the lungs:  the bronchial region (BB), the 
bronchiolar region (bb), and the alveolar-interstitial (AI) region.  The ICRP recommends 
the use of equal weights, or detriment apportionment factors, for these three regions but 
points out the possibility, in view of the regional distribution of spontaneous lung cancers 
in the general non-smoking population, that uniform irradiation of the lungs may be more 
likely to lead to the induction of cancer in the bronchial region than in the alveolar and 
bronchiolar regions.   
 
Estimates of lung dose are relatively insensitive to the choice of regional apportionment 
factors for radionuclides that emit penetrating radiations because the three regions are in 
close proximity to one another and there is cross-irradiation from activity within these 
regions.  On the other hand, dose estimates may depend strongly on the choice of 
regional apportionment factors for some radionuclides with relatively non-penetrating 
radiations, i.e., radionuclides that emit mainly alpha or low-energy beta particles or 
discrete electrons. 
 
3.3. Existing evaluations of potential errors and uncertainties in HRTM components 
and predictions 
 
3.3.1. Expert judgments by the developers of the HRTM 
 
ICRP Publication 66 (1994a) gives brief summaries of uncertainties associated with 
many of the parameter values of the HRTM, representing the expert judgments of the 
ICRP task group that developed the model. For example, it is pointed out that reference 
values describing particle clearance 
 
 “are based on indirect information and therefore involve a considerable amount of 
judgment. Some rates are based entirely on animal studies, and extrapolating results 
to humans involves a possible systematic error, which could be large.  For example, 
the alveolar clearance rate at 100 d after inhalation in humans is about 5 times 
greater than in dogs, and 5 times lower than in mice…  Maximum mucociliary 
transport rates in the trachea ranged from 2 mm min-1 in rats to 10 mm min-1 in dogs. 
These are all, however, within a factor of 2.5 of the [reference value for humans] (5 
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mm min-1)…   Thus the combination of a high degree of intersubject variation and 
possible systematic errors means that the uncertainties in the reference values are 
large and difficult to quantify.  It is … assumed that the uncertainty in the reference 
value is lognormally distributed and …that there is a 95% probability that the true 
mean value lies within a factor of Φu of the true value…” 
 
The HRTM Task Group concluded that the two examples of interspecies differences 
suggest that a factor of 3 is reasonable whenever a rate is based entirely on animal data. 
With regard to estimated rates of clearance from the alveolar region, which are based 
mainly on data for human subjects, they indicate that the mean clearance rate up to 100 d 
may be known within about 20%, the rate at 200-300 d within a factor of 2, and the 
long-term removal rate from the AI region to the bronchioles (0.0001 d-1, corresponding 
to a half-time of almost 7000 d) within a factor of 3.  They do not address uncertainties 
associated with model structure, e.g., the use of three retention components to describe 
behavior of material in the deep lungs. 
 
3.3.2. Expert judgments by international experts 
 
In the mid-1990s a joint project was conducted by the NRC and the Commission of the 
European Communities (CEC) for the purpose of developing traceable uncertainty 
distributions for input variables to their probabilistic accident consequence codes (NRC-
CEC, 1997).  A procedure was devised to elicit expert judgment regarding uncertainties 
in input to that code.  Elicitation questions were developed, tested, and clarified.  
Internationally recognized experts were selected.  Probability training exercises were 
conducted to establish ground rules for the experts’ preparation of material and for the 
formal elicitation process.  Experts developed their uncertainty distributions and 
rationales independently.  A meeting was held in which the experts discussed their 
independent conclusions and rationales and were given the opportunity to change their 
conclusions before final, private solicitation interviews with individual experts. 
 
Several of the elicitation questions were directly related to parameters of the HRTM, e.g., 
ventilation rates, deposition fractions in different regions of the respiratory tract, and 
retention in different regions of the tract at different times.  The aggregated results 
generally gave surprisingly wide confidence intervals (5-95%), perhaps reflecting the fact 
that the participants were actually experts in a variety of different areas related to the 
radiation dosimetry and had much different levels of familiarity with behavior and 
dosimetry of inhaled radionuclides.  That is, the uncertainties expressed by several of the 
participants may have reflected their understanding of information partly outside their 
real areas of expertise, rather than the true state of knowledge of the behavior of inhaled 
radionuclides.  
 
3.3.3. Parameter uncertainty analysis applied to 222Rn daughter dosimetry 
 
Marsh et al. (2002) applied standard methods of parameter uncertainty analysis to 
examine the uncertainty in dose to an adult from inhalation of 222Rn progeny in the home. 
This was a slight variation of an earlier analysis by Birchall and James (1994) of the 
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uncertainty in dose from inhalation of 222Rn progeny by a miner.  The main purpose was 
to examine whether uncertainties in selected parameter values of the HRTM as applied to 
222Rn progeny could explain the discrepancy between the epidemiologically based 
estimate and the roughly three-fold greater HRTM-derived estimate of risk associated 
with unit exposure to radon daughters.  It was assumed that the HRTM is a realistic 
representation of the physical and biological processes, and that the parameter values are 
uncertain.  Uncertainties associated with the ICRP’s radiation weighting factor for alpha 
particles (20) were not considered, and the ICRP’s tissue weighting factor for the lung 
(0.12) was left fixed.  The investigators concluded that the uncertainties in the HRTM 
parameters, at least those that were considered in these two analyses, cannot totally 
account for the discrepancy between the dosimetric and epidemiological approaches. 
 
The rationale behind the analyses by Marsh, Birchall, and coworkers is not clear. The 
discrepancies between HRTM predictions and epidemiological data seem modest in view 
of the sizable uncertainties in the miner data and in components of the HRTM-based dose 
estimates not addressed in the analysis.  For example, the actual intakes of 222Rn progeny 
by uranium miners through about 1967 were based on sparse and often biased 
information (e.g., company records) and in many cases could be in error by an order of 
magnitude.  An example of uncertain input to dose estimates not addressed by Marsh, 
Birchall, and coworkers is the radiation weighting factor of 20 for alpha particles.  Also, 
the investigators may have overstated current understanding of the biokinetics of 222Rn 
daughters in the respiratory tract, such as the time course of absorption of 214Pb and 214Bi 
to blood. 
 
3.3.4. Detailed parameter uncertainty analysis for inhaled PuO2 or UO2/U3O8 
 
Bolch and coworkers (Bolch et al., 2001, 2003; Farfan et al., 2003; Huston et al., 2003)  
published a series of papers addressing uncertainties associated with predictions of the 
HRTM as discerned from parameter uncertainty analysis.  They reviewed the original 
data on which 69 default parameter values of the HRTM were based, selected subjective 
distributions that they referred to as “probability distributions” for these parameter 
values, and propagated these distributions through the HRTM to derive distributions of 
lung dose. Uncertainties in the following model predictions were addressed in separate 
papers:  particle deposition (Bolch et al., 2001); particle clearance for the specific cases 
of inhaled 239PuO2 or 238UO2/238U3O8 (Bolch et al., 2003); regional tissue doses for 
inhaled 239PuO2 or 238UO2/238U3O8 (Farfan et al., 2003); and identification of the input 
parameters to which their dose estimates for inhaled 239PuO2 were most sensitive (Huston 
et al., 2003).  Conclusions of Bolch and coworkers regarding the level of uncertainty in 
lung dose from inhaled 239PuO2 or 238UO2/238U3O8 varied markedly with particle size 
(Farfan et al., 2003).  For “typical exposure scenarios” involving these radionuclides, the 
ratio of their derived 95% to 5% confidence levels was on the order of 8-10 for particles 
diameters 0.1-1.0 μm. They concluded that the uncertainty in lung dose increases by 
factors of 50 or more over the particle size range from 0.1 to 20 μm.  
 
In the papers by Bolch et al., the term “uncertainty” refers to “both (1) a lack of 
knowledge of the model parameters, and (2) any biological variability these parameters 
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would exhibit within the population of interest” (Bolch et al., 2001).  This suggests that 
the results should be interpreted as reflecting the investigators’ uncertainty in a model 
estimate for a healthy individual, based on the assumption that model parameter values 
represent the only sources of uncertainty. This differs from the use of the term 
“uncertainty” in the present report, which refers to a confidence level regarding a central 
value for a population. 
  
For the case of inhaled 239PuO2, Huston et al. (2003) concluded that the following 
parameter values dominated the dose estimate:  the ventilation rate, fractional deposition 
in the AI region, the clearance rate constant for slow-phase absorption, and a clearance 
rate constant for particle transport from one of the AI compartments. This result cannot 
be carried over to inhalation of radionuclides in general because the dominant parameters 
will depend on factors such as half-life of the radionuclide, mode of decay, energies of 
emitted radiations, particle size, and solubility.   
 
3.3.5. A modification of the analysis of Bolch and coworkers for inhaled PuO2  
 
Aden and Scott (2003) modified the analysis by Huston et al. (2003) for inhaled PuO2 in 
an effort to improve the characterization of uncertainty in dose per unit intake as applied 
to a hypothetical population of nuclear workers engaged in light work-related exercise.  
Their parameter uncertainty distributions were similar to those selected by Huston and 
coworkers, with the main exception that polydisperse rather than monodisperse particles 
were considered.  Aden and Scott concluded that the HRTM overestimates deposition for 
most of the adult male population when aerodynamic particle sizes are greater than 10 
μm, especially for deposition in bb and AI. 
 
3.3.6. Comparison with an alternate ventilation model 
 
As discussed earlier, the ICRP modeled the ventilation rate by applying “time budgets” to 
ventilation rates observed in human subjects at different levels of activity.  Layton (1993) 
developed an alternate, independent model of ventilation based on energy requirements 
that is at odds with the ICRP model, particularly for adults (Figure 3.4). 
 
Layton’s ventilation model also involves uncertainties, but the potential underestimate 
does not seem large enough to explain the discrepancies between that model and the 
HRTM. Layton’s estimates are derived using the equation VE = E x H x VQ, where VE is 
the ventilation rate (L min-1), E is the average rate of energy expenditure (kilojoules 
min-1), H is the volume of oxygen (at standard temperature and pressure) consumed in the 
production of 1 kilojoule of energy, and VQ is the ratio of ventilation rate to oxygen 
uptake rate. The value H has been determined within narrow bounds.  Comparisons of 
different food consumption surveys for the U.S. population give reasonably consistent 
results, when biases in the data are taken into account as was done by Layton. The largest 
potential error in the method may lie in the parameter VQ.  Layton concluded that VQ is 
nearly independent of the ventilation rate and proposed the value VQ = 27 for all ages 
and activity levels and for both genders.  This value is based on data for adult humans 
(almost all male subjects, a large portion of which were highly trained athletes) and data 
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from two studies on newborns.  Little information is available for adult females, but 
results of a study on children of age 7-17 y (Zapletal et al., 1987) give a mean value for 
VQ of about 36 and suggest a slight increase with age, from about 35 at age 7 y to about 
37 at age 17 y. 
 
 
Figure 3.4.  Comparison of predictions of the ventilation submodel of the HRTM with 
values derived from an independent model based on energy requirement (Layton, 1993) 
 
 
Thus, the Layton model involves some uncertainties, but it seems at least as defensible as 
the ICRP model of ventilation. The discrepancies between the two models indicate a 
larger uncertainty in the ICRP’s ventilation model than might be assigned by assessing 
the data underlying the parameters of the ICRP model.  This illustrates how comparison 
of alternate models can provide insight into potential modeling errors that may not be 
revealed with parameter uncertainty analysis. 
 
3.3.7. Comparison with alternate parameter values for inhaled mercury vapor 
 
This example is concerned with potential errors in a specific application of the HRTM, in 
this case to inhaled mercury vapor, rather than in generic features of the HRTM.  The 
ICRP’s application of the HRTM to mercury vapor is compared with an alternate 
application based on revised parameter values developed from a critical review of the 
literature. 
 
The ICRP’s model for inhaled mercury vapor was introduced in ICRP Publication 30, 
Part 2 (1980) but later recast in the context of the HRTM (ICRP Publication 68, 1994b). 
According to the original and updated versions of the model, 70% of inhaled mercury 
vapor is deposited in the lungs, and all of the deposited mercury is absorbed to blood with 
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a half-time of 1.7 d.  In the original version, mercury vapor is assumed, in effect, to be 
distributed uniformly in the lungs.  In the updated version applied in ICRP Publication 68 
(ICRP, 1994b), 10% is assigned to the bound compartment of the large bronchi (BB), 
20% to the bound compartment of the small bronchi (bb), and 40% to the bound 
compartment of the alveolar-interstitial region (AI).  The bound compartments represent 
deeply penetrated material assumed not to be subject to removal by particle transport 
processes but cleared only to blood. 
 
A critical review of the literature on the biokinetics of inhaled mercury vapor was 
performed recently as part of an accident analysis for the Spallation Neutron Source 
(SNS) at ORNL (Leggett et al., 2001).  The SNS uses stable mercury as a target.  
Radioisotopes of mercury build up during irradiation of the target by neutrons and high 
energy protons and could be released as vapor during an accident, particularly a fire.  It 
was concluded from the review that the ICRP’s model for mercury vapor does not 
accurately represent current information, or even information available at the time the 
parameter values were developed for use in ICRP Publication 30. The evidence indicates 
that inhaled mercury vapor deposits largely in the AI region, most of the deposited 
mercury is nearly instantaneously absorbed to blood, and the remainder may have 
multiple components of retention in the lungs 
 
Parameter values of the HRTM were modified for agreement with reevaluated and 
updated bioassay data (Leggett et al., 2001).  In the modified version: 
1.  Total retention in the respiratory tract is increased from 70% to 80%. 
2.  2% of inhaled activity is assigned to the extrathoracic region (ET2) 1% to the 
large bronchi (BB), 2% to small bronchi (bb), 75% to AI, and 20% is exhaled.  As in 
the ICRP model, mercury atoms are assumed to be instantaneously transferred to the 
“bound” compartments in each region. 
3.  A portion of activity deposited in AI, equivalent to 70% of the deposition in the 
respiratory tract (that is, 0.7 × 80% = 56% of inhaled activity), is absorbed to blood 
with a half-time of 1 min; 80% of the remaining activity in all regions is absorbed 
with a half-time of 8 h; and 20% is absorbed with a half-time of 5 d. 
 
Dose estimates based on the ICRP model and the proposed revision are compared in 
Table 3.2. In each case, the ICRP’s current systemic biokinetic model for mercury was 
used. 
 
The revised model reduces the effective dose coefficients for 203Hg and 197Hg by factors 
of 4 and 10, respectively, due to the decreased mean residence time of these short-lived 
isotopes in the lungs.  The effective dose coefficient is increased slightly for the longer-
lived isotope 194Hg, for which a small, long-term component of retention in the updated 
model becomes a more important factor. 
 26
 
 
Table 3.2. Comparison of dose coefficients for inhalation of mercury 
vapor by a worker, based on the HRTM with current ICRP parameter 
values for mercury vapor (ICRP, 1994b) and parameter values 
proposed by Leggett et al. (2001) 
Ratio of dose coefficients B:A based on 
HRTM with (A) current and (B) proposed 
parameter values 
 
 
Mercury isotope 
 
 
Half-life 
Lung Kidneys Effective dose 
Hg-203 46.6 d 0.09 1.2 0.26 
Hg-197 64.1 h 0.06 1.7 0.10 
Hg-194 260 y 0.74 1.1 1.1 
 
 
3.3.8. Comparison with the NCRP respiratory model 
 
At the time of development of the HRTM by the ICRP, a committee of the NCRP was 
also developing a respiratory tract model (NCRP, 1997).  The ICRP and NCRP models 
are compared in NCRP Commentary No. 15 (1998) on the reliability of models used in 
radiation dose assessment, where it is pointed out that the differences in these two models 
offer a unique opportunity for assessing uncertainties about lung retention and dosimetry.  
 
The HRTM Task Group and NCRP committee considered essentially the same 
information but chose different model structures, made different assumptions, and 
sometimes emphasized different parts of the database.  According to the authors of NCRP 
Commentary No. 15, predictions of the two models are generally consistent where 
information is fairly clear but make different predictions where evidence is ambiguous or 
missing.  With regard to retention and uptake of activity inhaled in insoluble form, the 
HRTM and NCRP model both move away from the lung model of ICRP Publication 30 
in the same general direction.  For example, both models predict substantially lower 
absorption from relatively insoluble materials than is predicted by the lung model of 
ICRP Publication 30.  Predictions of total deposition are reasonably consistent, but 
noticeable differences in predictions are seen for regional depositions, particularly in the 
extrathoracic and tracheobronchial regions.  Comparisons are complicated by the fact that 
they are scenario dependent.  For example, regional depositions of inhaled material were 
compared using two different scenarios, one based on the ICRP’s default parameter 
values for breathing and aerosols and one based on corresponding parameter values taken 
from the NCRP report.  Good agreement between the ICRP and NCRP models was 
obtained in model predictions of deposition in all regions of the respiratory tract when the 
NCRP scenario was used.  When the ICRP scenario was used, good agreement was found 
for the alveolar-interstitial region, moderately good agreement (difference of 32%) was 
obtained for the tracheobronchial region, and a difference of 76% was observed for the 
extrathoracic region. 
 
We agree with the conclusion in NCRP Commentary No. 15 that comparison of the ICRP 
and NCRP respiratory models offers a unique opportunity for assessing uncertainties 
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about lung retention and dosimetry.  We believe that a detailed comparison of these two 
models should be performed as one of the initial tasks in a comprehensive assessment of 
potential errors in dose estimates for inhaled radionuclides. 
 
3.3.9. Comparison with independent data 
 
This section illustrates potential errors in the application of default absorption types used 
with the HRTM.  It is well known, of course, that the default absorption types may not 
provide close fits to data for specific materials, and the ICRP recommends that material-
specific parameter values be developed when information allows. Case studies involving 
inhalation of certain forms of enriched U or 238Pu show that the general pattern of 
monotonically declining dissolution rates depicted by all three default absorption types 
can differ radically from the real situation. 
  
In the late 1960s a group of workers was exposed over several months to high 
concentrations of airborne uranium aluminide (UAlx), a material used in fuels for 
research and test reactors. Exposure to UAlx occurred mainly in a work area where UAlx 
powder was formed and pressed into a compact to be used in the core of a fuel plate.  
Monitoring of urinary data over the first few months of the program did not indicate 
unusually high exposures to uranium.  Several months after the start of the UAlx fuel 
fabrication program, however, it became evident that urinary uranium lagged far behind 
UAlx intake.  For example, in workers who had been removed from exposure, the rate of 
urinary excretion of uranium continued to rise over a period of months, reached a peak, 
and then decreased sharply (Figure 3.5).  High lung burdens in several workers had 
resulted before the problem was recognized.  Retrospective estimates of lung dose based 
on revised parameter values for the ICRP respiratory model (based on intake and 
excretion data for the aluminide workers) were in the range 0.5-2 Sv for 18 of the 
workers and 3.5 Sv for the most highly exposed worker.  
 
As illustrated in Figure 3.5 for Type M and Type S aerosols, the urinary data are 
inconsistent with the ICRP’s default absorption types for inhaled particulates.  Each of 
the three sets of default parameter values (F, M, or S) depicts a monotonically decreasing 
rate of dissolution and absorption to blood following acute intake.  When combined with 
the ICRP’s systemic biokinetic models for specific elements, the modeled pattern of 
dissolution and absorption is reflected in the urinary excretion rate over time.  That is, the 
ICRP models with default parameter values predict a decreasing rate of urinary excretion 
as a function of time following acute intake, or a rise and fall in the excretion rate 
reflecting changing exposure levels during chronic exposure. 
 
The authors developed parameter values for the HRTM to describe the behavior of UAlx 
seen in these workers, using parameter values for Type S as a starting point.  The 
parameter values that were adjusted included those representing the dissolution rate as 
well as those representing mechanical clearance rates from the AI region.  While it was 
the intention of the HRTM Task Group that the parameters sp, spt, and st (Figure 3.2) be 
modified to fit material-specific information, they considered the particle clearance rates 
to be fixed.  The assumption that the particle clearance rates from AI are the same for the 
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initially deposited material and transformed material appears to be a convenient 
assumption with little or no physiological basis. 
 
 
 
Figure 3.5.  Urinary excretion data for a worker exposed to airborne UAlx, compared with 
predictions of the HRTM based on Type M or Type S aerosols; rise and fall of the model 
predictions during the exposure period reflect the change in measured air concentrations of 
UAlx during that period 
 
 
 
The fit of the HRTM with parameter values adjusted by the present authors to account for 
a different dissolution kinetics model is illustrated in Figure 3.6 for one of the most 
heavily exposed workers.  
 
As illustrated in Table 3.3, dose coefficients for inhalation of 234U based on the UAlx-
specific parameter values differ substantially from those assuming Type M or Type S for 
some tissues.  However, the effective dose for all three cases is largely determined by the 
lung dose, which does not differ greatly for these cases.  The effective dose for “Type 
UAlx” is slightly less than that for Type S and about 2.5 times that for Type M. 
 
Particularly large uncertainties in predictions of the HRTM with default parameter values 
arise in dose reconstructions based on urinary data.  Table 3.4 compares back calculations 
of effective dose based on parameter values for Type M or Type S with calculations 
based on the UAlx specific parameter values developed by the authors (labeled as ORNL 
estimates). The comparisons are made for acute inhalation of UAlx, assuming that a 
single urinary U measurement is available at 7 d, 15 d, 30 d, or 90 d after intake. Of 
course, there are uncertainties in the dose estimates based on ORNL’s material-specific 
parameter values.  Nevertheless, the material-specific parameter values are consistent 
with a large amount of urinary and fecal data for these workers. 
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Figure 3.6.  Comparison of the predictions of the modified HRTM with urinary U 
data for a worker who was heavily exposed to UAlx 
 
 
 
Table 3.3. Comparison of 50-y committed equivalent dose 
coefficients (Sv Bq-1) for inhalation of 234U based on models for 
Type M and Type S and the UAlx model described in this report 
Tissue Type M Type S This model 
Bone surface 2.7E-6 2.7E-7 1.1E-6 
Red marrow 2.8E-7 2.8E-8 1.2E-7 
Liver 3.8E-7 3.8E-8 1.6E-7 
Lung 1.6E-5 4.1E-5 3.6E-5 
Effective dose 2.1E-6 6.8E-6 5.4E-6 
 
 
 
A review of the literature revealed that the general pattern of delayed excretion seen for 
the workers exposed to UAlx has been observed for several actinide elements including 
plutonium, americium, and californium (Healy, 1957; King, 1980; Wood and Sheehan, 
1971; Rundo and Sedlet, 1973).  For example, Wood and Sheehan (1971) reported 
follow-up measurements on five workers exposed to an accidental release of 238Pu oxide. 
The assay of initial urine samples indicated some uptake of plutonium but did not 
indicate, on the basis of the monotonically declining model predictions available at the 
time, that any of the intakes had exceeded 10% of the limit in place at the time.  The rate 
of excretion of plutonium in urine continued to increase over a period of months in all 
five subjects. In each of the subjects, urinary excretion rates peaked about 6-8 mo after 
the incident and then declined with a half-time of about 8 mo.  It belatedly became 
apparent that intake limits had been exceeded in some workers. 
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Table 3.4.  Comparison of effective dose estimates derived with 
Type M or Type S parameter values with estimates derived 
from UAlx - specific parameter values developed by ORNLa 
Ratio of estimates of effective dose Day of urine 
measurement Type M : ORNL Type S : ORNL 
7 0.014 1.5 
15 0.027 2.9 
30 0.059 6.6 
90 0.20 19 
aBased on a single urinary U measurement made on the 
indicated day after acute inhalation of UAlx by a worker 
 
 
In addition, on the basis of a study of the fate of inhaled 238PuO2 in beagle dogs, 
Mewhinney and Diel (1983) concluded that eventual fragmentation of 238PuO2 particles 
deposited in the lung leads to enhanced dissolution, translocation and excretion of 238Pu 
compared with 239PuO2 as measured in previous studies.  Mewhinney and Diel listed 
several inferences that may be drawn from their results in evaluations of cases of human 
inhalation of 238PuO2:  (1) During the first 2-3 months after exposure the behavior of 
inhaled 238PuO2 in the lungs is expected to be similar to the reasonably well established 
behavior of inhaled 239PuO2. (2) At roughly 100 d after exposure, the dissolution rate of 
238PuO2 may start to increase substantially, leading to rapid decrease of the lung burden 
and a concurrent increase in urinary excretion of 238Pu. (3) Increased bioassay sampling 
may be appropriate during this period. (4) Depending on the level of urinary 238Pu, 
chelation therapy might be initiated after about 100 d and continued for several hundred 
days to reduce uptake and retention of 238Pu in the liver and skeleton. (5) Translocation of 
238Pu from the lungs and tracheobronchial lymph nodes may alter interpretation of data 
from in vivo chest counting.  
 
The cases of human exposure to UAlx and 238PuO2 and the study of inhaled 238PuO2 in 
dogs illustrate the potential error in the HRTM default assumption of a monotonically 
declining rate of absorption of material from the respiratory tract. The study on dogs also 
illustrates the value of animal studies in illuminating the processes controlling the 
biokinetics of a radionuclide in the body. Such information is required for development 
of process models that reflect interactions of the physiochemical forms of the 
radionuclides on biokinetics.  Taking this information into account is an important step 
toward reducing potential errors associated with predictions of the biokinetics of a 
radionuclide in the body.  
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4.  GASTROINTESTINAL TRACT MODEL:  UNDERLYING DATA AND 
INITIAL ASSESSMENTS OF VARIABILITY AND UNCERTAINTY 
 
This section addresses data and methods used by the ICRP to model the biokinetics of 
radionuclides in the gastrointestinal tract and resulting doses to tissues of the tract. The 
gastrointestinal model used by the ICRP since the late 1970s is described briefly. A new 
“alimentary tract model” (i.e., including all segments of the alimentary tract) to be used 
in future ICRP documents is described in greater detail. The basis for the new alimentary 
tract model is discussed, uncertainties in model components and predictions are 
examined, and variability in rates of transfer of material through different segments of the 
tract is assessed on the basis of published measurements. 
 
4.1. The ICRP’s gastrointestinal tract model used to derive current dose coefficients 
 
The gastrointestinal (GI) transit model used in the derivation of current ICRP dose 
coefficients (Figure 4.1) was adopted by the ICRP in Publication 30 (ICRP, 1979).  That 
model was developed to calculate doses from occupational exposure. It divides the GI 
tract into four segments or compartments:  stomach (St), small intestine (SI), upper large 
intestine (ULI), and lower large intestine (LLI), and depicts first-order transfer of 
material from one segment to the next.  Material is assumed to transfer from St to SI at 
the fractional rate of 24 d-1, from SI to ULI at 6 d-1, from ULI to LLI at 1.8 d-1, and from 
LLI to Feces at 1 d-1.  With a few exceptions, absorption is assumed to occur only from 
SI. 
 
 
 
Figure 4.1.  Structure of the gastrointestinal tract model used by the ICRP since the 
late 1970s (ICRP, 1979)  
 
 32
 
4.2. The ICRP’s updated GI tract model 
 
An updated model of the GI tract, called the Human Alimentary Tract Model (HATM), 
has just been completed by an ICRP task group and adopted by the ICRP.  The structure 
of the HATM is shown in Figure 4.2.  The HATM involves greater detail and 
physiological realism than the ICRP’s longstanding GI model but is less complicated than 
it may at first appear.  The organs and fluids represented in Figure 4.2 by dashed boxes 
are not part of the HATM but are included in the schematic to show connections between 
the GI model and the respiratory tract model or systemic biokinetic models.  Also, many 
of the compartments and directions of movement of activity were included to address 
special situations and would not be used in standard applications. 
 
   
 
 
 
 
 
Figure 4.2.  Structure of the HATM (dashed boxes included to show connections between 
the HATM and the respiratory model or systemic biokinetic models) 
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In its entirety, the HATM depicts the following processes: 
1. entry of a radionuclide into the oral cavity by ingestion or into the esophagus after 
mechanical clearance from the respiratory tract; 
2.  sequential transfer through the contents of the oral cavity, esophagus, stomach, 
small intestine, and segments of the colon, followed by emptying in feces; 
3.  radionuclide deposition and retention on or between teeth and return to the oral 
cavity; deposition and retention in oral mucosa or stomach and intestinal walls; 
4.  transfer from the oral mucosa or walls of the stomach and intestines back into the 
lumenal contents or into blood (absorption); 
5.  transfer from various secretory organs or blood into the contents of certain segments 
of the gastrointestinal tract (secretion). 
 
The HATM divides the colon into the right colon, left colon, and rectosigmoid. The right 
colon is defined as the cecum, ascending colon, and proximal half of the transverse colon; 
the left colon is the distal half of the transverse colon plus the descending colon; and the 
rectosigmoid is the sigmoid colon plus the rectum. This division is often used for 
diagnostic and experimental examinations of colonic transit, and considerable 
information is available on transit times through each of these three segments. 
 
First-order kinetics is assumed.  This is a considerable simplification of transfer kinetics 
through the GI tract that obviously does not match the actual discontinuous pattern of 
fecal excretion of swallowed activity.  As discussed later, however, this simplification of 
the actual kinetics of material in the GI tract does not appear to be a source of major 
errors in dose estimates for the segments of the tract considered in the HATM. 
 
For computational purposes, each parameter value of the model is represented by a 
transfer coefficient, also called a rate coefficient or rate constant.  A transfer coefficient 
describes the rate of outflow of a substance from a compartment and is defined as the 
instantaneous fraction of the contained substance leaving the compartment per unit time.   
 
Application of the model to specific radionuclides requires both generic parameter values 
and element-specific values.  The generic parameter values are those describing bulk 
flow of material through the lumen of the gastrointestinal tract and are provided in the 
HATM report. Element-specific parameter values are those describing retention in tissues 
of the gastrointestinal tract, the rate and location(s) of absorption to blood, and secretion 
from systemic organs or blood into the lumen of tract.  Recommended baseline parameter 
values for individual elements will be provided in ICRP documents in which the HATM 
is applied.  In some applications it may be feasible to replace generic or element-specific 
parameter values to reflect case-specific information. 
 
An element-specific transfer coefficient is assumed to be zero if information is not 
available to support and select a non-zero transfer.  As a minimum, information generally 
is available to derive non-zero transfer coefficients describing total absorption to blood. 
In the common situation in which absorption is assumed to occur only in the small 
intestine and there is assumed to be no retention in the wall of the small intestine, the 
parameters can be calculated from an assumed absorption fraction in the same way as in 
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current ICRP documents. The HATM report gives examples of elements for which there 
is known to be absorption in segments of the tract other than the small intestine or 
retention or secretion in some segments of the tract. 
 
The HATM report provides baseline regional transit times (Table 4.1).  These are central 
estimates, usually mean values, derived from collected age- and gender-specific data for a 
given type of material (e.g., solids, liquids, caloric liquids, or non-caloric liquids). 
 
Transit of material through each of the major segments of the tract shows considerable 
inter- and intra-subject variability even under normal conditions.  Large deviations from 
the norm may result from such factors as unusual diet, constipation, diarrhea, 
pharmaceuticals, physical activity, stress, and a variety of diseases that affect the nervous 
system or increase energy requirements. This means that the default transit times given in 
the HATM document may not be appropriate for specific applications, such as 
interpretation of fecal monitoring results following accidental exposure. 
 
Table 4.1. HATM default transit times for luminal contents of the regions of the 
gastrointestinal tract 
Age group  
Segment and material  
Newborn 
 
1 y 
 
5-15 y 
 
Adult 
males 
 
Adult 
females 
 
Mouth 
    Solids 
    Liquids 
    Total diet 
 
 
-- 
2 s 
2 s 
 
 
15 s 
2 s 
12 s 
 
 
15 s 
2 s 
12 s 
 
 
15 s 
2 s 
12 s 
 
 
15 s 
2 s 
12 s 
 
Esophagus-fast (90%) 
      Solids 
      Liquids 
      Total diet 
Esophagus-residual (10%) 
      Solids 
      Liquids 
      Total diet 
 
 
-- 
4 s 
4 s 
 
-- 
30 s 
30 s 
 
 
8 s 
5 s 
7 s 
 
45 s 
30 s 
40 s 
 
 
8 s 
5 s 
7 s 
 
45 s 
30 s 
40 s 
 
 
8 s 
5 s 
7 s 
 
45 s 
30 s 
40 s 
 
 
8 s 
5 s 
7 s 
 
45 s 
30 s 
40 s 
 
Stomach 
    Solids 
    Liquids: caloric 
    Liquids: non-caloric 
    Total diet 
 
 
-- 
75 m 
10 m 
75 m 
 
 
75 m 
45 m 
30 m 
70 m 
 
 
75 m 
45 m 
30 m 
70 m 
 
 
75 m 
45 m 
30 m 
70 m 
 
 
105 m 
60 m 
30 m 
95 m 
 
Small intestinea 
 
4 h 
 
4 h 
 
4 h 
 
4 h 
 
4 h 
 
Right colona 
 
8 h 
 
10 h 
 
11 h 
 
12 h 
 
16 h 
 
Left colona 
 
8 h 
 
10 h 
 
11 h 
 
12 h 
 
16 h 
 
Rectosigmoida 
 
12 h 
 
12 h 
 
12 h 
 
12 h 
 
16 h 
aIntestinal transit times apply to all material 
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4.3. Summary of the database on transit times 
 
4.3.1. Sources of information  
 
The following summary of information on the rate of transit of material through the 
gastrointestinal tract is a condensation of a chapter and an annex prepared by one of the 
authors (Leggett) for the HATM report. The extensive bibliography of sources of 
information used to determine reference values is available from the authors. 
 
4.3.2. Oral cavity 
 
The oral cavity was included in the HATM for consideration of special cases, such as 
ingestion of radionuclides that tend to deposit on the teeth or between the teeth and gums, 
or ingestion of ultra-short-lived radionuclides.  Typical transit times of radionuclides in 
the mouth are of little importance for most applications of the model.  
 
The length of time that different foods are held in the mouth has been measured in many 
human subjects, but the data are difficult to interpret in terms of a mean transit time.  The 
time between intake and swallowing of a liquid usually is about 1-3 s, but liquids with a 
pleasing or interesting taste are sometimes held longer.  The time that food is held in the 
mouth varies from a few seconds to 30 seconds or more, depending on age, the 
composition and texture of the food, the level of hunger, personal habits, customs, and 
other factors (Figure 4.3). 
 
Figure 4.3.  Effects of age and food type on residence times in the mouth 
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4.3.3. Esophagus 
 
When material is swallowed, a coordinated and sequential set of peristaltic contractions 
produces a zone of pressure that moves down the esophagus with the bolus in front of it.  
As the bolus approaches the lower esophageal sphincter, the sphincter relaxes, allowing 
the bolus to enter the stomach.  The rate of movement of a bolus varies with its 
composition and location within the esophagus and the position of the body.  Velocities 
ranging from about 40 cm/sec to about 1 cm/sec have been reported for different 
segments of the esophagus and different conditions.  Because many people suffer from 
abnormalities in esophageal transit of swallowed food related either to peristaltic 
contractions or the esophageal sphincter, the rate of movement of different materials 
through the esophagus has been investigated in numerous studies involving unhealthy 
persons and control subjects.   
 
In the HATM, esophageal transit is assumed to have two components, one representing 
relatively fast transfer of most of the swallowed amount and one representing relatively 
slow transfer of a small fraction of residual material. Mucus and associated material 
escalated from the respiratory tract enter the esophagus via the oropharynx.  It is assumed 
that the slow esophageal transit times for the second component of ingested material 
apply to the transit of all material escalated from the respiratory tract. 
 
For normal subjects, transit times for liquids are generally in the range 3-12 s for the fast 
component. Esophageal transit of solids varies considerably with the composition of the 
ingested material and the amount of fluid ingested with the solid.  Transit is particularly 
slow for relatively dry, non-viscous solids.  The portion of swallowed material remaining 
after the initial peristaltic wave and the time that the residual material remains in the 
esophagus are both highly variable.  Measurements involving liquids or semi-solids 
swallowed by supine or sitting subjects suggest that, on average, residual material may 
represent about 8-10% of the swallowed amount.  Residual material usually is cleared 
completely within 30-45 sec and often within a much shorter time, but capsules or solid 
food ingested without water may remain in the esophagus for several minutes or even 
hours.  Transit times are increased by cold fluids and decreased by warm fluids. 
Esophageal transit is faster in the upright than the supine position, particularly for solids.  
Changes with age in esophageal transit in healthy persons appear to be modest. 
 
Esophageal transit can be seriously affected by a hiatal hernia, esophageal reflux, 
esophageal spasm, and esophageal diverticulosis.  Transit is particularly slow in persons 
with achalasia, a condition in which the lower esophageal sphincter fails to relax during 
the swallowing mechanism.  In achalasia, the residual component often represents half or 
more of the swallowed material. When achalasia becomes severe, the esophagus may not 
empty swallowed food for many hours. 
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Figure 4.4.  Differences with age, food type, and body position in transit times through the 
lumen of the esophagus, excluding a “slow component” representing a few percent of 
swallowed material that may reside in the esophagus for periods from about 30 s to a few 
hours (vertical lines represent the range of observed values for the fast component) 
 
4.3.4. Stomach 
 
The kinetics of gastric emptying is affected by a variety of factors, including composition 
of the ingested material, gender, and age.  Typically, liquids are emptied from the 
stomach faster than digestible solids, and digestible solids are emptied faster than 
nondigestible solids.  Gastric emptying of liquids usually begins within 1-3 min of their 
arrival in the stomach and can be described reasonably well by a mono-exponential 
function, although a lag-phase of several minutes has been reported for liquids of high 
caloric density.  Removal of the solid component typically consists of an initial lag-phase 
of several minutes in which there is relatively slow emptying, followed by an extended 
phase of nearly linear emptying. Nondigestible solids are retained in the stomach until the 
digestible solids have been evacuated. During the latter stages of gastric emptying, a 
series of migrating motor complexes occurring at regular intervals move distally through 
the stomach, effectively sweeping the nondigestible solids into the small intestine.  
Normally, food is largely removed from the stomach in 2-3 h and completely removed in 
5 h, but the emptying time can be affected by alcohol consumption or other factors. 
 
The rate of emptying of material from the stomach is often reported as a half-emptying 
time, which refers to the time required for 50% of the ingested material to be removed 
from the stomach.  Reported central estimates of half-emptying times for solids, all 
liquids, and non-caloric liquids are summarized in Figure 4.5.  The data points indicated 
as “All liquids” represent primarily measurements of caloric liquids but also include 
collected data for non-caloric and unspecified liquids. 
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Figure 4.5.  Comparison of reported gastric half-emptying times for solids, a variety of test 
liquids, and non-caloric liquids in healthy adults (circles represent reported central values, 
usually means, for different study groups)  
 
 
For healthy adult subjects, reported central values for observed gastric half-emptying 
times range from 40 to 160 min for solids and from 8 to 107 min for liquids.  The means 
and standard deviations of the collected central values are 91 ± 30 min for solids and 36 ± 
22 min for liquids.  
 
Reported gastric half-emptying times for meals in infants vary with the type of milk 
ingested, the maturity of the infant, and the measurement technique.  Reported values 
range from 15 to 100 min and average about 50-55 min. Estimated half-emptying times 
of water in healthy infants average about 6 min.  Reported gastric emptying times for 
toddlers, young children, and adolescents generally are within the range of values 
determined for adults.  Gastric emptying appears to be slower in elderly persons than in 
young and middle-aged adults, but this has not been firmly established. 
The rate of gastric emptying of ingested material depends strongly on its composition and 
the level of nutrients in the jejunum.  The emptying time increases nearly linearly with 
the caloric content of the meal and also is increased substantially by fat. 
 
The emptying time of either solids or caloric liquids is substantially greater on average in 
women than in men (Figure 4.6).  Based on various measures of central tendency 
including the median, mean, and weighted mean (i.e., weighted by the number of subjects 
in a study), a typical or central half-emptying time for solids is about 75-80 min in adult 
males and 100-110 min in adult females.  For caloric liquids, a typical half-emptying time 
is 30-35 min in males and 40-45 min in females.  For non-caloric liquids, a typical half-
emptying time for either gender may be about 20-25 min.  Differences with gender in 
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gastric emptying appear to diminish with aging due to an increase in the emptying rate in 
females, perhaps beginning after menopause. 
 
Figure 4.6.  Comparison of gastric half-emptying times of solids in adult male and female 
subjects in nine studies 
 
 
Gastric emptying times are altered by a number of diseases, including several diseases 
that affect the nervous system or alter energy requirements. Substantially altered rates are 
seen in cirrhosis and hypothyroidism. Emptying rates are not consistently increased or 
decreased in diabetics but appear to be considerably more variable in diabetics than in 
control subjects.  The gastric emptying rate is altered by some pharmaceuticals. 
 
4.3.5. Small intestine 
 
Movement of material through the small intestine appears to be a nearly linear process. 
Measured transfer rates through the small intestine generally are reported as transit times. 
 
The ileum, the distal part of the small intestine, acts as a reservoir and transfers boluses of 
variable sizes into the colon.  Intake of a subsequent meal may stimulate transfer into the 
colon, but this appears to depend on the composition of the material in the ileum.  Some 
studies suggest faster transfer of liquids than solids in the small intestine, while others 
indicate that liquids and solids transit the small bowel together, which is assumed in the 
present model. Fat in the small intestine induces faster transit than proteins but delays 
ileocolonic transit.  Ingestion of oleic acid appears to slow the transit of material through 
the small intestine. 
 
The transit time through the small intestine shows some variation with contents or other 
factors but appears to be much less variable than transit through the stomach or colon. 
Most reported values based on currently favored techniques (e.g., excluding estimates 
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based on the frequently applied hydrogen breath test, which are regarded by many 
investigators as unreliable) fall in the relatively narrow range of 3-4 h.  The range of 
reported central estimates is 1.8-8 h and the mean ± standard deviation is 3.9 ± 1.5 h 
(Figure 4.7).  Limited comparisons of small intestinal transit in adult males and females 
and in adults and children have not revealed significant differences with gender or age in 
the rate of transit of material through the small intestine. 
 
The rate of movement of material through the small intestine may be increased by 
diarrhea and decreased by constipation but appears from limited information to be much 
less affected by either condition than is the rate movement through the large intestine. 
The transit time through the small intestine appears to be altered by some 
pharmaceuticals.  Limited data suggest that the transit time through the small intestine 
may be reduced by stress and physical exercise and increased during pregnancy. 
 
 
Figure 4.7.  Reported small intestinal transit times in subjects without gastrointestinal 
disorders (circles represent central values determined in separate studies, and the bar 
represents the mean of these values) 
 
 
4.3.6. Colon and rectum 
 
Flow of material in the colon is slow and highly variable.  Periods of contraction between 
longer periods of quiescence result in mass movements of colonic material a few times 
during the day.  Fluids may move ahead of solids in the proximal right colon, but solids 
and fluids appear to move together throughout most of the colon. 
 
The rectum serves mainly as a conduit but can also serve as a storage organ. Entry of 
material from the sigmoid colon usually evokes the recto-anal inhibitory reflex, signaling 
the need to defecate.  The rectum serves as a storage organ when the amount of material 
received from the sigmoid colon is too small to evoke this reflex or when this reflex is 
 41
 
neglected.  The average residence time of material in the rectum cannot be estimated with 
much confidence. 
 
Reported central transit times through the total colon vary by about a factor of 4 (range, 
17-68 h) but are typically in the range 24-48 h.  On average, transit times are 30-40% 
greater in adult females than in adult males and appear to be greater in adult males than in 
children.  Figure 4.8 summarizes reported mean transit times through the total colon in 
men, women, and children. 
 
Figure 4.8.  Ranges (vertical bars) and overall means (circles) of reported colonic transit 
times for normal children, adult males, and adult females 
 
Reported central values for transit times in different portions of the colon are summarized 
in Figure 4.9.  Measurements of segmental transit times in relatively large study groups 
indicate upper 95% values of roughly 24 h for the right colon, 36 h for the left colon, and 
40 h for the rectosigmoid.  Average oro-rectal transit times, expected to represent 
primarily colonic transit, vary substantially from one region of the world to another, 
presumably due mainly to differences in dietary fiber.  For example, measured oro-rectal 
transit times were longer on average for populations whose diets consisted largely of 
refined, low-fiber foods (means, 48-83 h) than for populations that ate mainly unrefined, 
high-fiber foods (means, 34-36 h) or mixed diets (means, 41-47 h). 
 
Colonic transit times may be decreased by a factor of 3 or more in persons with diarrhea 
and increased by a factor of 3 or more in constipated persons. A number of disease states 
affect colonic transit.  Patients with progressive systemic sclerosis showed an increase in 
the estimated median gastric emptying time and colonic transit time compared with 
control subjects but no abnormality in the small intestine transit time.  Diarrhea and 
decreased gastrointestinal transit times are common manifestations of hyperthyroidism, 
whereas constipation frequently occurs in hypothyroidism.  The transit time through the 
colon may be altered substantially by drugs.  
 
 42
 
  
Figure 4.9. Summary of reported transit times in right colon, left colon, and rectosigmoid in 
normal human subjects (diamonds, children; triangles, adult males; plus signs, adult 
females; circles, data for adults not separated by gender or of unspecified gender) 
 
 
4.4. Contents of segments of the tract and fecal excretion rates 
 
Development of the HATM was coordinated with the revision (ICRP Publication 89, 
2002b) of the ICRP’s Reference Man (ICRP Publication 23, 1975). The ICRP’s Task 
Group on Reference Man reviewed data on anatomical and physiological features of the 
alimentary tract and selected reference values for those features, which were carried over 
to the HATM.  These features included the contents of the stomach and different 
segments of the intestines, and the mass of feces excreted per day.  Reference values for 
these features are listed in Table 4.2. 
 
 
Table 4.2. Reference values for contents of segments of the alimentary tract and daily fecal 
excretion (g) (ICRP Publication 89, 2002b) 
Age Total Stomach 
Small 
intestine 
Right 
colon 
Left 
colon 
Recto-
sigmoid 
Daily 
feces 
Newborn 144 40 56 24 12 12 24 
1 y 240 67 93 40 20 20 40 
5 y 300 83 117 50 25 25 50 
10 y 420 117 163 70 35 35 70 
15 y male 720 200 280 120 60 60 120 
15 y female 720 200 280 120 60 60 120 
Adult male 900 250 350 150 75 75 150 
Adult female 830 230 280 160 80 80 120 
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4.5. Basis for the dosimetric model of the human alimentary tract 
 
4.5.1. Limitations of the GI tract model of ICRP Publication 30 
 
The dosimetric aspects of the HATM represent an important departure from the approach 
taken by the ICRP in the current GI tract model (ICRP, 1979).  In the case of beta 
radiation, it is assumed in the current model that the dose to the wall of the tract is 
equivalent to the dose at the surface of the contents.  For beta particles of low energy this 
approach overestimates the dose to the wall and to the cells associated with maintaining 
the epithelial lining of the wall.  For alpha radiations the dose to the wall has been taken 
as 1% of the dose at the surface of the contents.  This value is not based on calculations 
of energy deposition but has been applied as a cautious assumption.  As judged from 
limited studies on laboratory animals, it is expected to overestimate dose to sensitive cells 
in the walls of the gastrointestinal tract. 
 
4.5.2. A more direct approach taken in the HATM 
 
With the main exception that the gross morphometry of the GI tract is still represented as 
a set of idealized geometric figures, an attempt is made in the HATM to address these 
dosimetric limitations of the GI tract model of ICRP Publication 30.  For example, 
retention of radionuclides in the walls can be specified when information is available 
(Figure 
 4.2), and the location of sensitive cells of different regions of the GI tract is modeled 
explicitly (Table 4.3). The summary of information for the small intestine given below 
illustrates the dosimetric approach used in the HATM. 
 
 
Table 4.3. Target cell depths and masses for regions of the 
HATM for adult males 
Region Target cell depth 
(μm) 
Target cell mass 
(g) 
Oral cavity 190-200 0.23 
Esophagus 190-200 0.091 
Stomach 60-100 0.62 
Small intestine 130-150 3.6 
Right colon 280-300 1.3 
Left colon 280-300 1.2 
Recto-sigmoid 280-300 0.73 
 
4.5.3. Illustration of dosimetric data and assumptions: Small intestine 
 
The small intestine is used to illustrate the HATM approach for estimating dose to the 
walls of the intestines from non-penetrating radiations originating in the contents or 
emitted by radionuclides retained in the walls after uptake from the lumen.   
 
The small intestine is represented as a right circular cylinder. The source within this 
cylinder is assumed to be uniformly distributed in water that fills the cylinder. Tissue 
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comprising the walls of the small intestine is assumed to have a density of 1 g cm-3 and 
the composition of soft tissue defined by the ICRU (1989). 
 
The values for the physiological length of the small intestine are as given in Publication 
89 (ICRP, 2002b).  Measurements of physiological length are available for newborn 
infants (~80 cm) and adult males (~280 cm), and the central estimates of the length of the 
small intestine were approximately 1.6 times body height for both ages.  For purposes of 
developing reference values for physiological length of the small intestine, the authors of 
ICRP Publication 89 assumed the relation holds for ages 1-15 y and for adult females. 
 
The diameter of the lumen of the small intestine changes with age and varies with 
location within the intestine.  Reported data for newborn infants and adults were used to 
estimate average diameters at each age, assuming that reported values apply to the entire 
length of the small intestine. For intermediate ages these values were interpolated with 
average height. Derived values are 1, 1.2, 1.4, 1.6, 2, and 2 cm for infants and ages 1, 5, 
10, and 15 y, and adult, respectively. 
 
The lining of the small intestine possesses gross and microscopic structures for increasing 
the surface area available for digestive and absorptive processes.  The surface is covered 
with numerous projections, the villi, which serve as absorptive units and which are 
unique to this segment of the alimentary tract.  At their bases are simple tubular 
invaginations, called crypts of Lieberkühn, that extend to the muscularis mucosae but do 
not penetrate it.  The villi have a single columnar epithelial cover and a core of highly 
cellular reticular connective tissue.  The villi vary in height and form in different regions 
of the human small intestine.  In the HATM, the villus height is taken to be 500 μm for 
age 10 y or greater and 400 μm for younger children, based on ultrastructural studies. 
 
The epithelial stem cells responsible for continuous renewal of the epithelial layer are 
located towards the base of the crypts, immediately above a group of secretory cells, 
called Paneth cells, at the base of the crypts. Reported measurements of the depth from 
the intercryptal plate to the top of the Paneth cell zone are 144 ± 8 μm based on data for 
three adults. The target layer is taken to be 3 cells deep, assumed to be at a depth of 130 –
150 μm from the intercryptal plate.  This depth is assumed to apply at all ages, although 
there is evidence that crypts are somewhat longer in young children.  
 
The geometric model used to estimate energy deposition in sensitive regions of the walls 
of the intestines from emissions in the lumenal contents is shown in Figure 4.10.  Target 
cells are assumed to form a continuous layer at a defined depth from the lumenal surface. 
In the case of the small intestine, the target cells in the epithelial lining are assumed to 
extend from 130 to 150 µm below the intercryptal plate. Absorbed fractions of emitted 
energies for non-penetrating radiations from radionuclides in the lumenal contents are 
based on the assumption that activity is uniformly distributed throughout the contents of a 
cylinder. The presence of the villi along the small intestine wall is ignored.  This is 
considered to be a reasonable assumption because gut contents penetrate between the villi 
as far as the intercryptal plate.  It is assumed that gut contents do not penetrate into the 
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crypts against the flow of secretions from crypt cells.  The presence of mucus on the 
lumenal surface is ignored. 
 
In considering retention of radionuclides in the wall of the small intestine, the general 
assumption is made in the HATM that retention is confined to the absorptive region of 
the villi.  This is modeled as a uniform layer of tissue above the intercryptal plate, 500 
μm thick in adults and children of 10 years and older and 400 μm thick in younger 
children.  Thus, the spaces between villi, occupied by gut contents, are ignored for this 
purpose.  In a limited number of cases, information may be available suggesting retention 
in deeper mucosal tissues, within the lamina propria between crypts.  To model retention 
in the wall of the small intestine, other than retention in villi, uniform distribution 
throughout the region of the mucosa beneath the villi is assumed, to a depth of 200 μm 
(base of crypts).   
 
 
 
Figure 4.10.  Schematic of the geometric model used to estimate energy deposition 
in radiosensitive cells in the walls of tubular regions of the alimentary tract, from 
decay of radionuclides in the lumen (presence of mucus on the lumenal surface is 
ignored; target cells assumed to form a continuous layer at a defined depth from 
the lumenal surface)  
 
 
4.5.4. Systemic activity in the walls of the GI tract  
 
Most of the ICRP’s systemic biokinetic models include compartments with names such 
as “other tissues” or “other soft tissues” that represent retained activity not accounted for 
in explicitly identified tissues and fluids.  The walls of the HATM regions are included as 
these non-explicit source regions, taking account of normal processes of circulation and 
distribution of systemic activity. Thus, the target regions of the HATM can receive doses 
from this activity as well as from activity in the contents of the lumen or retained in the 
walls during absorption. For non-penetrating radiation, including electrons and alpha 
particles, all tissues that constitute “other tissues” are assigned the same dose.  This dose 
estimate is applied to the all target regions of the HATM.  Systemic activity often 
contributes the main component of dose, particularly for compartments of relatively rapid 
transit, such as the mouth and esophagus, and for radionuclides with tenacious retention 
in soft tissues. 
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4.5.5. Implications of the HATM for alpha emitters 
 
When target cells are situated at a depth of greater than around 40 or 50 μm in the wall, 
alpha particles emitted by important radionuclides cannot penetrate the wall to the depth 
of the target region.  Thus, the dose to sensitive cells of the GI tract wall from alpha 
emissions in the contents is now estimated to be zero due to the depth of the target cells 
in relation to the range of an alpha particle in tissue.  
 
In the simple geometric model of the stomach, some energetic alpha particles could 
penetrate to the target region (60 – 100 μm). However, there is a layer of mucus on the 
lumenal surface of the stomach that is roughly 20 μm thick, so that it seems reasonable to 
assume that alpha particles emitted in the stomach do not reach the sensitive cells.  
 
4.6. Expert judgments of potential errors in HATM features and predictions 
 
4.6.1. The group of experts 
 
The HATM report discusses sources of error in the model as assessed by the ICRP task 
group that developed the model.  The method of assessment by the task group is 
essentially expert judgment, considering the underlying information and, where 
applicable, the sensitivity of predictions to alternate plausible approaches or parameter 
values.  The conclusions of the task group regarding some of the major sources of 
potential error in the HATM and the sensitivity of model predictions to those potential 
errors are summarized below.  
 
4.6.2. Potential errors associated with limitations in model structure 
 
Two main sources of potential error in the HATM associated with model structure are 
discussed in the HATM document:  the division of the alimentary tract into 
compartments, and the use of first-order kinetics to describe transfer of material. 
 
Except for the division of the colon, the compartments used to describe transfer of 
material through the lumen of the alimentary tract represent anatomically and 
functionally distinct regions of the tract.  The colon has been divided in a number of 
different ways in different radiation protection models. The model of ICRP Publication 
30 (1979) divides the colon into the upper large intestine (ULI) and the lower large 
intestine (LLI), where the ULI includes the ascending and transverse colons and the LLI 
includes the descending colon, sigmoid colon, and rectum.  A model developed for use in 
nuclear medicine (NCRP, 1998) divides the colon into the ascending colon, transverse 
colon, and descending colon plus rectosigmoid.  The HATM divides the colon into the 
right colon, left colon, and rectosigmoid, a division often used for diagnostic and 
experimental examinations of colonic transit.  The HATM Task Group concluded that 
use of this division would allow best estimates of the time-dependent distribution of 
ingested, inhaled, or secreted activity in the colon, based on modern data. 
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The HATM Task Group considered whether the rectum should be represented as a 
separate compartment, since it is commonly assumed to function mainly as conduit rather 
than a storage organ. Information found in the literature indicated, however, that the 
rectum can serve for extended periods as a storage organ and in some cases could contain 
a substantial portion of the total activity in the alimentary tract. In view of such findings, 
and because of the difficulties in determining a meaningful transit time separately for the 
rectum, the Task Group concluded that the rectum should not be treated as a separate 
compartment. 
 
Representation of movement of material through the lumen of the alimentary tract as a 
series of first-order transfers between well-mixed pools is a considerable simplification of 
real events. For example, studies indicate that material traverses the human small 
intestine in a more or less linear fashion and is transferred to the ascending colon in 
multi-bolus form. Flow of material in the rectosigmoid region of the colon is slow, 
variable, and intermittent, with periods of contraction between longer periods of 
quiescence resulting in mass movements of material a few times during the day. 
 
The assumption of first-order kinetics is made for computational convenience.  The 
emptying half-time for a segment of the tract is set to reproduce central estimates of 
reported mean transit times of material through that segment, in the absence of 
radioactive decay.  For relatively short-lived radionuclides, first-order kinetics can 
overestimate decays in the lower regions of the tract because it implies an immediate 
appearance of some ingested atoms in all regions of the tract. For example, few if any 
atoms of an ingested radionuclide with half-life ≤ 20 min are expected to reach the colon, 
but the HATM predicts on the basis of first-order kinetics that about 3% of the total 
decays in the alimentary tract would occur in the colon. 
 
The HATM or any other first-order gastrointestinal model will not yield meaningful 
predictions of the fecal excretion rate during the early hours after intake. For the case of 
ingestion of a radionuclide by an adult male, the HATM predicts that, in the absence of 
absorption to blood, total fecal excretion is about 3% of the ingested amount after 12 h. 
Studies indicate that the time to first appearance of ingested markers in feces of healthy 
adults is more than 12 h in most cases. 
 
The HATM predicts that total fecal excretion of an unabsorbable marker would be about 
22% of the ingested amount after 1 d, 69% after 2 d, 91% after 3 d, 98% after 4 d, and 
>99.5% after 5 d.  These predictions are broadly consistent with reported data for markers 
used in experimental studies (e.g., carmen red) and within the range of data from 
accidental intakes of radionuclides, although it appears that fecal excretion often is more 
nearly complete after about 3 d than the model predicts.  It can be misleading to check the 
model against small numbers of individual cases due to substantial inter- and intra-
subjects variability in the transit time. In some individual cases, nearly all the swallowed 
amount appears in feces during the first day. In other cases, a few days may elapse before 
there is any appreciable fecal excretion of ingested material. 
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4.6.3. Potential errors in transit times 
 
In the years since the development of the Publication 30 model (ICRP, 1979), numerous 
investigations of the kinetics of material in the gastrointestinal tract have been conducted 
by improved, non-invasive techniques such as external viewing of radio-labeled foods, 
liquids, or indigestible substances. While the uncertainties associated with measurement 
techniques have been substantially reduced, the difficulties involved in determining true 
transit times should not be underestimated.  For example, the physical characteristics of 
markers used in modern studies may affect colonic transit times.  Also, some methods 
still in common use, such as the hydrogen breath test used to estimate transit through the 
small intestine, do not appear to provide representative or reproducible results.  
 
Uncertainties also are inherent in the assumptions and algorithms used to translate 
measurements into estimates of the mean transit time.  For example, measurements of 
colonic transit frequently are based on counts of ingested radio-opaque markers in the 
regions of interest.  Some investigators have argued that this technique may substantially 
underestimate actual transit times in many cases because the experimental methods may 
not closely approximate the underlying assumptions of continuous ingestion of markers 
and attainment of steady-state by the time of counting.  The extent of underestimate may 
vary considerably from one study to another due to differences in numbers and patterns 
of administration of the marker and times of measurement. 
 
Considering the limitations of measurement techniques and reported average residence 
times in different segments of the alimentary tract in healthy individuals, the HATM Task 
Group made judgments concerning the potential error in the transit time of material in 
major segments of the tract in the adult male.  The transit time of material in the 
esophagus was judged to be known with a factor of 2 (UF = 2; see definition of UF in 
Section 2). The transit time of material in the stomach, small intestine, right colon, left 
colon, or rectosigmoid colon in the adult male was judged to be known within a factor of 
about 1.5 (UF=1.5). 
 
Based on the UFs for transit times, effective dose coefficients and equivalent dose 
coefficients to the colon were calculated for ingestion of 90Sr, 106Ru and 239Pu by adult 
males.  In the cases of 90Sr and 106Ru the resulting UFs for colon dose were 1.5 and 1.4 
respectively, which are nearly the same as that for transit time, reflecting their close 
association. For 239Pu, colon dose arises solely from activity absorbed to blood, and 
variations in transit time have no effect on colon dose because colon dose arises almost 
entirely from activity absorbed to blood. 
 
For 106Ru the colon dose from activity in the contents makes an important contribution to 
effective dose, and the potential errors in transit times yield a UF for effective dose of 
about 1.2.  For 90Sr and 239Pu, however, colon dose contributes little to the effective dose, 
which is virtually unaffected by potential errors in estimated gastrointestinal transit times. 
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4.6.4. Simplifications of anatomical features of the alimentary tract 
 
The dimensions and geometrical configurations of the structures of the tract were 
formerly estimated from measurements on cadavers, and those estimates often did not 
closely reflect conditions in the living body.  More accurate determination of the 
geometry of the gastrointestinal tract of a living person has become possible with the 
advent of external visualization techniques with high resolution.  Nevertheless, it remains 
difficult to determine typical sizes, shapes, and relative positions of structures of the tract 
with high accuracy due to the considerable variability in these features from one person 
to another and from one body position to another in the same person. 
 
The HATM Task Group assigned UFs of about 1.4 to the dimensions (e.g., length, width, 
or internal diameter of a segment of the intestines) of most structures within the 
alimentary tract.  They noted that UF = 1.4 for the length of a region would lead to the 
same UF for dose to the region from activity in the contents if all other parameters remain 
unchanged but pointed out that the length of a region may be correlated with the transit 
time. For example, an increase in length of a region could lead to an increase in transit 
time by the same factor with the result that the dose is unaltered. This would tend to 
reduce UF for dose to below 1.4.  
 
The HATM Task Group examined the sensitivity of dose from beta emitters in the 
intestinal contents to the uncertainty in the diameter of the intestines.  Strontium-90 
(mean beta energy = 0.20 MeV) and 90Y (mean beta energy = 0.94 MeV) were chosen to 
represent relatively low and relatively high beta energies.  Based on an assigned UF of 
1.4 for the diameter of the intestines, the resulting UF for dose to the wall is about 1.9.  In 
contrast to most parameters, this is a case where UF for the result (dose) is larger than 
that in the parameter (diameter). This is because the UF in the cross-sectional area of the 
section, which is an indicator of the extent of energy absorption within the lumen, is 2 for 
a UF of 1.4 in the diameter. However, such uncertainties in colon dose from 90Sr/90Y will 
have a negligible effect on committed effective dose which is dominated by doses to 
tissues from activity absorbed to blood.  
 
4.6.5. Uncertainties in the location of target regions for cancer induction 
 
Doses may be calculated separately for the mucosal layer of each region of the HATM.  
For penetrating radiations, the average dose to the walls of each region may be used as a 
measure of the dose to the mucosal layer.  For non-penetrating alpha and beta particle 
emissions originating in the contents of the tract, the dose is dependent on assumptions 
regarding the location of target cells for cancer induction.  For each region of the 
alimentary tract, the target is taken to be the stem cells that are located in the basal layer 
of the stratified squamous epithelia of the mouth and esophagus and within the crypts that 
penetrate the mucosal layer in the stomach and small and large intestines. 
 
The HATM Task Group considered potential errors in estimates of dose to the colon due 
to uncertainties in the location of the target cells.  They considered both the uncertainty in 
the depth of the stem cells and the uncertainty as to whether it is only the stem cells that 
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should be regarded as targets. Table 4.4 compares colon doses for different assumptions 
of target location, normalized to the default assumption that the sensitive cells form a 
continuous layer at a depth of 280 – 300 μm from the lumenal surface of the colon. The 
possibility addressed in the last column of Table 4.4, that target cells could be distributed 
over depths from 0-300 μm, is an extreme situation based on observations in human 
subjects of preneoplastic cells on the lumenal surface but not in crypts. 
 
 
Table 4.4. Differences (%) in dose coefficients for the colon, compared to the 
default casea, resulting from considerations of target depth in the mucosa, 
considering ingestion by adult males 
Assumed location of the target region – depth from lumen, μm Nuclide 
220 – 240 340 - 360 200-300 0-300 
Sr-90 7% -6% 5% 21% 
Ru-106 3% -2% 2% 8% 
U-234 0% 0% 0% 148% 
Pu-239 0% 0% 0% 317% 
aDefault case assumes a target depth of 280 – 300 μm 
 
4.6.6. Potential errors in element-specific parameter values of the HATM 
 
The above discussion addresses potential errors associated with generic features of the 
HATM.  Errors in predictions of the HATM also arise from element- or radionuclide-
specific parameter values, such as uptake from the contents of the tract to blood or 
retention in the walls of the tract.  The databases for specific radionuclides are addressed 
in a later section.  Due to the importance of gastrointestinal uptake on doses from intake 
of radionuclides, however, it is worthwhile to summarize the current state of information 
on absorption of essentially all elements as assessed by the HATM Task Group. 
 
The potential error in fractional uptake from the gastrointestinal tract to blood varies 
considerably from one element to another.  In a relative sense, errors in estimated in 
fractional uptake are likely to be smallest for elements that are known to be nearly 
completely absorbed, including hydrogen (as tritium), carbon, sodium, chlorine, 
potassium, bromine, rubidium, molybdenum, iodine, cesium, thallium, fluorine, sulfur, 
and germanium.  A value UF in the range 1.1-1.5 might be appropriate for each of these 
elements, depending on the quality and completeness of the data base for individual 
elements.  Average uptake from the gastrointestinal tract is also reasonably well 
established for several frequently studied elements whose absorption is incomplete but 
represents at least a few percent of intake, such as copper, zinc, magnesium, technetium, 
arsenic, calcium, strontium, barium, radium, lead, iron, manganese, cobalt, and uranium.  
UF for these elements would also vary with the element and generally would be greater 
than 1.5 but no more than about 3.  Relative errors generally are greater for the remaining 
elements due to the sparseness of direct observations on human subjects (e.g. ruthenium, 
silver), inconsistencies in reported absorption fractions (e.g. beryllium, antimony, 
silicon), or absorption too low to be determined with much precision under most 
conditions (e.g. most actinide and lanthanide elements).  Absorption of a few poorly 
absorbed elements such as plutonium, americium, and curium has been studied under 
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controlled conditions in human subjects, and average uptake in the adult may be known 
within a factor of 3 – 4 for these elements.  Relative errors may be greatest for several 
elements whose absorption has not been studied in man but for which animal data or 
other indirect evidence indicates absorption of at most a few hundredths of a percent, 
such as samarium, gadolinium, dysprosium, erbium, thulium, actinium, yttrium, and 
scandium.  Absorption fractions for these elements are order-of-magnitude estimates.  
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5.  DEMONSTRATION OF DIFFERENT LEVELS OF  
KNOWLEDGE OF THE BIOKINETICS AND DOSE PER UNIT 
INTAKE FOR SPECIFIC RADIONUCLIDES 
 
This section demonstrates different levels of information available to estimate tissue 
doses from exposure to different radionuclides, summarizes information on the variability 
of biokinetics and dose per unit intake or exposure in each case, and critically evaluates 
previously published uncertainty assessments on those cases.  Five radionuclides are 
addressed in order of decreasing levels of H1 data (i.e., direct information on their 
behavior in humans):  137Cs, 90Sr, 60Co, 106Ru, and 252Cf.  Discussions of the two extreme 
cases, 137Cs and 252Cf, illustrate how recent critical reviews of the literature have led to 
improved biokinetic models and in turn to reduction in the potential errors associated 
with predictions of models currently used by the ICRP. 
 
5.1. Cesium-137:  Level 1 (Highest level of information) 
 
5.1.1. Overview 
 
Cesium-137 is one of the most extensively studied and best understood radionuclides 
with regard to biological behavior and tissue doses following intake. Cesium is a 
chemical and physiological analogue of the essential element potassium. Most commonly 
encountered forms of cesium are highly soluble and nearly completely absorbed to blood 
from the gastrointestinal or respiratory tract.  Whole-body retention of cesium has been 
studied in numerous human subjects, some exposed to elevated concentrations of 
radiocesium in the environment and others exposed for experimental purposes. Whole-
body retention can be described reasonably well as a sum of two exponential terms, with 
the long-term component representing the preponderance of the systemic deposit.  
Autopsy studies on environmentally exposed humans as well as experimental studies on 
laboratory animals indicate that cesium is somewhat uniformly distributed in the body, 
with skeletal muscle gradually becoming the dominant repository. The half-time of the 
long-term component has been found to vary with age, gender, diet, race, muscle mass, 
pregnancy, and elevation above sea level (Lloyd et al., 1966, 1973; Zundel et al., 1969; 
Leggett, 1986; ICRP, 1989; Leggett et al., 2003).  Cesium-137 is a beta emitter but is 
accompanied by the short-lived daughter 137mBa that emits relatively energetic gamma 
radiation that allows external measurement of internal deposits.  
 
5.1.2. Biokinetics 
 
5.1.2.1. Physiological analogues 
 
Cesium follows the movement of potassium in the body and competes with potassium 
and its chemical analogue rubidium for both active and passive membrane transport 
across cell membranes, but cesium is generally transported less readily than potassium or 
rubidium by these processes.  Quantitative differences in transport rates across 
membranes result in a total-body retention time for cesium about three times greater than 
 53
 
that for potassium and two times greater than that for rubidium. Cesium, potassium, and 
rubidium generally have much higher concentrations inside cells than in extracellular 
fluids, in contrast to the largely extracellular alkali metals, Na and Li (Eisenman, 1963; 
Kernan, 1972; Leggett et al., 2003). 
 
Variability in cesium biokinetics in the population can be explained largely by 
differences in the mass of potassium in the body; the level of the hormone aldosterone in 
blood, which affects release of potassium and cesium from cells and the urinary excretion 
rate of cesium; and the level of potassium in diet (Leggett, 1986).  The latter two factors 
are related, e.g., ingestion of a high-potassium diet increases aldosterone secretion.    
 
5.1.2.2. Behavior in the respiratory tract 
Information on the behavior of cesium in the respiratory tract was reviewed in ICRP 
Publication 71 (ICRP, 1995b) and recently by a task group of the ICRP (to be published in 
an ICRP document).  Data on inhalation of cesium as chloride, nitrate, or sulfate, or as 
residues from a reactor fuel cooling pond indicate relatively rapid and nearly complete 
absorption from the respiratory tract, consistent with highly soluble material. Results of 
in vitro studies of the solubility of irradiated fuel fragments containing radiocesium 
suggest that the material was only moderately soluble.  In animal studies of inhalation of 
cesium incorporated into fused aluminosilicate particles, only a small fraction of material 
was rapidly absorbed from the lungs, and the rest was absorbed at rates consistent with 
moderately soluble or relatively insoluble material, depending on the experiment. No data 
on variability of respiratory kinetics associated with age, gender, or other individual 
characteristics was found. 
 
5.1.2.3. Fractional uptake from the gastrointestinal tract 
 
Information on gastrointestinal uptake of cesium was reviewed by Harrison et al. (2001).  
Human volunteer studies using 137Cs in soluble inorganic form (e.g., as 137CsCl) have 
shown virtually complete absorption (~0.99).  Cesium incorporated into relatively insoluble 
particles is less available for absorption.  For example, absorption of 137Cs from irradiated 
reactor fuel particles was less than 0.1 in rats.  Estimated absorption after ingestion of real 
or simulated fallout by human volunteers has varied from less than 0.1 to nearly complete 
absorption.  Measurements of uptake of 137Cs in human volunteers who ingested meat 
(venison, mutton, caribou) contaminated after the Chernobyl accident have given values in 
the range 0.6 - 0.99.  No data on variability of gastrointestinal absorption of cesium 
associated with age, gender, or other individual characteristics was found.   
 
In ICRP documents, complete absorption of cesium from the gastrointestinal tract is 
assumed, except after transfer of moderately soluble or insoluble cesium from the 
respiratory tract to the gastrointestinal tract.  For Type M, fractional absorption of 0.2 is 
assumed for infants and 0.1 for ages 1 y and greater. For Type S, absorption of 0.02 is 
assumed for infants and 0.01 for ages 1 y and greater. 
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5.1.2.4. Systemic biokinetics  
 
5.1.2.4.1. ICRP model 
 
The ICRP’s current systemic biokinetic model for cesium was originally developed for 
application to workers (ICRP, 1979).  The model does not have a biologically realistic 
structure.  It is essentially a “retention function”, i.e., a sum of exponential terms that 
describe a net rate of movement of absorbed activity from tissues to excretion pathways.  
The implied model structure is shown in Figure 5.1. 
 
 
Figure 5.1.  Structure of ICRP’s current systemic biokinetic model for cesium 
 
Whole-body retention at t days after injection is described by a sum of two exponential 
terms: 
R(t) = a exp(-0.693t/T1) + (1 - a) exp(-0.693t/T2). 
Values a = 0.1, T1 = 2 d, and T2 = 110 d were applied to the worker in Publication 30.  
An age-specific version of the cesium model was adopted in ICRP Publication 56 (1989).  
The parameters a, T1, and T2 were assumed to vary with age, reflecting more rapid 
turnover of cesium in children than in adults.  The parameter values for ages up to 15 y 
were taken from a model of Leggett (1986) with the same formulation and with age- and 
gender-specific parameter values a, T1, and T2 related to total-body potassium for ages 
1 y or greater and based on measured half-times in infants.  For the adult, the parameter 
values used in ICRP Publication 56 (a = 0.1, T1 = 2 d, and T2 = 110 d) were carried over 
from the cesium model in ICRP Publication 30 (1979) but do not differ greatly from the 
parameter values derived for adult males by Leggett (1986).  For all age groups, cesium 
is assumed to be uniformly distributed in the body. 
 
A number of studies of 137Cs retention in human subjects have been published since the 
development of the current ICRP model, and a detailed physiologically based systemic 
biokinetic model for Cs reflecting the current database has been developed (Leggett et al., 
2003).  The model has been tentatively selected by an ICRP task group for use in the 
revision of ICRP dose guidance for workers and will be referred to as the “ICRP’s 
proposed model”. 
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The structure of the proposed model is shown in Figure 5.2.  The model is constructed 
around a blood flow model (data type P) and, in contrast to the two-exponential model for 
cesium currently used by the ICRP, depicts a non-homogeneous distribution of activity 
the body soon after entry into blood.  For derivation of parameter values, information on 
the biokinetics of cesium in the human body (H1) or laboratory animals (A1) was 
supplemented with data on potassium and rubidium and information on patterns of 
discrimination between these three elements by tissues (H2, A2).  As illustrated in Figure 
5.2 for whole-body retention data in adult males, model predictions are consistent with 
the database on the time-dependent distribution and retention of cesium in the human 
body at early, intermediate, and late times after exposure.  The model depicts a small 
component of very long-term retention observed in subjects involved in the accident in 
Goiania, Brazil, and in some animal studies. This component does not represent an 
important contribution to dose per unit intake of radiocesium but can be important with 
regard to interpreting bioassay data collected long after exposure.  The model can be used 
to describe the behavior of cesium during Prussian Blue treatment by reducing or 
eliminating transfer from the gastrointestinal contents back to blood. 
 
 
 
Figure 5.2.  Structure of a physiologically based biokinetic model for Cs in the human body 
(Leggett et al., 2003) (solid arrows represent plasma flow and broken arrows represent flow 
not involving plasma; percentages indicate distribution of cardiac output; numbers beside 
SWEAT, URINE, and FECES are fractions of cumulative excretion) 
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5.1.2.4.2. Database for adult male humans 
 
The biokinetics of cesium in healthy adult males is well understood from experimental 
studies involving human volunteers, follow-up of subjects receiving occupational or 
environmental exposure to 137Cs, and autopsy measurements of the distribution of 137Cs 
in the body.  Whole-body retention of acutely ingested 137Cs has been followed in a 
number of adult males until little of the intake remained in the body (Figure 5.3). A 
number of these studies had been completed by the mid-1970s and the results were 
considered in the development of the ICRP’s current retention-function model for 
cesium. 
 
Results of 14 studies of the long-term half-time in healthy adult males yield mean long-
term half-times in the range 79-133 d with an overall mean of about 97 d (Figure 5.4).  
The number of subjects per study varied from 2 to 239.  Inter-subject variability within a 
given study generally was small, with a typical coefficient of variation of about 20% and 
a typical geometric standard deviation of about 1.2 (Lloyd et al., 1973; Leggett, 1986; 
ICRP, 1989; Leggett et al., 1998, 2003). 
 
 
 
Figure 5.3.  Whole-body retention of ingested cesium as predicted by the proposed cesium 
model update (Leggett et al., 2003) and measured in several adult male humans followed for 
an extended period 
 
5.1.2.4.3. Differences with gender 
 
In at least eight studies, retention half-times have been measured in adult female as well 
as adult male subjects (Figure 5.5).  Although there is some overlap in individual half-
times for male and female subjects, the mean half-time for the female subjects is 15-35% 
lower than that for male subjects in each of these studies.  The long-term half-time of 
cesium in the body usually is reduced during pregnancy to about two-thirds of the value 
when not pregnant, perhaps due to increased aldosterone levels in blood during 
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pregnancy (Lloyd et al., 1966; Zundel et al., 1969; Leggett, 1986; ICRP, 1989; Melo et 
al., 1997; Thornberg and Mattsson, 2000). 
 
Schwartz and Dunning (1982) collected data from the literature on the equivalent 
biological half-time of 137Cs in the human body.  The equivalent half-time is estimated 
from simultaneous measurement of the total body content and the excretion rate and 
assumes that total-body 137Cs is a well-mixed pool.  They determined means of 96 ± 23 d 
(range 47-152 d) from data 116 adult males and 65 ± 29 d (range 30-141 d) for 29 adult 
females.   
 
Figure 5.4.  Mean long-term half-times (d) for total-body retention of cesium in 14 studies 
involving healthy adult male subjects.  The number of subjects in individual studies ranged 
from 2 to 239. 
 
 
 
 
 
Figure 5.5.  Comparative total-body half-times of cesium in adult males and adult 
females in eight studies 
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5.1.2.4.4. Variation with age 
 
Variation with age in the retention time of radiocesium in the human body has been 
investigated in controlled studies, in subjects exposed to contamination from the 
Chernobyl accident or other sources of environmental contamination, and in subjects 
exposed in the accident in Goiania, Brazil.  Data from three studies (Lloyd et al., 1973; 
Lebedev and Yakovlev, 1993; Melo et al., 1997) are shown in Figure 5.6.  Typical long-
term half-times as a function of age and gender are given in Table  5.1 (McCraw, 1965;  
Lloyd et al., 1973; Leggett, 1986; Lebedev and Yakovlev, 1993; Melo et al., 1997; 
Leggett et al., 1998). 
 
 
 
Figure 5.6.  Measured 137Cs whole-body retention half-times at different ages 
 
 
 
Table 5.1. Typical age- and gender-specific long-term 
retention half-times for cesium in the human body 
Long-term half-time (d)  
Age Males Females 
Infant (100 d) 17 17 
1 y 19 19 
2 y 22 22 
5 y 32 32 
10 y 46 46 
15 y 75 65 
35 y 100 75 
60 y 85 65 
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5.1.2.4.5. Effects of disease 
 
The biokinetics of cesium may be strongly affected by diseases that affect the behavior of 
potassium or its mass in the total body or in skeletal muscle. For example, persons with 
Duchenne dystrophy have low concentrations of potassium in skeletal muscle and also 
show rapid removal of 137Cs from the body due to its limited uptake or retention by 
skeletal muscle, which is typically the main repository of cesium in the body (Lloyd et 
al., 1973; Leggett, 1986). 
 
5.1.2.4.6. Behavior of radioactive progeny 
 
In the estimation of dose from intake of radionuclides, it must be considered that 
radioactive progeny produced in the body may have different biokinetics from the parent 
radionuclide.  Approximately 94.6% of decays of 137Cs go to 137mBa.  Despite its short 
half-life (2.55 min), 137mBa apparently migrates to a large extent from sites of decay of its 
parent, 137Cs, to sites that accumulate barium when introduced directly into blood.   For 
example, at 4-7 days after administration of 137Cs to rats, 137mBa was found to exceed 
equilibrium proportions in bone and plasma by factors of 3 and 14, respectively.  Liver 
tissue was slightly deficient in 137mBa, whereas bone marrow and spleen showed little 
deviation from equilibrium (Wasserman et al., 1959).  Sensitivity tests indicate that the 
standard assumption that 137mBa decays at its site of production may overestimate doses 
from intake of 137Cs to most tissues but could underestimate doses to barium repositories 
(e.g., bone surfaces and colon) by 50% or more.  In the best estimates of 137Cs doses from 
inhalation or ingestion given in this document, independent biokinetics of 137mBa is 
assumed; i.e., 137mBa produced in the body is assigned the current ICRP model for 
barium. 
 
5.1.3. Dosimetry 
 
The decay schemes for 137Cs and its daughter 137mBa, including half-lives, modes of 
decay, and energy spectra, have been studied extensively.  Cesium-137 is a beta emitter 
that decays 94.6% of the time to 137mBa, which emits penetrating gamma radiations.  Per 
nuclear transformation of 137Cs, the energy of emitted gamma and x rays for the chain of 
decays is 0.664 MeV and the average energy of emitted beta radiation is 0.249 MeV 
(ICRP, 1983).  The beta radiation generally will be absorbed in the organ in which it 
originates. Exceptions occur when source and target tissues are separated by only a few 
microns (e.g., when the source is trabecular bone and the target is trabecular marrow), in 
which case the dosimetry becomes an important source of uncertainty in estimates of 
dose to the target region.  For emitted gamma radiations, energy absorbed fractions can 
be estimated with reasonable accuracy for different combinations of source and target 
organs, but some error arises from incomplete knowledge of shapes and relative 
geometries of organs in the living body. 
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5.1.4. Variability of dose per unit intake or per unit exposure 
 
As discussed earlier, the biokinetics of cesium varies with age, gender, muscle mass, diet, 
pregnancy, and other factors.  Age has a particularly large effect on biokinetics, with 
retention time in infants typically less than one-fifth the retention time in adults.  There 
are environmental factors that may affect the biokinetics of cesium such as ambient 
temperature or height above sea level, but these effects generally appear to be modest. 
 
With regard to dose per unit intake, the effects of age, gender, and muscle mass on the 
retention time of cesium are largely offset by corresponding changes in body size, with 
infants being the only subgroup of the population with noticeably higher estimated dose 
per unit intake than the young adult male.  This is illustrated in Table 5.2 for the case of 
ingestion of 137Cs.  Note that this table addresses relatively large subpopulations rather 
than individuals, but none of the available data suggested that individuals within these 
subgroups might receive substantially higher doses than the average member of the 
subpopulation. 
 
When differences in intake of 137Cs in food or air are considered, the young adult male is 
estimated to receive higher doses from ingestion of 137Cs than other members of the 
population (Table 5.2).  The estimates in Table 5.2 are based on current information as 
interpreted by the authors of this report rather than the ICRP’s current systemic model, 
but differences from ICRP model estimates are modest. 
 
 
Table 5.2. Expected differences with age and gender in dose from 
ingestion of 137Csa 
Dose per unit activity 
in food supply 
Group Dose per 
unit activity 
ingested Based on 
calorie intake 
Based on 
potassium intake 
Infants 1.6 0.3 0.7 
1-y-old 0.9 0.2 0.5 
5-y-old 0.8 0.4 0.5 
10-y-old 0.8 0.5 0.6 
15-y-old male 0.9 0.7 0.8 
15-y-old female 0.9 0.6 0.6 
25-y-old male 1.0 1.0 1.0 
25-y-old female 0.9 0.6 0.6 
65-y-old male 0.8 0.6 0.8 
65-y-old female 0.7 0.4 0.5 
aValues normalized to 1.0 for 25-y-old male. 
 
 
5.1.5. Existing uncertainty assessments for intake of 137Cs 
 
Uncertainty assessments have been performed for different aspects of the biokinetics or 
dosimetry of 137Cs, including fractional absorption from the gastrointestinal tract 
(Harrison et al., 2001), cumulative activity in the total body after acute uptake of a unit 
activity to blood (Leggett et al., 1998), and dose per unit of ingested or inhaled activity 
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(Schwarz and Dunning, 1982; Bogen et al., 1997; NCRP, 1998; NRC-CEC, 1998; 
Apostoaei and Miller, 2004).  Methods of assessment have included expert judgment 
based on a consensus of several national or international experts (e.g., Harrison et al., 
2001; NCRP, 1998), collection of independent judgments of several international experts 
(e.g., NRC-CEC, 1998); and parameter uncertainty analyses by small groups of 
investigators (e.g., Schwarz and Dunning, 1982; Apostoaei and Miller, 2004).  The 
general conclusion is that 137Cs is well understood with regard both to its biological 
behavior and the dose per unit intake following intake of highly soluble forms of this 
radionuclide.  Methods and conclusions of a typical parameter uncertainty analysis are 
described below. 
 
Apostoaei and Miller used parameter uncertainty analysis to assess uncertainty in dose 
coefficients for ingestion of 137Cs.  Their analysis was based on the age- and gender-
specific retention-function model of Leggett (1986):  
R(t) = a exp(-0.693 t / T1) + (1-a) (-0.693 t /T2).   
As discussed earlier, the ICRP adopted this model in ICRP Publication 56 (1989) for ages 
1-15 y but kept the gender-independent model of ICRP Publication 30 to adults.  In the 
model, each of the coefficients and the short- and long-term half-times T1 and T2 (days) is 
linearly related to the amount of potassium Ktb in the total body (Leggett, 1986). 
 
Apostoaei and Miller assigned an uncertainty distribution for Ktb by propagating the 
variability in reported concentration of potassium and total-body mass. Based on reported 
values for measured absorption of 137Cs in inorganic form or in food, the uncertainty in 
GI uptake of 137Cs was assigned a triangular distribution having a minimum of 80% and a 
mode and maximum of 100%.  They assumed that 137Cs is uniformly distributed in the 
body, the sites of decay of 137mBa produced in vivo are the same as that of the parent 
137Cs, and energy from beta radiation is completely absorbed in the organ in which the 
decay occurs.  They noted that the fraction of energy from gamma emissions from 137mBa 
absorbed by an organ is uncertain due to such factors as “the lack of knowledge about the 
precise position and shape of each target organ” and “statistical uncertainties introduced 
by the methods used to solve the radiation transport problem”.  “In the absence of better 
information, the uncertainty in the absorbed fraction for gamma radiation for all target 
organs was assumed to be 50%” and a “log-uniform distribution” was assigned. Their 
uncertainty distributions for the mass of the total body or specific organs were estimates 
of inter-individual variability based on information from ICRP’s Reference Man 
document (1975).  
 
On the basis of their parameter uncertainty analysis, Apostoaei and Miller concluded that 
the probability distributions for ingestion dose coefficients for 137Cs can be fitted 
reasonably well by either normal or lognormal distributions.  The derived GSD was 1.24 
for males and 1.40 for females, with the larger uncertainty for females due to the larger 
variation of the amount of potassium in the body.  The magnitude of the uncertainty was 
judged to be similar among organs “because the main contributor to the uncertainty in the 
dose coefficients…is the biokinetic model, which affects all organs in the same way.”  
The GI uptake fraction, mass of each organ, and absorbed fraction (gamma) for 
individual organ did not appear to contribute greatly to the total uncertainty.  The 
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estimated 95% confidence intervals encompassed the ICRP’s dose coefficients for adults, 
but the means and medians of the derived uncertainty distributions for specific organs 
were lower than the ICRP values by 2-18% for males and 2-27% for females.  The main 
reason for these differences from ICRP was that the ICRP’s long-term half-time of 110 d 
for adults, carried over from ICRP Publication 30 to Publication 89, is longer than those 
of the Leggett model for average adult males (~100 d) and average adult females (~85 d). 
 
Apostoaei and Miller explained that their results reflect inter-individual variability as 
well as lack of knowledge about model parameters 
 “Dose coefficients … are regarded as central estimates for large populations…  
Many physical and physiological parameters influencing absorption and movement 
of a radioactive substance in the human body vary from one individual to another, 
introducing uncertainties due to inter-individual variability.  In addition, some 
parameters are not well known, and one must therefore deal with uncertainty due to 
lack of knowledge about the true means and variances of these parameters.  The two 
types of uncertainty can be combined if the assessment end point is the lack of 
knowledge in the dose to a reference individual, but they must be separated if the 
assessment end point is variability of doses in a population...” 
 
For example, Apostoaei and Miller used observed variability in total body potassium or 
organ masses as uncertainty distributions for these parameters, and they assigned an 
arbitrary uncertainty distribution to the absorbed fraction for gamma radiation mainly due 
to lack of knowledge.  Thus, their results apparently represent statements concerning 
uncertainty in the dose to an individual from ingestion of 137Cs, which would indicate that 
their results overstate uncertainty as defined in the present report. 
 
An issue related to the definition of uncertainty is that the level of confidence that should 
be placed in a dose coefficient may depend strongly on the nature of its application.  The 
uncertainty distributions derived by Apostoaei and Miller for ingested 137Cs depend on 
their relatively narrow uncertainty distribution for fractional uptake of 137Cs from the GI 
tract. That distribution may be appropriate, for example, for ingestion of 137Cs 
biologically incorporated in food or ingestion of soluble inorganic forms of 137Cs, but it 
would not be appropriate for application to ingestion of particulate 137Cs deposited on 
raw fruit or vegetables following a reactor accident or nuclear bomb test, because 
uncertainty in gastrointestinal uptake of 137Cs would be relatively large in this case. 
 
An issue mentioned by Apostoaei and Miller but not considered in their analysis is model 
structure.  The model that they applied has two retention components, and it is assumed 
that activity associated with each component is uniformly distributed in the body.  This is 
generally considered to be a reasonable assumption because 137Cs is fairly uniformly 
distributed compared with most radionuclides and because the short-lived daughter 
137mBa emits penetrating radiations that would help to correct for any error in the 
assumption of a uniform distribution.  However, calculations based on the detailed 
cesium model shown in Figure 5.2 indicate that doses to some tissues may be 
overestimated by as much as 40% due to the assumption of a uniform distribution.  The 
main reason is that 137Cs accumulates largely in skeletal muscle, and beta emissions from 
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decay of 137Cs in skeletal muscle will not reach more sensitive tissues such as lung and 
colon.  
 
Apostoaei and Miller discussed the possibility of migration of the short-lived daughter 
137mBa from the site of decay of 137Cs but did not include this uncertainty in their 
analysis. In fact, it is not feasible to address this source of error within the model 
structure that they used, because a substantially different structure is required to model 
the biokinetics of barium.  Barium-137m represents more than half of the energy 
involved in the decays of this chain, and experimental evidence indicates that it can 
migrate from 137Cs to sites where absorbed Ba would normally be found in high 
concentration including the skeleton and the colon.  Our computations indicate that the 
effective dose from ingestion of 137Cs might be underestimated by as much as 30-40% 
due to the assumption that 137mBa remains with 137Cs in the body.  While the problem of 
migration of progeny from the parent is not major for 137Cs dosimetry, it is a major issue 
for some other important radionuclides. 
 
 
5.2. Strontium-90:  Level 2  
 
5.2.1. Overview 
 
Strontium-90 is used to illustrate a second level of information on biological behavior 
and dose per unit intake, that is, relatively good information but not as detailed or easily 
interpreted as that for 137Cs. As is the case for 137Cs, there is a large biokinetic database 
for 90Sr, including much H1 data.  Also like 137Cs, 90Sr has a close chemical and 
physiological analogue (calcium) that has been studied extensively as an essential 
element.  Nevertheless, dose per unit intake cannot be determined as narrowly for 90Sr as 
for 137Cs due to the less complete and more variable absorption of 90Sr to blood, the more 
heterogeneous distribution of 90Sr in the body, and the lack of penetrating radiations from 
the 90Sr chain, which prevents measurement of 90Sr or 90Y in vivo and presents some 
dosimetric difficulties for some source and target regions that are narrowly separated 
such as in the lungs and skeleton. 
 
5.2.2. Biokinetics 
5.2.2.1. Physiological analogues 
Strontium is an alkaline earth element that follows the biological behavior of its close 
chemical analogue calcium, but the biokinetics of calcium and strontium differ somewhat 
due to discrimination between these elements by biological membranes.  Experimental 
data indicate that strontium is less effectively absorbed from the intestines, more 
effectively excreted by the kidney, and less readily removed from bone surfaces than 
calcium (see reviews in Leggett, 1992; ICRP, 1993). However, strontium is a better 
quantitative tracer for calcium than are the heavier alkaline earth elements, barium and 
radium. Calcium and strontium are excreted primarily in urine, while barium and radium 
are excreted mainly in feces, with the total excretion rate soon after injection being higher 
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for the heavier alkaline earths than for calcium and strontium (Harrison et al. 1967).  All 
four elements have similar skeletal uptake and distribution at early times after injection 
(Ellsasser et al., 1969; Wood et al., 1970; Liniecki, 1971; Stather, 1974; Lloyd et al., 
1976).  Within a few months after administration of isotopes of calcium, strontium, 
barium, or radium, nearly all of the remaining total-body activity is associated with bone 
mineral (ICRP, 1973; Schlenker, 1982). 
 
5.2.2.2. Behavior in the respiratory tract 
 
Information on the behavior of different forms of inhaled strontium in the respiratory 
tract was reviewed in ICRP Publication 71 (1995) and recently by an ICRP task group (to 
be published in an ICRP document).  Data are available for workers accidentally exposed 
to various strontium compounds (H1) and for laboratory animals exposed to well 
characterized forms of strontium (A1).  Data for accidental intake of strontium as 
chloride or carbonate indicate that most of the deposited activity is cleared to blood at a 
rate reasonably consistent with the ICRP’s HRTM parameter values for Type F material 
(fast dissolution and absorption).  Rapid clearance of strontium inhaled as chloride or 
sulfate also has been observed in laboratory animals.  Measurements following the 
accidental inhalation of mixtures of fresh fission products indicate Type M behavior of 
most of the strontium present.  Results of an in vitro study on airborne fission products 
are consistent with assignment to Type F.  Strontium inhaled in fused aluminosilicate 
particles or polystyrene have shown low absorption to blood, consistent with Type S.  
Studies of the rate of clearance of inhaled strontium titanate (SrTiO3) from the lungs in 
laboratory animals and an accidentally exposed subject indicate slow absorption 
consistent with HRTM parameter values for Type S material (slow dissolution and low 
absorption to blood) or perhaps Type M material (moderate dissolution and absorption) in 
some cases. 
 
5.2.2.3. Fractional uptake from the gastrointestinal tract 
 
Information on gastrointestinal uptake of strontium was reviewed by Harrison et al. (2001).  
Data from several controlled studies on human subjects ingesting inorganic forms of 
radiostrontium in solution or known quantities of radiostrontium incorporated in food 
indicate that absorption is generally in the range 8-35% and averages about 20-25%.  
Absorption of strontium from fallout was in the range 0-9% in 10 subjects and averaged 
about 3%.  For simulated fallout prepared as glass microspheres, average absorption was 
about 16% (range 6 – 25%).  A number of factors have been found to increase absorption, 
including fasting and low dietary levels of calcium, Mg and P.  Milk diets and vitamin D 
may also increase absorption.  Overnight fasting or a low calcium diet can increase 
absorption by a factor of 2 or more.  Results from animal studies generally support the 
quantitative estimates based on data for human subjects.  Animal data show substantially 
elevated absorption of strontium early in life. Data on uptake and retention of 
environmental 90Sr by humans suggest but do not firmly established elevated absorption 
during periods of rapid bone growth, including adolescence.  Absorption of strontium 
administered as titanate (SrTiO3) to rats show low levels of absorption, on the order of 1%. 
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5.2.2.4. Systemic biokinetics 
 
5.2.2.4.1. ICRP model 
 
The ICRP’s systemic model for strontium was developed within a generic model 
structure (Figure 5.7) for a class of elements that follow the movement of calcium in the 
skeleton.  This class includes the alkaline earth elements barium and radium and more 
distant physiological relatives of calcium such as lead and uranium.  The structure and 
parameter values for the alkaline earth elements were developed in the early 1990s 
(Leggett, 1992) and was first used by the ICRP in its series on age-specific doses to 
members of the public (ICRP 1993, 1995).  The following paragraphs explain the basis 
for the generic model structure for calcium-like elements and selection of the ICRP’s 
parameter values for strontium. 
 
Plasma is treated in the generic model structure as a uniformly mixed pool, although this 
is not strictly true for calcium and its close physiological analogues.  For example, 
slightly more than half of plasma calcium is in ionic form and readily exchangeable with 
extravascular calcium, while the rest is bound to proteins and not "diffusible" (Borle 
1981).  Since the alkaline earth elements are known to have little affinity for red blood 
cells (RBC), the RBC compartment is not considered explicitly in applications to these 
elements, but it used in the models for lead and uranium.  
 
Kinetic analysis of plasma disappearance curves for normal subjects intravenously 
injected with calcium or strontium tracers indicates that these elements initially leave 
plasma at a rate of several hundred plasma volumes d-1 and equilibrate rapidly with an 
extravascular compartment roughly three times the size of the plasma pool (Heaney 1964, 
Harrison et al. 1967, Hart and Spencer 1976).  This extravascular compartment 
presumably consists largely of interstitial fluids.  At times greater than a few minutes 
after injection, a transfer rate from plasma of about 15 d-1 yields a reasonable fit to 
plasma disappearance curves for strontium or calcium tracers.  The models for strontium 
and calcium do not depict the extremely rapid removal of activity during the early 
minutes but assign a removal rate from plasma of 15 d-1.  
 
 The behavior of strontium in soft tissues was modeled by relating strontium-specific data 
on uptake and retention in soft tissues to the kinetics of calcium, for which more 
information was available (H2 data).  Kinetic analysis of data for human subjects 
administered radiocalcium indicate that readily exchangeable calcium in soft tissues 
represents an estimated 0.35% of total-body calcium in a middle-aged adult human 
(Heaney 1964, Borle 1981, Schlenker et al. 1982).  Plasma contains about 0.03% of total-
body calcium in the adult.  The rapid-turnover soft-tissue compartment ST0 shown in 
Figure 5.7 was used to represent the roughly threefold larger extracellular pool in 
exchange with plasma calcium.  Thus, ST0 contains about 0.09% of total-body calcium. 
This leaves 0.26% for the intermediate-term compartment, ST1.  If ST1 receives a 
fraction F of calcium leaving plasma and loses calcium to plasma with a half-time of T d, 
then F and T are related by the equation 0.0003 x F x 15 d-1 = 0.0026 x (ln(2)/T) d-1.  In 
this equation, 0.0003 is the fraction of total-body calcium in plasma and 15 d-1 is the rate 
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of removal of calcium from plasma.  Thus, the product of F and T should be about 0.4.  A 
good fit to data on retention of 45Ca in human soft tissues over the first 124 d after 
injection (Schulert et al., 1959) is obtained with F = 0.1 and T = 4 d. 
 
 
 
 
 
Figure 5.7.  ICRP’s generic model structure for calcium-like elements, introduced in ICRP 
Publication 67 (1993) and applied in that document or subsequent ICRP documents to 
calcium, strontium, barium, radium, lead, and uranium 
 
 
A soft-tissue compartment ST2 with very low uptake from blood, thus having little 
influence on model predictions during the first 124 d after injection, was used to 
represent relatively non-exchangeable calcium resulting from dystrophic calcification of 
tissues such as arterial plaque and calcified nodes, a normal occurrence in humans.  It has 
been estimated that older persons have 50-100 mg dystrophic calcium kg-1 soft tissue 
(Heaney, 1964).  The deposition fraction and removal half-time for calcium in ST2 were 
set to give about 0.1% of total-body calcium in ST2 in older adults.  A removal half-time 
from ST2 to blood plasma of 5 y was estimated for calcium and applied to strontium, 
barium, and radium.  Differences in accumulation of calcium, strontium, barium, and 
radium in soft tissues, as indicated for example by the fraction of total-body activity in 
soft tissues in chronically exposed persons, were modeled using element-specific 
transfers from plasma to ST2. 
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Uptake and retention of radiostrontium in soft tissues has been measured in several 
human subjects, all seriously ill (Figure 5.8).  For example, comparisons of 85Sr and 45Ca 
retention in soft tissues were made in several human subjects injected with these 
radionuclides 0.12-124 d before their deaths (Schulert et al., 1959).  Data from this study 
indicate that soft tissues initially contain about as much strontium as bone, but the soft-
tissue content falls off sharply after a few weeks while the bone content declines little 
over the first few months (Figure 5.9). 
 
Figure 5.8.  Retention of strontium in soft tissues as a function of time after intravenous 
injection of radiostrontium into human subjects 
 
Figure 5.9.  Division of activity between bone and soft tissues as a function of time after 
intravenous injection of radiostrontium into human subjects 
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The soft-tissue retention data for strontium and comparisons with the more frequently 
studied element, calcium, were used to model the kinetics of strontium in soft tissues. 
Fractional deposition in soft tissues was assumed to be the same for strontium as for 
calcium.  A longer removal half-time from ST1 for strontium than calcium was needed to 
obtain a good fit to measurements of injected 85Sr in human soft tissues at about 1-4 mo 
after injection.  Fractional deposition of strontium in the "tenacious-retention" 
compartment, ST2, was set to yield reasonable agreement with the estimate of Schlenker 
et al. (1982) that about 1% of the body's natural strontium resides in soft tissues in the 
average adult. 
 
The pools ST0, ST1, and ST2 are defined on a kinetic basis but have a physical 
interpretation. Compartment ST0 may consist of interstitial fluids plus some rapidly 
exchangeable cellular calcium; compartment ST1 may be a composite of several pools 
with slower exchange rates, including mitochondrial calcium, cartilage calcium, and 
exchangeable "dystrophic" calcium (e.g., arterial plaque and calcified nodes); and 
compartment ST2 may be associated largely with relatively non-exchangeable dystrophic 
calcium that normally accumulates in the human body over a period of many years.  
Compartment ST2 is of limited importance for calcium but becomes more important for 
consideration of the heavier calcium-like elements, for which relatively immobile 
deposits may represent most of the soft-tissue burden at times remote from injection. 
 
Provision is made in the generic model structure to treat the liver and kidneys separately 
from other soft tissues if information is available. In the case of strontium, no reason was 
found to distinguish the behavior in liver and kidneys from that in other soft tissues.  
 
In the generic model, bone is divided into cortical and trabecular bone, and each of these 
bone types is further divided into bone surfaces and bone volume.  Bone volume is 
viewed as consisting of two pools, one that exchanges with activity in bone surface for a 
period of weeks or months and a second, non-exchangeable pool from which activity can 
be removed only by bone restructuring processes. Activity depositing in the skeleton is 
assigned to bone surface, from which it is removed with an element-specific half-time on 
the order of days.  Over a period of days a portion of the activity on bone surfaces moves 
to exchangeable bone volume and the rest returns to plasma. Activity leaves 
exchangeable bone volume with an element-specific half-time, on the order of a few 
weeks or months.  Part of the activity leaving exchangeable bone volume is assumed to 
return to rapidly exchanging bone surfaces and part is assigned to non-exchangeable bone 
volume, from which it is assumed to be removed to plasma only by bone resorption.  The 
rate of removal from non-exchangeable bone volume is assumed to be the (age-specific) 
rate of bone turnover and hence is independent of the element. 
 
Uptake and retention of strontium by bone has been measured in terminally ill human 
subjects.  Retention in bone can also be inferred from total-body retention following 
acute administration of radiostrontium, since this is nearly the same as bone retention at 
times greater than a few weeks after injection of strontium. Total-body retention of 
radiostrontium has been measured in many human subjects, including healthy subjects as 
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well as hospital patients.  Variability of total-body retention data is high, apparently due 
in large part to an age effect even during adulthood (Figure 5.10).  The bone remodeling 
rate, which determines the level of deposition of calcium and related elements in bone, 
remains elevated until about age 25 y.  This is reflected in measurements of total-body 
retention of strontium, which is generally much higher for young adults than for middle-
aged or elderly persons. 
 
Figure 5.10.  Differences with age in whole-body retention of strontium (references to 
original studies given in Leggett, 1992)  
 
Data for laboratory animals indicate that fractional deposition on bone surfaces, as judged 
by the total skeletal content in the first few hours after injection, is similar for calcium, 
strontium, barium, and radium, despite the different excretion rates of these elements 
(Bligh and Taylor 1963; Kshirsagar et al. 1966; Domanski et al. 1969, 1980).  Use of a 
common bone-surface deposition fraction for all four elements is also consistent with the 
limited human data, including:  autoradiographic measurements of surface activity in 
bone samples taken at autopsy from subjects injected with radiocalcium at 0.6 d or longer 
before death (Riggs et al. 1971, ICRP 1973); calcium and strontium concentrations in 
autopsy samples of bone from subjects injected with radiocalcium and radiostrontium at 3 
h or longer before death (Schulert et al. 1959); externally measured buildup and decline 
of injected radiocalcium over areas of the human body where bone activity is expected to 
predominate (Anderson et al. 1970, Heard and Chamberlain 1984); and external 
measurements of the peak skeletal content of intravenously injected 133mBa in human 
subjects (Korsunskii et al. 1981).  Based on these data, it is assumed that 25% of calcium, 
strontium, barium, or radium leaving plasma is deposited on bone surfaces of the mature 
adult.   
 
The initial distribution between different bones of the skeleton and between the two bone 
types (cortical and trabecular) also appears to be similar for calcium, strontium, barium, 
and radium (Ellsasser et al. 1969, Wood et al. 1970, Liniecki 1971, Stather 1974, Lloyd 
et al. 1976).  As discussed below, relative deposition of alkaline earth elements on 
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trabecular and cortical bone surfaces is based on the estimated calcium turnover of each 
bone type.  This approach agrees with measurements on laboratory animals (Kshirsagar 
et al. 1966, Norrdin and Arnold 1980).  As an average over adult ages, deposition on 
trabecular bone is estimated to be 1.25 times that on cortical bone (Leggett et al. 1982).     
 
The residence time on human bone surfaces has not been determined with much precision 
for any of the alkaline earth elements.  A common removal half-time of 1 d is assigned to 
all four elements, based on the same data as considered in estimating the deposition 
fraction for bone surfaces, plus measurements of the early decline in whole-body 
retention of intravenously injected radioactive calcium, strontium, barium, or radium in 
human subjects (Spencer et al. 1960; Bishop et al. 1960; Heaney et al. 1964; Harrison et 
al. 1967; Phang et al. 1969; Carr et al. 1973; Likhtarev et al. 1975; Malluche et al. 1978; 
Henrichs et al. 1984; Newton et al. 1990, 1991) coupled with measurements of soft-tissue 
retention as described earlier.  A removal half-time of 1 d refers to the half-time that one 
theoretically would observe if recycling of activity to bone surfaces could be stopped.  
Given the considerable amount of recycling from plasma to bone surfaces, the 
corresponding net or apparent half-time would be 3 d or more. 
  
Parameter values for exchangeable bone volume are estimated from whole-body 
measurements using data for times after bone surfaces and soft tissues have largely 
cleared of activity but before loss from bone resorption becomes an important 
consideration.  Based on data for human subjects injected with radioisotopes of calcium, 
strontium, barium, or radium (Spencer et al. 1960; Bishop et al. 1960; Heaney et al. 1964; 
Harrison et al. 1967; Phang et al. 1969; Carr et al. 1973; Likhtarev et al. 1975; Malluche 
et al. 1978; Henrichs et al. 1984; Newton et al. 1990, 1991), it was concluded that the 
fraction of injected activity released from bone over the intermediate term (and thus 
assigned to exchangeable bone volume) is roughly one-sixth of activity leaving bone 
surfaces for all four elements.   
 
Removal half-times for radium, barium, strontium, and calcium from the exchangeable 
bone volume compartments are set at 30 d, 50 d, 80 d, and 100 d, respectively.  These 
values are based in part on fits to intermediate-term retention data for human subjects 
injected with radioisotopes of these elements and in part on the observation that the half-
time of the intermediate component for a given element appears to increase roughly in 
proportion to the likelihood of entering non-exchangeable sites in bone mineral, as 
judged either by in vitro experiments with hydroxyapatite crystals or by data on whole-
body retention of alkaline earth elements in human subjects. 
 
Discrimination between different alkaline earth elements by bone is accounted for by 
fractional transfer of activity from exchangeable bone volume to non-exchangeable bone 
volume.  It is assumed, in effect, that calcium, strontium, barium, and radium are all 
equally likely to become temporarily incorporated in bone mineral after injection into 
blood but that the likelihood of reaching a non-exchangeable site in bone crystal 
decreases in the order calcium > strontium > barium > radium.  Fractional transfers of 
calcium, strontium, barium, and radium from exchangeable bone volume to deep bone 
volume are assumed to be 0.6, 0.5, 0.3, and 0.2, respectively, with the remainder 
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(fractions 0.4, 0.5, 0.7, and 0.8, respectively) assumed to go from exchangeable bone 
volume to bone surface.  Thus, with the probability of permanent fixation in bone crystal 
(i.e., removable only by bone resorption) used as a measure of discrimination, bone 
mineral is estimated to discriminate among the alkaline earths in the ratios 
calcium:strontium:barium:radium = 1.0:0.83:0.50:0.33 as an average over forming and 
existing bone in the adult.  These values reproduce whole-body retention curves for 
humans injected with radioisotopes of calcium, strontium, barium, and radium, and are 
reasonably consistent with results of in vitro measurements.  For example, under 
conditions approximating physiological, Neuman (1964) found that calcium incorporated 
into forming hydroxyapatite crystals is 65% nonexchangeable, and Stark (1968) 
determined discrimination ratios calcium:strontium:barium:radium = 1.0:0.93:0.56:0.32 
in forming crystals.  Such in vitro results have varied, however, with experimental 
conditions, length of aging of the crystals, and the definition of discrimination (Neuman 
1964, Stark 1968).   
 
Fractional transfer from exchangeable bone volume to deep bone volume is described 
above.  Biological removal from deep bone volume is assumed to occur only by bone 
turnover.  Reference age-specific bone turnover rates were taken from an earlier paper 
(Leggett et al., 1982).  The turnover rates are based on histomorphometric measurements 
on human subjects as well as studies of retention of certain bone-seeking radionuclides in 
human subjects.  Most histomorphometric measurements are on ribs and iliac crest, but 
there are also a few measurements for various long bones.  It is assumed that there are no 
differences in turnover rates of cortical and trabecular bone early in life but differences 
gradually appear during childhood and eventually grow to about a factor of 5 in the 
mature adult (Leggett et al. 1982).   
 
Clearance of alkaline earths from plasma to urine and feces has been studied in a large 
number of human subjects, many of them healthy.  Clearance is usually expressed in 
terms of liters of plasma per day, but in the models for calcium and related elements, 
movement of activity to urine and feces is expressed in terms of deposition fractions in 
the urinary bladder and the GI tract contents.  It is assumed that alkaline earth elements 
are secreted into the upper large intestine and are not reabsorbed to blood.  
 
5.2.2.4.2. Database for adult male humans 
 
Most of the H1 data for strontium summarized above represents measurements on adult 
males.  For example, the whole-body retention curve for young adults given in Figure 
5.10 is based on measurements on 44 males of median age 22 y (Likhtarev et al., 1975), 
and most of the data represented by the curve for middle-aged adults are for males. 
 
Variability in whole-body retention of strontium in young adult males during the first few 
months after acute intake can be estimated from data of Likhtarev et al. (1975).  
Geometric standard deviations (GSDs) of whole-body retention at given times, the 
urinary excretion rate at early times, and the fecal excretion rate at 4 d did not exceed 1.4 
for subjects receiving 85Sr by injection.  Calculated GSDs based on ingestion data from 
that study are in the range 1.6-1.7.  Higher variability in retention or urinary excretion is 
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to be expected in the case of ingestion due to additional variability associated with the 
gastrointestinal absorption fraction. 
 
Schubert and coworkers (1967) concluded that the concentration of 90Sr in bones of a 
large number of environmentally exposed human subjects was lognormally distributed 
when populations were suitably narrowed according to age, location (areas of the world), 
and time period.  The GSD of the distribution was close to 1.6 for each sub-population 
considered.  Since some of the variation in tissue concentrations in these subjects 
probably arose from variation in exposure to 90Sr and hence could overstate variation in 
biokinetics of absorbed 90Sr.  
 
5.2.2.4.3. Differences with gender 
 
Around 1950, a plutonium production facility in Russia released large amounts of 90Sr 
into the nearby Techa River.  Shagina et al. (2003) measured whole-body content of 90Sr 
over a 24-year period in thousands of persons living near the Techa River.  They 
concluded that the rate of 90Sr elimination is different for adult males and adult females.  
An increase with age in the 90Sr elimination rate was indicated for adults of both genders 
but was much more pronounced in women than men.  The results are consistent with a 
higher rate of bone loss in aging females than in aging males.   
 
5.2.2.4.4. Variation with age 
As illustrated in Figure 5.10, experimental and environmental studies have also revealed 
considerable variation with age in the biokinetics of strontium during growth.  There is 
evidence of elevated skeletal uptake but also relatively rapid skeletal losses of strontium 
during periods of rapid bone growth and turnover. 
 
A large data base related to the transfer of 90Sr from food and milk to the human skeleton 
was developed in the 1950s and 1960s.  Those data indicate that much higher transfer of 
90Sr from the environment to the skeleton occurs in growing children than in adults, with 
highest transfer occurring in infants and toddlers and a second phase of elevated uptake 
occurring during adolescence (Figure 5.11). 
 
Conclusions regarding variation with age in strontium biokinetics indicated by H1 data 
are supported by studies on laboratory animals (ICRP, 1993).  This illustrates the typical 
use of the large A1 database on strontium for purposes of biokinetic modeling, that is, as 
secondary, supporting information rather than as primary information.  As discussed later 
for other cases (e.g., 106Ru), A1 data is a primary source of biokinetic information for 
many radionulides. 
 
5.2.2.4.5. Effects of disease 
 
It seems likely that diseases affecting the rate of bone remodeling or bone loss could have 
a substantial effect on whole-body retention of strontium, but no data were found that 
strongly supports this hypothesis. 
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Figure 5.11.  Differences with age in the concentration of 90Sr in human vertebrae during a 
period of elevated fallout (Leggett et al., 1998) 
 
 
5.2.2.4.6. Biokinetics of radioactive progeny 
 
Strontium-90 (T1/2  = 28.7 y) decays to the short-lived radionuclide 90Y (T1/2  = 64.1 h).  
Strontium and yttrium have much different chemical and biokinetic properties, although 
both are bone seekers.  Strontium is deposited mainly on skeletal surfaces in areas of 
growth and remodeling but within a few days is distributed throughout the bone volume.  
Only a small portion of systemic strontium can be found in non-skeletal tissues within a 
few weeks after uptake to blood.  Yttrium is deposited on resorbing and resting surfaces 
of bone and is likely to remain on bone surfaces for an extended period until removed to 
bone marrow, blood, or bone volume by bone remodeling processes.  Yttrium also 
appears to be tenaciously retained in the liver. 
 
Experimental evidence for laboratory animals indicates that 90Y decays at its site of 
production in bone volume but migrates to a large extent from sites of production in soft 
tissues, except perhaps liver (Arnold et al., 1955; Lloyd, 1961).  In experiments where 
rabbits were injected either with 91Y or 90Sr free from 90Y, 91Y showed greater uptake and 
more tenacious retention than 90Sr in soft tissues.  There was a secondary uptake of 90Y in 
the liver, kidneys, and spleen due to escape from 90Sr in various parts of the body.  By 
measuring the relative activities of 90Sr and 90Y in various tissues of a beagle, Arnold and 
coworkers (1955) concluded that 90Y does not escape from its parent in bone volume to 
any appreciable extent. 
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5.2.3. Dosimetry 
The decay schemes for 90Sr and its daughter 90Y, including half-lives, modes of decay, 
and energy spectra, have been studied extensively.  Both radionuclides are beta emitters.  
Strontium-90 emits a relatively weak beta (mean energy = 0.20 MeV) and 90Y a relatively 
energetic beta (mean energy = 0.94 MeV). The beta radiation from both radionuclides 
generally will be absorbed in the organ in which it originates. Exceptions occur when 
source and target tissues are separated by only a few microns, such as when the source is 
trabecular bone and the target is trabecular marrow.  In such cases the dosimetry model 
becomes an important source of error for 90Sr dosimetry. 
 
5.2.4. Variability of dose per unit intake or per unit exposure 
 
Table 5.3 compares the estimated effective dose from ingestion of 90Sr in different 
subgroups of the population.  The estimates are based on a modification of the ICRP’s 
age-specific biokinetic model for strontium that takes account of changes in bone 
remodeling rates during adulthood.  
 
 
Table 5.3.  Estimated effective dose from ingestion of 1 Bq of 90Sr 
for different groups, relative to the estimated value for a young 
adult male 
Dose per unit activity 
in food supply 
Group Dose per 
unit activity 
ingested Based on 
calorie intake 
Based on 
calcium intake 
Infants 8.2 1.3 5.8 
1-y-old 2.6 0.7 2.0 
5-y-old 1.7 0.9 1.3 
10-y-old 2.1 1.3 1.7 
15-y-old male 2.8 2.3 3.1 
15-y-old female 3.0 1.9 2.1 
25-y-old male 1.0 1.0 1.0 
25-y-old female 1.2 0.8 0.8 
65-y-old male 0.9 0.7 0.7 
65-y-old female 0.9 0.5 0.5 
 
 
5.2.5. Existing uncertainty assessments for intake of 90Sr 
 
Uncertainties in the biokinetics of 90Sr in humans and in doses from intake of 90Sr have 
been addressed in several studies (NRC-CEC, 1998; Bogen et al., 1997; Leggett et al., 
1998; EPA, 1999; Harrison et al., 2001; Apostoaei, 2002; Apostoaei and Miller, 2004).  
The general conclusion is that the doses from intake of 90Sr are reasonably well 
understood, but an unstated assumption appears to be that 90Sr is ingested in relatively 
soluble form. 
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Harrrison et al. (2001) concluded from a literature review that high-confidence intervals 
for average fractional absorption of strontium from the gastrointestinal tract are relatively 
narrow compared with other incompletely absorbed elements:  0.1-0.4 for adults, 0.1-0.5 
for age 10 y, and 0.15-0.75 for infants. Apostoaei (2002) concluded that the uncertainty 
in the gastrointestinal absorption fraction for strontium in adults is well represented by a 
lognormal distribution with GSD of 1.44 and 95% confidence interval 0.11 to 0.46.  
Apostoaei’s conclusion apparently refers to uncertainty for an individual and results 
primarily from inter-individual variability, while Harrison and coworkers are referring to 
the uncertainty in the central value.  On the basis of a literature review and limited 
sensitivity analysis, Leggett et al. (1998) concluded that the ICRP’s systemic biokinetic 
model for strontium has moderate to high reliability (uncertainty factor of about 3) with 
regard to predicted cumulative activity of 90Sr in bone volume. 
 
Apostoaei and Miller (2004) used parameter uncertainty analysis to investigate 
uncertainties in tissue doses from ingestion of 90Sr.  They collected data on strontium 
biokinetics in humans, on the energy deposited in each organ, and on the masses of the 
organs.  They derived distributions from these data which they interpreted as representing 
uncertainties in parameter values, and they attempted to identify correlations between 
parameters.  Monte Carlo methods were used to propagate uncertainties through the 
biokinetic and dosimetric models.  According to the investigators: 
 
“Throughout this work, the uncertainties represent, to the extent possible, inter-
individual variation of the given parameter.  In those cases when data were 
insufficient to clearly describe the inter-individual variability, the uncertainty 
describes the range of possible values obtained by professional judgment.”  
 
The ICRP’s current systemic biokinetic model for strontium (Figure 5.7) was used. 
Organ-specific dose factors were calculated for different cases: (1) assuming no age-
dependency in parameter values and assuming that 90Y produced in vivo has the same 
kinetics as 90Sr; (2) using age-dependent parameter values and assuming that 90Y 
produced in vivo has the same kinetics as 90Sr; (3) assuming no age-dependency in 
parameter values but assigning the ICRP’s biokinetic model for Y to 90Y produced in 
vivo.  According to Apostoaei and Miller, “The analysis of data for deriving model 
parameter distributions follows the logic used by Leggett (1992) to select the default 
parameter values for the ICRP biokinetic model for 90Sr”.  They explained this as 
follows:  Initial selections were made for individual parameter values based on the best 
available evidence for the pathway considered, and then, due to the interdependence of 
the parameter values, repeated tuning of initial selections was performed until satisfactory 
fits to available human data were obtained.  Because the analysis by Apostoaei and Miller 
was an uncertainty analysis rather than model construction, “the parameters were derived 
as probability distribution functions, and comparisons with the experimental data 
consisted of two important aspects: a) the predicted central value should reproduce the 
observed central tendency of the data, and b) the range of the predicted values at any 
moment in time should cover inter-individual variation of the data for that moment.”  The 
investigators concluded that the uncertainties in ingestion dose coefficients for 90Sr are 
described by lognormal distributions.  The largest derived uncertainties are for bone 
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surface (GSD = 2.6) and bone marrow (GSD=2.4).  They concluded that the 
contributions to organ dose uncertainties decreased in the following order of importance:  
variability in biokinetic model parameters > mass of target organ > energy deposition in 
target organ. 
 
The methods of the analysis indicate that the results should apply to uncertainty in dose 
estimates for an individual, which would overstate the uncertainty in dose as defined in 
the present report.  Also, the results of Apostoaei and Miller may overstate variability in 
the biokinetics of strontium for the adult as defined by the ICRP.  The ICRP defines the 
adult to be 25 y old or greater in the case of strontium biokinetics because of the sizable 
differences in kinetics between very early adulthood and the greater portion of adulthood 
(Figure 5.10).  
 
5.3. Cobalt-60 (Level 3) 
 
5.3.1. Overview 
 
The biokinetic database for cobalt includes results of controlled studies on human 
subjects (H1), follow-up studies of accidentally exposed workers (H1), and data for 
different animal species (A1).  There have been several human studies of the biokinetics 
of inhaled cobalt in the respiratory tract and of gastrointestinal uptake, but results vary 
considerably with the form of cobalt taken into the body and conditions of the study.  
Whole-body retention of inorganic cobalt in adults can be estimated with reasonably high 
confidence from results of controlled human studies (H1), but information on the internal 
distribution comes mainly from studies on laboratory animals (A1). The animal data 
cannot be extrapolated to humans with high confidence because of apparent species 
differences in the behavior of cobalt.  For example, the long-term retention component is 
considerably larger in human subjects than other studied species, and the difference 
cannot be explained by metabolic rate or body size.  Also, although H1 data on hepatic 
retention of cobalt are limited, it appears that the liver is a more important long-term 
repository for cobalt in humans than in other studied species. Model development is 
complicated by the fact that environmental cobalt may have substantially different 
biokinetic properties from the inorganic forms of cobalt generally used in experimental 
studies. Age-specific data for cobalt are available only for rats, which is not a preferred 
species for age-specific modeling.  With regard to dose estimates for internally deposited 
60Co, the fact that there is substantial cross-irradiation of tissues by the high-energy 
photon emissions from 60Co tends to offset uncertainties in the systemic distribution of 
cobalt to some extent. Nevertheless, dose estimates for internally deposited 60Co seem 
much less reliable than estimates for internally deposited 90Sr or 137Cs.   
 
5.3.2. Biokinetics 
5.3.2.1. Physiological analogues 
Cobalt is an integral component of vitamin B12, but humans are exposed to many forms 
of cobalt other than B12.  Cobalt shows some chemical and physiological resemblance to 
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iron but is not a close physiological analogue of iron.  Absorption of cobalt in the small 
intestine appears to involve a transport mechanism that is partly shared with iron (Pollack 
et al. 1965, Schade et al. 1970a, 1970b).  Iron deficiency leads to increased absorption of 
both iron and cobalt (Pollack et al. 1965).  Iron absorption is reduced when it is 
administered together with cobalt (Schade et al. 1970a, 1970b), but absorption of cobalt 
is not diminished in iron-replete human subjects, indicating that competitive 
displacement of the elements is directed against iron but not against cobalt (Valberg et 
al., 1969, 1972).   
 
5.3.2.2. Behavior in the respiratory tract 
 
Information on the behavior of inhaled cobalt in the respiratory tract has been reviewed in 
ICRP Publication 71 (1995) and recently by an ICRP task group (to be published in an 
upcoming ICRP document).  Recent experimental data on inhaled cobalt were also 
discussed in an ICRP guidance document on applications of the HRTM (ICRP, 2002a).   
 
Extensive data are available on the fate of inhaled cobalt in the respiratory tract, in part 
due to frequent occupational exposures and in part because 60Co, with its easily measured 
gamma emissions, has been used frequently in experimental studies of the behavior of 
inhaled particles.  Workers have been exposed to cobalt as metal dusts, oxides or soluble 
salts.   
 
Although numerous studies have been carried out on the toxicity of inhaled cobalt-
containing alloys, the data do not reveal the clearance kinetics of cobalt.  Data obtained 
from diamond polishers and experimental data for rats suggest long-term retention in the 
lungs indicative of Type M or S behavior after inhalation of alloys. 
 
Studies in several animal species have shown that most of the cobalt deposited in the 
lungs after inhalation as chloride or nitrate is rapidly absorbed, but a few percent of the 
inhaled material is absorbed over several months.  Overall, the absorption is consistent 
with assignment to Type F. 
 
Detailed studies have been conducted of the lung clearance kinetics of various physical 
forms of cobaltosic oxide (Co3O4), including comparisons of clearance from the lungs of 
human volunteers, baboon, dog, guinea pig, rat, hamster and, mouse.  Lung retention was 
longer in humans and baboons than in the other species.  The inhaled material was 
designed to be moderately soluble, and it was determined that the rate of absorption was 
reasonably consistent with Type M parameter values. When the test material was selected 
to be less soluble, absorption in baboons and dogs was consistent with assignment to 
Type S.  Studies of lung retention in workers after accidental inhalation of radioactive 
cobalt oxide aerosols show slow removal from the lungs, broadly consistent with Type S 
parameter values. 
 
Highly insoluble polystyrene or fused aluminosilicate particles (FAP) labeled with 60Co 
have been used as relatively insoluble particles in inhalation studies of biokinetics and 
radiation effects.  After inhalation of either material, a small fraction of the inhaled 
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activity is rapidly absorbed, but the rest is retained within the particles and is absorbed 
slowly, from polystyrene at a rate of about 0.00005 d-1 and from FAP at a rate of about 
0.0005 d-1.  These values are broadly consistent with the long-term rate of 0.0001 d-1 for 
particle removal from AI assumed for Type S material. 
 
5.3.2.3. Fractional uptake from the gastrointestinal tract  
 
Information on gastrointestinal uptake of cobalt was reviewed by Harrison et al. (2001).  
Except where a specific study is cited, the following summary is taken from that review. 
 
Human data on uptake are highly variable.  Three studies involving relatively large study 
groups (n = 37 in one study) have been performed using CoCl2 (H1).  The results indicate 
mean absorption on the order of 0.02-0.08 with administration of tracer quantities, 
increasing to about 0.25-0.30 with added carrier.  In rats, only a few percent of cobalt is 
absorbed after ingestion of inorganic forms, but 30-70% is absorbed after ingestion in 
vitamin B12.  An absorption fraction of about 0.05 was estimated for 60Co ingested in crab 
meat by human subjects. 
 
Christensen (1995) studied gastrointestinal absorption of cobalt in adult males and 
females.  Soluble cobalt (chloride) was absorbed much more than insoluble (oxide) 
cobalt, and females absorbed much more than males.   
 
Studies on rats indicate that GI uptake of cobalt is highly elevated during the first few 
weeks of life, being nearly complete for organic forms and up to an order of magnitude 
greater than in adults for inorganic forms.  Absorption was also elevated in newborn 
guinea pigs but lower than in rats. Human data are available from a balance study of girls 
aged between 6 and 10 years in which absorption was estimated as 0.57.  This is higher 
than most reported values for absorption of cobalt in adult humans, but absorption 
estimates based on balance data generally involve sizable uncertainties. 
 
The ICRP’s current absorption values for cobalt are 0.1 for adults, 0.3 for children from 1 
y to 15 years of age and 0.6 for 3 month-old infants.  
 
5.3.2.4. Systemic biokinetics 
 
5.3.2.4.1. ICRP model 
 
The ICRP’s current systemic biokinetic model for cobalt (ICRP, 1993) does not have a 
physiologically meaningful structure. As in the model structure shown in Figure 5.1 for 
cesium, the cobalt model depicts one-directional movement of activity from blood to 
tissues to excretion pathways. The model divides systemic cobalt between liver and all 
other tissues combined, and activity in each of these repositories is assigned three 
retention components.  Cobalt is assumed to leave blood with a half-time of 0.5 d, with a 
fraction 0.5 going to excretion pathways, 0.05 going to the liver, and 0.45 uniformly 
distributed among the other organs and tissues.  Fractions 0.6, 0.2, and 0.2 of activity 
translocated from blood to tissues are assumed to be retained with biological half-times 
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of 6, 60, and 800 d, respectively, and to be lost directly to excretion pathways.  Activity 
moving to excretion pathways is divided between the urinary bladder contents and the 
upper large intestine contents in the ratio 6:1.  The biokinetics of systemic cobalt is 
assumed to be independent of age. 
 
5.3.2.4.2. Summary of biokinetic data on absorbed cobalt 
 
Whole-body retention or other aspects of cobalt biokinetics have been investigated by 
external measurement in several human subjects after accidental intake or administration 
of inorganic forms (Taylor, 1959; Smith et al., 1972; Letourneau et al., 1972; Beleznay 
and Osvay, 1994; Jansen et al., 1996).  The collective data indicate biological removal of 
perhaps three-fourths of the injected amount from the body over the first few days, 
another 10-15% over a period of weeks or months, and the remainder with a half-time on 
the order of 2 y.  Whole-body measurements in two subjects over a period of 1000 days 
after intravenous injection of 60CoCl2 indicated that retention could be described by a 
four component exponential function with the following average biological half-times 
(and component sizes):  0.54 days (44%); 5.6 days (32%); 63 days (13%) and 800 days 
(11%) (Smith et al., 1972).  Based on whole-body counting of 16 male subjects over a 
1-y period following intravenous injection of 58CoCl2, Letourneau and coworkers (1972) 
determined a five-component retention function with half-times (and component sizes)  
0.25 days (36%); 1.8 days (24%); 8 days (19%) 47 days (13%) and 608 days (9%). 
 
Beleznay and Osvay (1994) measured retention of 60Co between 10 and 1850 d in six 
workers who accidentally inhaled 60Co aerosols during manipulation of a high-activity 
source. A retention component of 25-78 d was interpreted as activity leaving the deep 
lungs.  A long-term component of retention determined in five of the workers followed 
for extended periods was interpreted as the slowest component of systemic retention of 
cobalt.  The half-time of the long-term component varied from about 500 d to about 
1200 d and averaged about 900 d in the five subjects. 
 
Plasma clearance of cobalt following intravenous injection of 60Co-chloride is rapid 
(Smith et al., 1972).  A substantial portion of the uptake to blood is rapidly excreted in 
urine.  Taylor (1959) measured the urinary excretion of 57Co in 13 normal human 
subjects (9 male, 4 female) during the first 24 hours after intravenous injection of cobalt 
glycinate; the average excretion was 34% of the injected activity with a range of 23% to 
47%.  There was no significant difference between the first day urinary excretion in 
males and females.  Measurements of the excretion of 60Co in the urine and feces of six 
subjects studied over 2 to 8 days showed that the greater proportion of the cobalt was 
eliminated by the kidneys, 22% being eliminated on the first day; fecal excretion during 
the study periods ranged from 5% to 30%, with an average of about 15%.  Taylor (1959) 
also reported a urinary to fecal excretion ratio of about 6:1 in one subject studied over a 
period of three days. 
 
Smith et al. (1972) concluded from external measurements that the amount of cobalt 
present in the liver may represent roughly one-fifth of the total-body content as an 
average over 0-1000 d (Smith et al. 1972).  More recently, Jansen et al. (1996) used 
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positron emission tomography to study the retention of 55Co in the liver in two male 
volunteers and concluded that ~50% of 55Co intravenously injected as 55CoCl2 deposited 
in the liver. 
 
The biokinetics of cobalt has been studied in a number of different animal species, 
including mice, rats, hamsters, guinea pigs, dogs, monkeys, and baboons (A1).  These 
studies provide information on the time-dependent distribution of absorbed cobalt as well 
its retention time in the body. However, extrapolation of the data to man is fraught with 
uncertainty due to apparent species differences in the biokinetics of cobalt.  For example, 
even though long-term retention times do not appear to vary greatly among species, the 
portion of administered activity that is retained for a long period is much greater in 
human subjects than in non-human species that have been studied (Figure 5.12).  Also, 
comparison of external data for human subjects with findings for laboratory animals 
suggests that the liver is a much more important long-term repository for cobalt in man 
than in the studied animal species. 
 
Characterization of the typical biokinetics of cobalt is further complicated by evidence 
that its biological behavior depends on the chemical form taken into the body.  For 
example, marked differences were seen in uptake and tissue distribution of 60Co in rats 
gavaged with inorganic 60CoCl2 or with a homogenate of fish in which 60Co had been 
biologically incorporated (Inaba et al., 1982). 
 
Figure 5.12. Species comparison of the size of the long-term retention component for 
inorganic cobalt (after Figure 8 of Leggett et al., 1998) 
 
 
5.3.2.4.3. Database for adult male humans 
 
Most of the H1 data for cobalt described above are for adult males. For example, a study 
of the biokinetics of intravenously administered 58Co by Letourneau et al. (1972) 
involved 16 adult males, a study by Smith et al. (1972) of the behavior of intravenously 
 81
 
administered 60Co involved 11 adult males. A related study of the behavior of orally 
administered 60Co by Smith et al. (1972) involved 12 adult males and one adult female. 
 
 
5.3.2.4.4. Differences with gender 
 
Christensen (1995) observed that urinary cobalt was higher in females than in males after 
ingestion of cobalt and hypothesized that this was due to higher GI uptake of cobalt by 
females, possibly associated with iron deficiency.  Comparative data on the systemic 
biokinetics of cobalt in adult males and females are limited but do not indicate important 
differences with gender.  For example, the measured long-term retention half-time in a 
female subject was within the range determined in male subjects (Figure 5.12).  After 
intravenous injection of 57Co glycinate into nine adult males and four adult females, no 
significant difference between the first day urinary excretion in males and females 
(Taylor, 1959).   
 
5.3.2.4.5. Variation with age 
 
It is assumed in ICRP Publication 67 (1993) that the systemic biokinetics of cobalt is 
independent of age.  This assumption was made partly on the weak basis that no evidence 
for age dependence was seen in a study on rats, and in part due to lack of a physiological 
basis for deriving age-specific parameter values. 
 
5.3.2.4.6. Effects of disease 
 
No data were found regarding effects of disease on the biokinetics of cobalt. 
 
5.3.2.4.7.  Biokinetics of radioactive progeny 
 
Cobalt-60 does not have radioactive progeny. 
 
5.3.3. Dosimetry 
 
Decay properties of 60Co including half-life, modes of decay, and energy spectra are well 
understood.  It produces two gamma rays with energies of 1.17 MeV and 1.33 MeV and 
is also a beta emitter with maximum beta energy of 1.55 MeV.  The dosimetric model is 
not an important source of uncertainty in dose estimates for 60Co.  
 
 
5.3.4. Variability of dose per unit intake or per unit exposure 
 
Adult females may receive higher tissue doses than adult males per unit ingestion of 60Co 
due to elevated GI uptake of cobalt in adult females. Elevated absorption of cobalt in 
infants is suggested by animal data (A1) but has not been confirmed by human studies.  
Elevated GI uptake of cobalt in children and adolescents, particularly adolescent girls, 
may occur due to an apparent relation between cobalt and iron absorption.  Also, results 
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of a balance study on girls up to age 10 y indicate relatively high uptake of cobalt. For the 
most part, however, the age-specific dose coefficients for 60Co provided in ICRP 
documents are based on assumptions rather than real information. 
 
5.3.5. Existing uncertainties assessments for 60Co 
 
Based on a critical review of the literature, Harrison et al. (2001) assigned the following 
high-confidence intervals for average fractional absorption of environmental cobalt from 
the GI tract:  0.02-0.2 for adults, 0.03-0.5 for age 10 y, and 0.04-0.8 for infants.  On the 
basis of a literature review and limited sensitivity analysis, Leggett et al. (1998) 
concluded that the ICRP’s systemic biokinetic model for cobalt has relatively low 
reliability with regard to predicted cumulative activity of 60Co in the liver.  Apostoaei et 
al. (1998) used parameter uncertainty analysis to assess uncertainties in dose coefficients 
for ingestion of 60Co on the basis of the ICRP’s simplistic model structure and derived an 
uncertainty factor, which they defined as the ratio of the 97.5th to 50th percentiles of the 
derived “probability distribution”, of about 8 for all tissues. Sensitivity analyses 
performed during the development of FGR13 (EPA, 1999) suggest moderate to high 
uncertainty, depending on the tissue, in dose estimates from inhalation or ingestion of 
60Co. 
 
 
5.4. Ruthenium-106 (Level 4) 
 
5.4.1. Overview 
 
The biokinetics of ruthenium is not as well understood as that of cobalt, for example, due 
mainly to a paucity of H1 data.  The behavior of ruthenium has been studied in several 
animal species, but a consistent picture of the fate of inhaled, ingested, or absorbed 
ruthenium has not developed.  Dose estimates for 106Ru are sensitive to gaps in the 
biokinetic information. 
 
5.4.2. Biokinetics 
 
5.4.2.1. Physiological analogues 
 
Ruthenium is in Group VIII of the periodic chart, also referred to as the platinum metals.  
In addition to ruthenium and platinum, this group includes iron, osmium, cobalt, 
rhodium, iridium, nickel, and palladium.  Available data do not reveal a close 
physiological analogue of ruthenium in this group.  Ruthenium and rhodium have similar 
chemical properties and appear to have broadly similar biokinetics in rats, but 
comparative data for these two elements are limited and the database for rhodium is too 
sparse to be of much use in modeling the biokinetics of ruthenium. 
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5.4.2.2. Behavior in the respiratory tract 
 
Information on the behavior of inhaled ruthenium in the respiratory tract has been 
reviewed in ICRP Publication 71 (1995) and recently by an ICRP task group (to be 
published in an upcoming ICRP document).  The following summary of inhalation data is 
abstracted from those reviews. 
 
In seven persons who accidentally inhaled 103RuO2 the effective half-life of the 
radioactivity in the chest was found to be 26.6 days.  In five men who accidentally 
inhaled 106RuO2 over a brief period, the mean biological half-time for retention in the 
chest was 206 ± 30 d (range, 174-428 d).  In beagles, inhaled 106RuO2 was avidly retained 
in the lungs, with an estimated biological half-life of ~2000 days.  Based on these studies 
and data for rats, the retention pattern for inhaled 106RuO2 seems broadly consistent with 
Type S.  Results from an in vitro dissolution study of samples of particles released from 
the Chernobyl accident indicate that ruthenium associated with irradiated fuel fragments 
should be assigned to default Type M in lieu of more specific information.  
 
Ruthenium may exist in gas or vapor form as well as in particulate form.  Measurements 
on a person accidentally exposed to ruthenium tetroxide vapor (RuO4) indicated that 
deposition occurred only in the extrathoracic airways, where the compound was 
subsequently retained.  Observations of the fate of inhaled 106RuO4 in dogs and rats 
indicate that deposition was primarily in the nasopharyngeal and tracheobronchial regions 
and that most of the deposited activity was lost in feces over a period of days. 
 
5.4.2.3. Fractional uptake from the gastrointestinal tract 
 
The following summary of the database on GI uptake of ruthenium was abstracted from a 
review by Harrison et al. (2001).  
 
Measurements of the absorption of ruthenium in male volunteers after ingestion of 
chloro-complexes of Ru(III) and Ru(IV) or absorption from contaminated clams gave 
values of about 0.01. Values for nitrosyl Ru(III) were about three times greater.  Results 
from studies of the absorption of 106Ru administered as the chloride to mice, rats, rabbits, 
guinea pigs, chickens, cats, dogs and monkeys, including values for fasted animals, 
indicate fractional uptake in the range of 0.03 - 0.06.  Values for 106Ru administered as 
the oxide to rats and rabbits were in the range of 0.003 - 0.03.  Absorption of ruthenium 
administered to rats and rabbits as a nitrato-nitrosyl complex was 0.06 and 0.13, 
respectively.  A value of 0.04 was reported for the absorption of ruthenium administered 
to rats as a nitro-nitrosyl.  (Nitrato and nitro- complexes of nitrosyl ruthenium are formed 
during dissolution in nitric acid in the reprocessing or U fuels.)  
 
Data on rats and mice indicate that fractional uptake of ruthenium from the GI tract may 
be as high as 0.07-0.08 in newborn animals. The ICRP’s currently recommended 
absorption values for ruthenium ingested by members of the public are 0.1 for infants and 
0.05 for ages 1 y or greater, both of which are cautiously high values. 
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5.4.2.4. Systemic biokinetics 
 
5.4.2.4.1. ICRP model 
 
The ICRP’s current systemic biokinetic model for ruthenium (ICRP, 1989, 1993) does 
not have a physiologically meaningful structure but depicts one-directional movement of 
activity from blood to tissues to excretion pathways.  Activity is assumed to be removed 
from blood with a half-time of 0.3 d, with 15% going to excretion pathways.  The 
remainder is assumed to be uniformly distributed throughout all organs and tissues of the 
body and is divided into three retention components:  35% is removed to excretion 
pathways with a biological half-time of 8 d, 30% with a half-time of 35 d, and 20% with 
a half-time of 1000 d.  Activity assigned to excretion pathways is divided between the 
urinary bladder contents and the upper large intestine contents in the ratio 4:1.  The 
systemic biokinetics of ruthenium is assumed to be independent of age. 
 
5.4.2.4.2. Summary of biokinetic data on absorbed ruthenium 
 
Direct information on the systemic biokinetics of ruthenium in the human body (H1) is 
sparse.  Yamagata et al. (1969, 1971) measured whole-body retention of ruthenium in a 
healthy adult male who ingested different chemical forms of 103Ru (T1/2 = 39.3 d) or 
106Ru (T1/2  = 373.6 d) on different occasions.  Results of the study using 103Ru suggested 
the possibility of two retention components for absorbed activity, one with a biological 
half-life of 2.3 d and one with a half-time of about 30 d.  The estimate for the early 
component is not particularly useful for modeling purposes because it could reflect 
mainly unabsorbed activity. The longer-term behavior of ruthenium in the body could not 
be determined with much confidence due to the short half-life of 103Ru.  Results from a 
later study on the same subject using 106Ru suggested a retention component with half-
time of about 9 d and a second component with half-life 32 d.  At longer times, the 
estimated biological “half-time” lengthened with the period of observation:  81 d based 
on observations in the period 40-80 d after intake, 122 d at 80-150 d after intake, 158 d at 
150-350 d after intake, and 385 d at 350-660 d after intake. 
 
Veronese et al. (2001) studied the blood kinetics of ruthenium in three healthy volunteers 
using the stable isotope 101Ru.  The results depend on the mode of intake (intravenously 
injected or ingested) and the chemical form injected and add little to our understanding of 
the systemic biokinetics of ruthenium. 
 
Due to the limitations of data on the biokinetics of ruthenium human subjects (H1), the 
ICRP based its systemic biokinetic model on observations of the behavior of ruthenium 
in laboratory animals (A1).  The studied animal species include mice, rats, guinea pigs, 
rabbits, cats, dogs, and monkeys (Burykina, 1962; Furchner et al., 1971; Stara et al., 
1971; ICRP, 1989).  Reported long-term retention half-times range from about 200 d to 
about 1600 d and show no trend with body mass.  The longest “half-time” observed in the 
human subject studied by Yamagata (1971) is within this broad range of values (Figure 
5.13). 
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Data on the systemic distribution of ruthenium comes mainly from studies on rodents and 
suggest a somewhat uniform distribution, the main exception being an elevated 
concentration in the kidneys in the early weeks after injection.  The ICRP’s biokinetic 
model for ruthenium was based mainly on data for mice, rats, monkeys, and dogs 
(Furchner et al. 1971), which were interpreted as indicating that the systemic biokinetics 
of ruthenium is reasonably independent of species. 
 
Figure 5.13.  Species comparison of long-term retention of ruthenium in the total body 
 
 
5.4.2.4.3. Database for adult male humans 
 
With the exception of limited information on the blood kinetics of ruthenium, the only 
H1 data on the systemic behavior of ruthenium is the information described earlier for an 
adult male who ingested different forms of ruthenium on different occasions (Yamagata 
et al., 1969, 1971). 
 
5.4.2.4.4. Differences with gender 
 
No information was found on differences with gender in the biological behavior of 
ruthenium. 
 
5.4.2.4.5. Variation with age 
 
No information was found on age related changes in the systemic biokinetics of 
ruthenium. As discussed earlier, GI uptake of ruthenium appeared to be elevated in 
newborn rodents. 
 
5.4.2.4.6. Effects of disease 
 
No data were found relating to potential effects of disease on the biokinetics of 
ruthenium. 
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5.4.2.4.7.  Biokinetics of radioactive progeny 
 
Ruthenium-106 decays to the short-lived 106Rh (T1/2 = 29.9 s). It seems unlikely that 
106Rh migrates to any appreciable extent from 106Ru in view of the chemical similarity of 
ruthenium and rhodium and the short half-life of the 106Rh, but there is no direct 
information on the fate of 106Rh produced in vivo. 
 
5.4.3. Dosimetry 
 
The dosimetry model for the 106Ru chain does not appear to be an important source of 
error in dose estimates from intake of 106Ru.  Decays of the short-lived daughter 106Rh 
represent over 99% of the energy deposited in tissues.  The decay scheme for 106Rh is 
well established.  It is a beta and gamma emitter with half life of 29.9 s.  Its maximum 
beta energy is 3.54 MeV.  Its mean photon energy is 0.60 MeV.   
 
5.4.4. Variability of dose per unit intake or per unit exposure 
 
Available data provide little insight into the variability of dose in the population from 
intake of 106Ru.  Age-specific dose coefficients for 106Ru are provided in ICRP documents 
but are based on assumptions and suggestive data for rodents rather than real information 
for humans or preferred animal models. 
 
5.4.5. Existing uncertainties assessments for intake of 106Ru 
 
5.4.5.1. Summary of published assessments 
 
Harrison et al. (2001) concluded from a literature review that high-confidence intervals 
for average fractional absorption of ruthenium from the gastrointestinal tract are 0.005-
0.1 for adults, 0.005-0.15 for age 10 y, and 0.005-0.2 for infants.  On the basis of a 
literature review and limited sensitivity analysis, Leggett et al. (1998) concluded that the 
ICRP’s systemic biokinetic model for ruthenium has relatively low reliability with regard 
to predicted cumulative activity of 106Ru in the total body.  Apostoaei et al. (1998) used 
parameter uncertainty analysis to assess uncertainties in dose coefficients for ingestion of 
106Ru on the basis of the ICRP’s simplistic model structure for ruthenium and derived 
uncertainty factors (ratio of 97.5th to 50th percentiles of the probability distribution) of 
about 3 for the intestines, 6 for stomach, and 9 for other tissues.  Sensitivity analyses 
performed during the development of FGR13 (EPA, 1999) suggest that dose from 
inhalation or ingestion of 106Ru cannot be determined with much confidence and that 
moderately high confidence can be placed in external dose coefficients for 106Ru. 
 
 
5.4.5.2. A preliminary assessment based on comparison of alternate models 
 
The authors of the present report performed limited calculations to examine the 
sensitivity of dose coefficients for 106Ru to uncertainties in the biokinetics of ruthenium 
in the adult. A comparison was made of dose estimates for intravenously injected 106Ru 
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generated by substantially different but equally plausible biokinetic models for 
ruthenium. This procedure is illustrated here for three such models, called Models A, B, 
and C, developed by different modelers.  Model A is the ICRP's current biokinetic model 
for this element, described earlier.  Model B, shown in Figure 5.14, was developed by 
Runkle et al. (1980) as a fit to their measurements of 106Ru in tissues and excreta of rats 
exposed to 106RuO4 by inhalation or ingestion. 
 
 
 
Figure 5.14.  Systemic biokinetic for ruthenium developed by Runkle et al. (1980) (Model B 
in text) based on data for rats exposed to 106RuO4 by inhalation or ingestion 
 
 
Model C has a structure similar to that of Model B but differs substantially from Model B 
with regard to rates of movement of activity between compartments.  Transfer rates for 
Model C were based on the broadly consistent whole-body retention data for dogs 
(Furchner et al., 1971) and a human subject (Yamagata et al., 1971) and on the 
distribution of systemic activity observed in guinea pigs (Burykina, 1962).  Activity is 
assumed to be removed from blood with a half-time of 0.25 d, with 20% depositing in the 
urinary bladder contents, 5% in the small intestine contents, 20% in liver (in a 
compartment called Liver 1), 10% in the kidneys (Kidney 1), 35% in other soft tissues 
(Other 1), and 10% on bone surface (Skeleton 1).  Activity leaves Liver 1, Kidney 1, 
Other 1, and bone surface with a half-time of 5 d.  Of activity leaving Liver 1 or Other 1, 
90% returns to blood and 10% moves to a long-term compartment of the same tissue 
(Liver 2 or Other 2, respectively).  Of activity leaving Kidney 1, 98% returns to blood 
and 2% moves to a long-term compartment in the kidneys (Kidney 2).  Of activity 
leaving bone surface, 75% returns to blood and 25% moves to bone volume (Skeleton 2).  
Activity moves from Liver 2 to the small intestine contents with a half-time of 100 d, 
from Kidney 2 to Kidney 1 with a half-time of 100 d, from Other 2 to Other 1 with a half-
time of 500 d, and from bone volume to bone surface with a half-time of 1000 d. 
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Dose coefficients for 106Ru based on the three different models are compared in 
Table 5.4.  Relative to the ICRP's model for ruthenium, Model C yields substantially 
higher estimates of dose equivalent to liver, kidneys, and skeletal tissues, generally lower 
estimates for other tissues, and a reasonably similar (30% greater) effective dose.  
Compared with the ICRP's model for ruthenium, Model B yields lower estimates of dose 
equivalent to all tissues except the kidneys, and estimates of the effective dose are 
reduced by a factor of 6.   
 
These comparisons of predictions of three equally plausible systemic models for 
ruthenium indicate the relatively large uncertainties in dose per unit activity of 106Ru 
reaching blood.  This analysis does not address the uncertainties associated with the 
behavior of inhaled 106Ru in the respiratory tract or the level of absorption of inhaled or 
ingested 106Ru to blood, and it provides an indication of only minimal uncertainties for 
absorbed 106Ru.  Thus, it is evident that dose estimates for inhaled or ingested 106Ru 
involve sizable uncertainties. 
 
 
Table 5.4. Comparison of injection dose coefficients for 106Ru (adult male) 
based on three different biokinetic models for ruthenium described in the text 
 
 
Tissue 
Dose coefficient 
based on Model A 
(Sv Bq-1) 
Ratio of dose 
coefficients 
B:A 
Ratio of dose 
coefficients 
C:A 
Bone surfaces 2.9E-08 0.13 4.5 
Stomach wall 2.9E-08 0.020 0.54 
Small intestine wall 2.9E-08 0.062 0.57 
Upper large intestine wall 3.3E-08 0.24 0.62 
Lower large intestine wall 4.1E-08 0.53 0.73 
Kidneys 2.9E-08 2.5 6.7 
Liver 2.9E-08 0.11 4.5 
Red marrow 2.9E-08 0.12 3.4 
Urinary bladder wall 3.4E-08 0.16 0.58 
Other tissues 2.9E-08 ~0.02 ~0.55 
Effective dose 3.0E-08 0.16 1.3 
 
 
5.5. Californium-252 (Level 5) 
 
5.5.1. Overview 
 
The biokinetic database for californium is sketchier than that for ruthenium.  The only H1 
data found for californium consists of limited measurements on two persons who 
accidentally inhaled 252Cf and a person who accidentally inhaled 249Cf together with its 
parent, 249Bk.  Excretion data for the person exposed to 249Cf are not consistent with any 
of the default absorption types used by the ICRP.  Information on GI uptake comes from 
measurements on rats.  Information on the systemic biokinetics of californium comes 
from studies on laboratory animals, including dogs.  The dosimetric model for 252Cf 
involves potentially large errors associated with the model of spontaneous fission and the 
radiation weighting factors for alpha particles and neutrons. For these reasons, dose 
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estimates for internally deposited 252Cf may involve even larger errors than estimates for 
internally deposited 106Ru.  
  
5.5.2. Biokinetics 
 
5.5.2.1. Physiological analogues 
 
Biokinetic studies of californium in laboratory animals indicate that its behavior is 
qualitatively similar to that of other transuranium elements.  Among the frequently 
studied transuranics, americium appears to be its closest physiological analogue.  The 
microscopic distribution of californium in soft tissues of beagles 1-3 wk after intravenous 
injection of a citrate solution was found to be similar to that of americium (Taylor et al., 
1972).  The gross distribution of californium in the skeleton, expressed as the percentage 
of skeletal californium in a given bone, is similar to that of americium (Lloyd et al., 
1972).  The microscopic distribution of californium in the skeleton is also similar to that 
of americium in rats, with heaviest deposits on the trabeculae of the primary spongiosa 
and on epiphyseal and metaphyseal trabeculae (Durbin 1973). 
 
5.5.2.2. Behavior in the respiratory tract 
A case of accidental inhalation of a mixture of 249Cf and its parent, 249Bk, by a chemist 
was studied by external measurements and excretion analysis over the first year after 
intake (Rundo and Sedlet, 1973). The inhaled material was ignited before intake and was 
presumably highly insoluble.  Except for an initially rapid clearance via feces, the urinary 
and fecal excretion rate of both radionuclides increased with time for 2-3 months after 
intake and then declined.  This pattern differs from the monotonically decreasing rates of 
transfer from lungs to blood and excretion in urine and feces depicted in models of the 
ICRP(1994a, 2002a).  
 
In another case, a chemist and an analyst inhaled airborne 252Cf while attempting to 
reprocess a medical source (Poda and Hall, 1975). Approximately 1 μg 252Cf2O3 was 
released when the end plug of the inner capsule was sheared during the removal of the 
outer capsule.  Both persons left the work area when an alpha air monitor sounded shortly 
after the accident.  An initial survey indicated contamination in the nostrils and on the 
clothing of the analyst (Subject 1), but no contamination was detected on the chemist 
(Subject 2).  Both persons were treated with chelates.  A rapid renal excretion of Cf was 
observed for the first 24-hour period in each subject but may have been strongly affected 
by DTPA treatment.  Total urinary excretion of 252Cf during the first month by the 
chemist was 1-2 orders of magnitude lower than that for the analyst. Urinary excretion 
patterns for the two subjects are shown in Figure 5.15, where excretion has been 
normalized to the percentage of the first day’s excretion for the respective individual. 
 
5.5.2.3. Fractional uptake from the gastrointestinal tract 
 
Gastrointestinal absorption of californium has been measured in rats administered 
252Cf(NO3)3 intragastrically.  Absorption is in the range 0.01-0.1% depending on the 
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method of estimation (ICRP, 1979).  The ICRP assumes absorption of 0.05% of ingested 
californium in an adult, which is consistent with values determined for plutonium, 
americium, and curium in human subjects (H2) as well as with the limited animal data for 
californium (A1). 
 
Figure 5.15.  Observed patterns of urinary excretion of 252Cf following acute inhalation.  
DTPA administered on Days 1, 4, and 18 (arrows) (data normalized to individual’s Day 1 
excretion) 
 
 
5.5.2.4. Systemic biokinetics  
 
5.5.2.4.1. ICRP model 
 
The ICRP’s current systemic biokinetic model for californium was introduced in ICRP 
Publication 30 (1979) and extended to a bioassay model in Publication 68 (1994). The 
model does not have a physiologically meaningful structure but depicts one-directional 
movement of activity from blood to tissues to excretion pathways.  It is assumed that 
californium leaves blood with a half-time of 0.25 d, with 65% depositing in the skeleton, 
25% in the liver, 0.011% in ovaries, and 0.035% in testes.  The rest (9.954%) is promptly 
excreted.  The removal half-time is 50 y for skeleton, 30 y for liver, and infinite for 
gonads.  Activity lost by prompt excretion or through biological removal from tissues is 
equally divided between the urinary bladder contents for removal in urine and the upper 
large intestine contents for removal in feces. 
 
5.5.2.4.2. Summary of biokinetic data on absorbed californium 
 
The biokinetics of californium has been studied in mice, rats, Chinese and Syrian 
hamsters, and beagles (Parker et al., 1962; Mewhinney et al., 1971, 1972; Lloyd et al., 
1971, 1972, 1974, 1976; Smith, 1972; Atherton and Lloyd, 1972; Bruenger et al., 1972; 
Stevens and Bruenger, 1972; Taylor et al., 1972; Durbin, 1973; Graham et al., 1978).  
Species differences have been observed.  For example, Mewhinney et al. (1972) found 
significant differences in the behavior of 252Cf in rats and Chinese hamsters over 64 d 
following intraperitoneal injection of the citrate complex, including lower uptake of 
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activity by the liver and kidneys and higher uptake by the skeleton in rats and much faster 
removal from the liver in rats (Table 5.5).  The behavior of californium in beagles 
receiving 249Cf or 252Cf by intravenous injection (Lloyd et al., 1971, 1972) was broadly 
similar to that in the hamster with regard to uptake and retention in major repositories.  
The fecal to urinary excretion ratio was much higher in rats than in dogs, probably due to 
a higher rate of biliary secretion of californium. 
 
 
Table 5.5. Species differences in the early distribution 
of 252Cf injected as citrate (Mewhinney et al., 1972; 
Lloyd et al., 1972; Durbin, 1973) 
% injected activity at 7-8 d  
Tissue or excreta Hamster Rat Dog 
Kidney 2.9 1.2 0.9 
Liver 25.6 3.5 19.2 
Skeleton 25.3 65.7 44.1 
Whole body 66.3 69.3 78.3 
Urine -- 7.8 15.1 
Feces -- 11.0 6.9 
 
 
Measurements on rats and mice indicate a biological half-time for the whole body on the 
order of 2 y (400-1000 d).  This reflects primarily skeletal retention on these animals 
because the removal half-time from the liver is short and other soft tissues do not retain 
much californium.  In dogs or hamsters, whole-body retention of californium reflects 
tenacious retention of in both the liver and skeleton.  For the beagle, half-times of 8.5 y 
and 4.2 y have been estimated for the whole body and liver, respectively. 
 
Observed species differences in the retention time of californium in the liver is consistent 
with a pattern seen for other transuranic elements.  That is, certain mammalian species 
show rapid removal of transuranics from the liver, while others show extremely slow 
removal. For example, rats, tree shrews, macaque monkeys, and baboons show rapid loss 
of plutonium from the liver, with half-times of 4-200 d, while another set of adult animals 
with an overlapping range of body weights, including hamsters, dogs, pigs, and humans, 
show tenacious retention of plutonium in the liver, with half-times measured in years or 
decades (Taylor, 1984).   
 
In the skeleton, californium appears to be deposited most heavily about the trabeculae of 
the primary spongiosa and on epiphyseal and metaphyseal trabeculae.  In soft tissues of 
dogs, relatively high concentrations are found in the hepatic cells of the liver, the 
glomeruli of the kidney, the interfollicular region of the thyroid, the cartilaginous tissues 
of the lung, and in the smaller arterioles of most organs.  Intense but scattered “hot spots” 
were found in the renal papillae and the submucosa of the bronchioles.  Except for 
deposition in hepatic cells, most of the deposition sites in soft tissues were extracellular, 
associated with connective tissue. 
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The beagle is expected to be a reasonable laboratory model for the biokinetics of 
californium in humans due to qualitative similarities in the biokinetics of other 
transuranics (plutonium, americium, and curium) in dogs and humans, particularly for the 
liver and skeleton. In extrapolating biokinetic data for californium from beagles to 
humans, species differences in rates of apparently pertinent physiological processes must 
be taken into account.  For example, the residence time of californium in bone may be 
substantially greater in adult humans than in adult beagles due to a slower rate of bone 
turnover in humans. 
 
5.5.2.4.3. Database for adult male humans 
 
The cases of accidental inhalation of californium isotopes described earlier involved adult 
males. No other H1 data for californium were found. 
 
5.5.2.4.4. Differences with gender 
 
No information was found on differences with gender in the biological behavior of 
californium.   
 
5.5.2.4.5. Variation with age 
 
No information was found on age related changes in the systemic biokinetics of 
californium. Based on findings for other transuranics in laboratory animals, it is expected 
that fractional deposition would be greater in the growing skeleton than the mature 
skeleton. 
 
5.5.2.4.6. Effects of disease 
 
No data were found relating to potential effects of disease on the biokinetics of 
californium. 
 
5.4.2.4.7.  Biokinetics of radioactive progeny 
 
The decay chain beginning with 252Cf includes 17 radionuclides, but the radioactive 
progeny of 252Cf can be neglected in dose estimates from intake of pure 252Cf due to the 
extremely long half-life of the next chain member, 248Cm (T1/2  =  3.5 x 105 y). 
 
5.5.3. Dosimetry 
 
The decay scheme for 252Cf is reasonably well understood with regard to half-life, modes 
of decay, and decay energies.  However, the dosimetric model used to convert 252Cf 
decays to equivalent doses to tissues involves potentially large errors.  These errors arise 
mainly from a simplistic representation of spontaneous fission and uncertain RBEs for 
alpha particles and neutrons. 
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The dosimetry model takes account of the fission decay fraction, the number of neutrons 
emitted per fission, and the intensities and energies for spontaneous fission fragments, 
neutrons, beta particles, prompt gamma rays, and delayed gamma rays. The assumption is 
made, however, that the energies associated with all of these sources are emitted at the 
time and point of alpha emissions from 252Cf, which is a considerably simplified 
depiction of actual events. 
 
The ICRP currently applies a radiation weighting factor of 20 for alpha radiation and 5-
20 for spontaneous fission neutron radiation, depending on the energy.  These weighting 
factors are representative values (perhaps on the cautiously high side of central estimates) 
of RBEs that have been estimated from studies of human populations or laboratory 
animals exposed to neutrons or alpha emitting radionuclides, in vitro data, and theoretical 
considerations (NCRP, 1990). 
 
Ranges of estimated RBE for alpha particles or neutrons are wide, depending on both the 
biological system and the observed endpoint (NCRP, 1990; EPA, 1999).  The uncertainty 
in the RBE estimated from an individual study also is usually large, primarily due to the 
uncertainty in extrapolation of low-LET data to low doses.  At relatively high doses, the 
effectiveness of alpha emitters has been found to be 15 to 50 times that of beta emitters 
for the induction of bone sarcomas, liver chromosome aberrations, and lung cancers 
(NCRP, 1990).  Since the LET of secondary protons produced by fission neutrons in 
living tissue is comparable to that for alpha particles, data on the RBE of fission neutrons 
provides ancillary information relevant to the estimation of alpha particle RBE.  
Experimental data as well as theoretical considerations indicate that the neutron RBE 
depends on energy.  Where the dose response data on carcinogenic endpoints are 
adequate to derive an estimate, fission neutrons have been found to have an RBE of 6-60 
times that of low dose gamma rays (NCRP, 1990).  Overall, experimental data for solid 
tumor induction with alpha particles and fission neutrons suggest a central value for RBE 
between 10 and 30 and a range of roughly 5 to 60 for the RBE relative to low-dose, low-
LET radiation (NCRP, 1990; EPA, 1999). 
 
The problem also arises that the effective RBE may vary with cancer type or cancer site.  
Site-specific cancer risk estimates for alpha particles have been calculated using human 
epidemiological data on low-LET radiation such as in the Atomic Bomb Survivor Study 
and laboratory data on the RBE of high-LET radiation compared to a reference low-LET 
radiation (NCRP, 1990).  There is evidence that the RBE of 20 commonly applied to 
alpha particles is much too high with regard to radiogenic leukemia.  In FGR13 (EPA, 
1999), an RBE of 1 was applied to alpha-particle irradiation of red marrow. 
 
Another important source of uncertainty regarding dosimetry of alpha emitters such as 
252Cf is the potentially heterogeneous distribution of the radionuclide or the target cells, 
or both, in tissues. Because alpha particles have an extremely short range, the fraction of 
alpha emissions reaching radiosensitive cells is difficult to estimate if either the cells or 
the alpha emitter is not fairly uniformly distributed. Tissues known or thought to have 
heterogeneous distributions of radiosensitive cells include the lungs, bone, bone marrow, 
and gonads. 
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As an illustration, the hematopoietic stem cells of bone marrow are known to be 
radiosensitive and to be heterogeneously distributed.  It is not feasible to model the 
distribution of these cells in much detail, and the ICRP assumes simply that the cells are 
uniformly distributed within the marrow space of trabecular bone.  If the sensitive cells 
were actually located more than 10 μm from the bone mineral surface, the fraction of 
alpha energy emitted by a radionuclide on the surface of trabecular bone that is absorbed 
by these cells would be no more than about 0.3 for alpha energy in the range 5-8 MeV, 
compared with the value 0.5 assumed by the ICRP.  For an alpha emitter uniformly 
distributed throughout the mineral of trabecular bone, the fraction of emitted energy 
reaching the red marrow depends on the energy of the alpha particle.  Calculations for 
bone-volume-distributed alpha emitters ranging in energy from 5 to 8 MeV indicate that 
the absorbed fraction in the marrow space ranges between 0.041 and 0.087, which 
bracket the value of 0.05 recommended by the ICRP.  If the sensitive cells were located 
more than 10 μm from the bone mineral surface, the relevant absorbed fraction would be 
reduced to 0.015-0.055.  Additional uncertainties in the dosimetry arise from the fact that 
the distribution of alpha emitters such as 252Cf on bone surfaces or within bone marrow is 
poorly characterized.  For example, 252Cf might accumulate in regions of bone marrow 
that contain relatively few radiosensitive cells, in which case alpha emissions from 252Cf 
in bone marrow would present little risk. 
 
5.5.4. Variability of dose per unit intake or per unit exposure 
 
There is no direct information on the variability of dose in the population from exposure 
to 252Cf.  On the basis of animal data for transuranium elements, it is expected that 
gastrointestinal absorption of 252Cf would be elevated in infants, and that the deposition 
ratio skeleton:liver would be greater during growth than after maturity. 
 
5.5.5. Existing uncertainties assessments for intake of 252Cf  
 
5.5.5.1. Published assessments 
 
No previous uncertainty assessments concerning the biokinetics of californium or dose 
from intake of 252Cf were found. 
 
5.5.5.2. Comparison with an alternate model 
 
It is evident that the ICRP’s current systemic biokinetic model for californium (described 
above) is not physiologically meaningful and does not fully reflect available information 
on the biokinetics of californium.  In fact, the model does not reflect specific data for 
californium but is based on the assumption that californium behaves the same as 
plutonium (ICRP, 1979).  The ICRP’s systemic biokinetic model for plutonium has been 
updated several times since the appearance of ICRP Publication 30, but the model for 
californium remains the same as originally formulated, although explicit excretion 
pathways were added in ICRP Publication 68 (1994). 
 
 95
 
A more detailed model based on current data for californium has been proposed (Leggett, 
2001).  The ICRP’s generic model for bone-surface-seeking radionuclides is applied 
(Figure 5.16).  Parameter values are based on the relatively detailed information on 
californium biokinetics in laboratory animals, particularly dogs, and the comparative 
biological behavior of californium and americium. The rationale is that there is relatively 
good information on the behavior of americium in human subjects and comparative data 
on americium and californium in animals. It seems reasonable to use the ICRP’s model 
for americium as a starting point for modeling the biokinetics of californium and adjust 
the parameter values for americium as indicated by comparative data on americium and 
californium in beagles. 
 
 
 
Figure 5.16.  Structure of the proposed model for californium (based on the ICRP’s 
generic model structure for bone-surface-seeking radionuclides - ICRP, 1993) 
 
 
The following adjustments to the ICRP’s systemic biokinetic model for americium were 
made (Leggett, 2001): the removal half-time from blood is 1 h, compared with 30 min for 
americium; deposition in liver plus skeleton is 70% (i.e., 70% of activity leaving the 
circulation), compared with 80% for americium; the division between liver and skeleton 
is 20%-50%, compared with 50%-30% for americium; deposition in urinary bladder 
contents is 11%, compared with 7% for americium; deposition in the contents of the GI 
tract is 6%, compared with 1.3% for americium; deposition in the urinary path (Kidneys 
1) is 2% and in other kidney tissues (Kidneys 2) is 1%,  compared with 2% and 0.5%, 
respectively, for americium; the removal half-time from Kidneys 2 to blood is 5 y, 
compared with 500 d for americium; the removal half-time from the intermediate-term 
soft-tissue compartment to blood is 100 d, compared with 50 d for americium.  
Otherwise, the biokinetics of californium is assumed to be the same as that of americium. 
 
The proposed model for californium was applied to estimate the rate of urinary excretion 
of californium and dose per unit intake of californium isotopes.  Predicted urinary 
excretion rates following introduction of californium to blood are compared in Figure 
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5.17 with predictions of the current ICRP model.  Predictions of the ICRP model are 1-2 
orders of magnitude lower than those of the proposed model from a few days to a few 
weeks after uptake of californium to blood.  
 
 
Figure 5.17. Comparison of predictions of urinary californium based on the systemic 
biokinetic model for californium given in ICRP Publication 68 and Publication 78 (1997) 
and a proposed model (Leggett, 2001), assuming intravenous injection of californium at 
time 0  
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6. DEMONSTRATION OF DIFFERENT LEVELS OF POTENTIAL 
ERROR IN EXTERNAL DOSE COEFFICIENTS 
 
This section discusses the basis for the external dose coefficients given in FGR12.  For 
selected radionuclides, potential errors associated with applications of those dose 
coefficients are examined.   
 
6.1. The external dose model of FGR12 
 
The dose coefficients in FGR12 (EPA, 1993) are based on idealized exposure geometries 
and a mathematical phantom representing a reference adult male standing in an upright 
position at the air-ground interface.  The calculation of external dose rates from 
radionuclides distributed in air, soil, or ground surfaces was divided into two steps: 
(1) calculation of the photon radiation field incident on the surface of the body and 
(2) calculation of organ dose rates due to a body surface source.  With the exposure 
geometry considered, an error in an external dose coefficient for a specific radionuclide, 
exposure scenario (e.g., standing on a contaminated ground surface), and tissue would 
reflect the error in the estimate of the radiation field incident upon the body and the error 
in the estimated dose rate to specific tissues due to a body surface source. The latter 
errors could arise in part from the simplified representation of the human body as a 
mathematical phantom.  In the adult phantom used in FGR12, the size and shape of an 
organ or tissue are approximated by a three-dimensional figure such as a portion of a 
sphere, cylinder, or cone, that can be represented by a relatively simple mathematical 
expression involving positional variables x, y, and z.  
 
Checks of external radiation fields derived in FGR12 against actual measurements and 
alternate theoretical methods suggest that, for photon energies above 200 keV, the 
methods of FGR12 generally are accurate within a few percent for the simple geometries 
considered.  Also, estimated organ dose rates due to a body surface source are expected 
to be accurate within a few percent in most cases for photon energies above 200 keV.  
Errors in estimated external dose increase with decreasing photon energy and can be 
greater than 100% for photon energies of a few tens of keV. 
 
Voxel phantoms have been used to investigate variability in external dose and provide a 
check on the accuracy of external dose estimates based on mathematical phantoms.  A 
voxel phantom is based on computed tomographic data for a real person, with each organ, 
tissue, or fluid represented as a set of points describing its volume and position as 
determined in the scan.  A voxel phantom is typically based on a living adult who is 
undergoing a scan for medical purposes but sometimes is based on a cadaver. 
 
Zankl et al. (2002) used seven adult male and female voxel models to examine inter-
subject variability of tissue doses for external whole body irradiation by photons of 
energies between 10 keV and 10 MeV.  The idealized geometries considered were broad 
parallel photon beams in anterior-posterior, posterior-anterior, left- and right-lateral 
direction and a full 360 degree rotation around the body length axis. Dose differences 
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between the different voxel models were below 30% for some organs and geometries for 
photon energy between 60 and 200 keV but were 100% or more in some cases due to 
differences in stature and individual anatomical details.  According to Zankl and 
coworkers, the inter-individual differences in body size and organ geometry could 
amount to several hundred per cent for low photon energies.  Comparison with estimates 
based on mathematical models indicated differences of several tens of per cent for some 
organs. 
  
6.2. Quality of the decay data 
 
The quality of current nuclear decay data was discussed briefly in previous sections in 
connection with conversion from internally deposited activity to tissue dose for selected 
radionuclides. For most radionuclides the quality of the nuclear decay data is expected to 
be a minor source of uncertainty.  Some exceptional cases are discussed in Section 7. 
 
The same nuclear decay data and anthropomorphic phantoms applied to internally 
deposited radionuclides are used to derive dose coefficients for external exposure.  In 
particular, the decay database described in ICRP Publication 38 (1993) and mathematical 
phantoms used to develop the inhalation and ingestion dose coefficients currently 
recommended by the ICRP were used to derive the external dose coefficients tabulated in 
FGR12.  The photon radiation field incident on the body depends on the energies and 
intensities of the photon emissions summarized in Publication 38.   
 
Uncertainties in the intensities of photon emissions are higher for x-rays where the 
intensities are based, in part, on the fluorescence yield in the electron shells.  Differences 
between theoretical and experimental fluorescent yields increase with increasing electron 
shell and atomic number.  However, the energies of the x-rays from the higher electron 
shells are low and thus their contribution to organ dose is reduced. 
 
6.3. Potential errors in external dose coefficients for selected radionuclides 
 
In occupational and public health applications of external dose coefficients, the largest 
uncertainties usually arise from differences between the actual distribution of the 
radionuclide in the environment and the ideal geometries assumed in the derivation of the 
dose coefficients.  For example, differences between the assumed infinite exposure 
geometries and real, finite exposure geometries often are significant.  An example is 
exposure to contaminated ground surface for which the source region is assumed to be a 
smooth plane.  In reality, external dose rates from sources on the ground surface 
generally are reduced by shielding due to surface vegetation and irregularities in the 
terrain.  In the present and proposed studies, statements concerning the potential error in 
an external dose coefficient are not intended to account for the differences between the 
real exposure geometry and the idealized geometry assumed in FGR12. 
 
If the decay data for a radionuclide are reasonably well established and fully reflected in 
the dose coefficients in FGR12, the potential errors associated with the dose coefficients 
are expected to be relatively low for high-energy photons and to increase with decreasing 
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photon energy.  For some of the radionuclides addressed in FGR12, however, available 
decay data are not fully reflected in the dose coefficients.  For example, the coefficients 
for 252Cf do not reflect radiations associated with spontaneous fission.  Preliminary 
estimates that include radiations associated with spontaneous fission other than neutrons 
raise the dose coefficient for exposure to 252Cf on the ground surface by three orders of 
magnitude. When neutron dose is added (calculations are not yet complete), the dose per 
unit concentration of 252Cf on the ground surface may approach that for high-energy 
photon emitters such as 60Co.  
 
For the five radionuclides addressed in Section 5, external dose coefficients are given in 
Table 6.1 for the case of exposure to contaminated ground surface.  A qualitative 
assessment of the potential error associated with each dose coefficient is given in the 
third column of the table.  The potential error is judged to be small for 60Co, slightly 
larger for 137Cs/137mBa or 106Ru/106Rh than for 60Co, and large for the low-energy photons 
associated with 90Sr/ 90Y.  The listed value for 252Cf is orders of magnitude lower than 
indicated by current information.  The potential error is large for 252Cf because the main 
sources of external dose from 252Cf are photons and neutrons associated with spontaneous 
fission, and spontaneous fission is not reflected in dose coefficients given in FGR12.  
 
 
Table 6.1. Comparative external dose coefficients from FGR12 (EPA, 1993) 
for exposure to contaminated ground surface (Sv per Bq s m-2) 
 
 
Radionuclide 
Dose coefficient 
for red marrow 
given in FGR12 
(Sv per Bq s m-2) 
 
Potential relative error for the 
geometry used in FGR12 
60Co 2.3E-15 Small 
137Cs + 137mBa 5.7E-16 Modest 
106Ru + 106Rh 2.1E-16 Modest 
90Sr + 90Y 4.8E-18 Large but usually inconsequential 
252Cf 1.9E-19 Too low by at least 3 orders of magnitude 
 
 
 
6.4. Variation of external dose with body size 
 
Calculations indicate that the dose to organs of the body from external radiation generally 
increases with decreasing body size since the shielding from the thickness of overlaying 
tissue decreases with decreasing body size.  Thus, external doses to tissues are expected 
to be somewhat higher in children than in adults.  The dose coefficients in FGR12 are 
based on an anthropomorphic phantom representing a typical adult male and are expected 
to underestimate doses received by children to an extent that depends on photon energies. 
The dependence on body size is more pronounced at low photon energy than at high 
energy and is also more pronounced for organs located deep in the body than for more 
shallow organs with less shielding by overlying tissues.  Variation of external dose with 
body size also depends on the nature of the radiation field. 
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As an extreme example, consider the dose to the stomach from a broad beam of photons 
incident on the right side of the body.  Under this exposure geometry, the dose to the 
stomach, most of which is on the left side of the body, is highly sensitive to body size and 
hence age (Figure 6.1, left panel).  The dose to the stomach of a child is estimated to be 
about 8 times that in the adult.  If the photons are incident on the front of the body 
(Figure 6.1, right panel), the dependence on body size and hence age is reduced and the 
estimated child-to-adult ratio is about 2. 
 
 
 
 
Figure 6.1. Age-specific equivalent dose to the stomach from monoenergetic photons 
incident on the body (graph on left based on the assumption that the photons are incident 
on the right side of the body; graph on right is for photons incident on the front of the body) 
(estimates by Yamaguchi, 1994) 
 
 
The dependence on body size is further reduced for exposure to a more uniform radiation 
field. Estimated doses to the liver of the adult male and female are shown in Fig. 6.2 for a 
monoenergetic photon source uniformly distributed in the air or on the ground surface. In 
this case, little difference is evident between the male and female at photon energies less 
than approximately 0.07 MeV for this non-directional exposure.  In addition to the non-
directional field, the scatter of photons in air results in a broad spectrum of energies 
incident on the body. Thus, integration over the energy and angular distribution of the 
incident radiation field has the effect of reducing the dependence of organ dose on body 
size.   
 
The effective dose exhibits less dependence on body size than seen in selected organs 
because it weights the dose to tissues at various depths in the body.  This is evident from 
Figures 6.3, based on the exposure geometries of Figure 6.1, and from Figure 6.4, based 
on an isotropic radiation field. 
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Figure 6.2. The equivalent dose to the liver of an adult male or female for a mononergetic 
photon source uniformly distributed in the air or on the ground surface (estimates by Zankl 
et al., 1997) 
 
 
 
Figure 6.3. Age-specific values of the effective dose per unit air kerma for monoenergetic 
photons incident on the front of the body (left panel) and on the right side of the body (right 
panel) (estimates by Yamaguchi, 1994) 
 
 
The largest uncertainty in application of external dose coefficients for individual organs 
is associated with assumptions regarding the exposure geometry.  In a highly directional 
radiation field such as that arising from a collimated source, differences in body size lead 
to substantial uncertainties in the dose to deep organs (Figure 6.1).  The dose coefficients 
indicated in Figures 6.1-6.4 were derived using anatomical models constructed similarly 
to the model for the adult used in FGR 12.  In that model the surface of the body is not 
represented in a realistic manner, and that may result in greater sensitivity to body size 
than the voxel models might indicate.  As noted above, however, Zankl et al (2002) have 
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observed dose differences as large as 100% among voxel models of adults.  Calculations 
have not been reported for a sufficient number of voxel models of children to quantify the 
contribution of these anatomical models to uncertainties in the dose coefficients.  
Differences between the actual exposure geometry and the idealized geometry used in the 
computation of dose coefficients remain a source of potential error in assessment of 
organ dose from external irradiation. 
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Figure 6.4. Age-specific values of the effective dose per unit air kerma for monoenergetic 
photons incident on the body in an isotropic geometry (estimates by Yamaguchi 1994) 
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7. DEMONSTRTION OF LEVELS OF POTENTIAL 
ERROR IN NUCLEAR DECAY DATA USED IN 
COMPUTATION OF DOSE COEFFICIENTS 
 
This section discusses the nuclear decay data used to develop current dose coefficients 
for radionuclides. Although nuclear decay data typically represent a minor source of error 
in dose estimates, examples are given to illustrate that these data can be an important 
source of error for some infrequently studied radionuclides. 
 
7.1. Nuclear decay data tabulations 
 
Dose coefficients for inhaled and ingested radionuclides published by the ICRP since the 
issuance of Part 1 of Publication 30 (ICRP, 1979) are based on the nuclear decay data 
tabulated in ICRP Publication 38 (1983).  External dose coefficients tabulated in FGR12 
(EPA, 1993) for radionuclides distributed in environment media are also based on ICRP 
Publication 38. 
 
The data of ICRP Publication 38 were computed by the ORNL code EDISTR (Dillman, 
1980) which analyzes information on the nuclear structure assembled as part of the 
National Nuclear Data Project.  The EDISTR code was designed to provide a compilation 
of the radiations accompanying the nuclear and atomic processes associated with 
radioactive decay, thus sparing the dosimetrist the tedious task of deriving the energies 
and intensities of the radiations.  The original stimulus for such compilations was the 
need within the field of nuclear medicine to compute doses from diagnostic radionuclides 
and radiopharmaceuticals (Dillman, 1969-1970).  Following the appearance of ICRP 
Publication 38, the current MIRD monograph on nuclear decay data was published 
(Weber et al, 1999).  Electronic files of the nuclear decay data tabulated in ICRP 
Publication 38 have been issued by Eckerman et al. (1994). 
 
The EDISTR code takes basic radioactive decay information as input and calculates 
intensities and energies of alpha, beta, gamma, internal-conversion electron, x-ray, 
Auger-electron, and bremsstrahlung radiations emitted as a result of nuclear decay.  If 
spontaneous fission is indicated, the yields of radiations concomitant with spontaneous 
fission are also computed.  Beta spectral shapes are calculated as needed in beta depth-
dose calculations, e.g., for skin dose.  Although the beta spectra were not given in ICRP 
Publication 38, they were used in the calculations of the skin dose from submersion for 
noble gas radionuclides and were made available in electronic form by Eckerman et al. 
(1994). They were also used in calculations done for FGR12 (EPA, 1993).  Detailed 
documentation of the EDISTR code is provided in a report by Dillman (1980). 
 
The mission of the National Nuclear Data Center (NNDC) includes collection, evaluation 
and dissemination of nuclear physics data for basic nuclear research and application.  
EDISTR uses data from the Evaluated Nuclear Structure Data File (ENSDF) from NNDC 
as input.  
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7.2. Selection of radionuclides 
 
In ICRP Publication 30, the ICRP limited consideration to parent radionuclides with 
physical half-life (T1/2) greater than 10 m.  ICRP Publication 38 includes decay data for 
820 radionuclides, consisting of 764 radionuclides with T1/2 greater than 10 m and 56 
radionuclides with T1/2 less than 10 m that are either decay chain members subsequent to 
one or more of those 764 radionuclides, or of interest in medical applications (e.g., 13N).  
It was also required that the ENSDF for the radionuclide be sufficiently complete to 
enable EDISTR to indicate a reasonable balance in energy.  No substantial effort was 
undertaken to investigate potential errors in the ENSDF input, although obvious missing 
data fields were corrected (for example, for identification of chain members).  These 
criteria limited ICRP Publication 38 to 820 radionuclides. The most recent version of 
NUBASE1 (Audi et al, 2003) identifies 3177 radionuclides.  The number of radionuclides 
with T1/2 > 10 m is 1052, for mass numbers up to 293. 
 
The decay of a radionuclide generally proceeds promptly to the ground state energy level 
of the newly formed daughter nucleus.  However, nuclear transformation may lead to an 
energy level in the daughter nucleus, referred to as an isomeric state, from which a 
transition to the ground state is delayed.  The half-lives of isomeric levels observed 
experimentally can range from 100 ns up to years.  It is necessary to establish criteria as 
to whether the radiations associated with transitions from the isomeric level are to be 
included with those of the parent or listed separately.  In the development of ICRP 
Publication 38, an effort was made to identify isomeric states and list the radiations 
separately if the half-life of the state exceeded 1 m.  The rationale was that isomeric 
states of half-life less than 1 m would be in secular equilibrium with the parent 
radionuclide with half-life of 10 m or more, so that inclusion of the emission with those 
of the parent seemed justified. 
 
There was at least one inadvertent deviation from this scheme in ICRP Publication 38. 
Emissions of 190mOs were included with those of the parent 190mIr (T1/2  = 3.1 h), despite 
the daughter’s half-life of 9.9 min. The emissions of 190mOs were separately tabulated; 
however, it was not identified as a daughter of 190mIr in the publication.  If a user elected 
to include the 190mOs emission with those of 190mIr, then an overestimate of dose would 
occur because energy from the daughter would be counted twice. 
 
ICRP Publication 38 included a number of isomers for which the ground state had not 
been clearly identified at the time of publication. For example, data for two isomers of 
236Np were tabulated, one with a half-life of 22.5 h and the other with a half-life of 
1.15 x 105 y.  The 22.5-h isomer is now identified to be an isomeric state and hence 
designated as 236mNp (Audi et al. 2003), with the longer lived isomer being the ground 
state. Similar situations existed for isomers of 89Nb, 110In, 150Eu, 186Ir, 190m/nIr, 182Re, 
120Sb, 124m/nSb, 128Sb, 178Ta, and 156m/nTb. 
 
                                                 
1 NUBASE is a database which contains values for the basic nuclear properties such as masses, excitation 
energies of isomers, half-lives, spins and parities, decay models and their intensities.   
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7.3. Physical half-life of the radionuclides 
 
The physical half-life of the radionuclide is often an important parameter in the 
calculation of dose.  For most radionuclides the values of T1/2 in ICRP Publication 38 are 
in good agreement with updated values in NUBASE (Audi et al, 2003) (within 25%).  
However, for some long-lived radionuclides, where accurate determination is difficult, 
the differences can be large.  Table 7.1 list radionuclides for which the NUBASE values 
differ substantially from the values of ICRP Publication 38.   
 
 
Table 7.1. Radionuclides for which updated (NUBASE) half-lives 
are substantially different from values in ICRP Publication 38 
(1983) 
 Half-life T1/2 
Nuclide ICRP 38 NUBASE 
Deviationa 
(%) 
In-115 5.1 Py 0.441 Py 1100 
Pb-202 300 ky 52.5 ky 470 
Si-32 450 y 132 y 240 
Tb-157 150 y 71 y 110 
Fe-60 100 ky 1.5 My 93 
Se-79 65 ky 295 ky 78 
Es-250 2.1 h 8.6 h 76 
Ag-108m 127 y 418 y 70 
Sn-126 100 ky 230 ky 57 
Hg-194 260 y 440 y 41 
Ca-41 140 ky 102 ky 37 
At-218 2 s 1.5 s 33 
La-138 135 Gy 102 Gy 32 
Ni-59 75 ky 101 ky 26 
Sn-121m 55 y 43.9 y 25 
a100(absolute value of difference)/ NUBASE 
 
The National Institute of Standards and Technology (NIST) has carried out 
measurements of T1/2 for a set of radionuclides of importance in industrial applications.  
Table 7.2 compares the values observed at NIST with the values in ICRP Publication 38.  
For most of these radionuclides the values are in reasonable agreement, with 
discrepancies less that 1%.  However, discrepancies beyond reported statistical error are 
seen for several nuclides as listed in the table, the largest being for 207Bi. 
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Table 7.2. Comparison of half-lives given in ICRP Publication 38 
with more recent measurements by NIST 
 Half-life T1/2 
Nuclide ICRP 38 NIST 
Deviationa 
(%) 
H-3 4511 d 4500 ± 8 d <1 
F-18 1.8295 h 1.82951 ± 0.00034 h <1 
Na-22 950.4 d 950.97 ± 0.15 d <1 
Na-24 15 h 14.9512 ± 0.0032 h <1 
P-32 14.29 d 14.263 ± 0.003 d <1 
Sc-46 83.83 d 83.831 ± 0.066 d <1 
Cr-51 27.704 d 27.7010 ± 0.0012 d <1 
Mn-54 312.5 d 312.028 ± 0.034 d <1 
Co-57 270.9 d 272.11 ± 0.26 d <1 
Fe-59 44.529 d 44.5074 ± 0.0072 d <1 
Co-60 1925 d 1925.20 ± 0.25 d <1 
Cu-62 9.74 m 9.6725 ± 0.0080 m <1 
Zn-65 243.9 244.164 ± 0.099 d <1 
Ga-67 3.261 d 3.26154 ± 0.00054 d <1 
Se-75 119.8 d 119.809 ± 0.066 d <1 
Kr-85 3915 d 3935.7 ± 1.2 d <1 
Sr-85 64.84 d 64.8530 ± 0.0081 d <1 
Y-88 106.64 d 106.626 ± 0.044 d <1 
Mo-99 66.0 h 65.9239 ± 0.0058 h <1 
Tc-99m 6.02 h 6.0123 ± 0.0032 h <1 
Ru-103 39.28 d 39.310 ± 0.044 d <1 
Cd-109 464 d 463.26 ± 0.63 d <1 
Ag-110m 249.9 d 249.950 ± 0.024 d <1 
In-111 2.83 d 2.80477 ± 0.00053 d <1 
Sn-113 115.1 d 115.079 ± 0.080 d <1 
Sn-117m 13.61 d 14.00 ± 0.05 d 2.8 
I-123 13.2 h 13.2235 ± 0.0019 h <1 
Sb-125 1010 d 1007.56 ± 0.10 d <1 
I-125 60.14 d 59.49 ± 0.13 d 1.1 
Xe-127 36.41 d 36.3446 ± 0.0028 d <1 
I-131 8.04 d 8.0197 ± 0.0022 d <1 
Xe-131m 11.9 d 11.934 ± 0.021 d <1 
Ba-133 3923 d 3854.7 ± 2.8 d 1.8 
Xe-133 5.245 d 5.24747 ± 0.00045 d <1 
Cs-134 753.1 d 753.88 ± 0.15 d <1 
Cs-137 10960 d 11018.3 ± 0.5 d <1 
Ce-139 137.66 d 137.734 ± 0.091 d <1 
Ba-140 12.74 d 12.7527 ± 0.0023 d <1 
La-140 40.272 h 40.293 ± 0.012 h <1 
Ce-141 32.501 d 32.510 ± 0.024 d <1 
Ce-144 284.3 d 284.534 ± 0.032 d <1 
Eu-152 4869 d 4947.2 ± 1.1 d 1.6 
Gd-153 242 d 239.472 ± 0.069 d 1.1 
Sm-153 46.7 h 46.2853 ± 0.0014 h <1 
Eu-154 3210 d 3145.2 ± 1.1 d 2.1 
Eu-155 1810 d 1739.06 ± 0.45 d 4.1 
Ho-166 26.80 h 26.794 ± 0.023 h <1 
Yb-169 32.01 d 32.0147 ± 0.0093 d <1 
Lu-177 6.71 d 6.64 ± 0.01 d <1 
W-181 121.2 d 121.095 ± 0.064 d <1 
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Table 7.2 (cont’d) 
Re-186 90.64 h 89.248 ± 0.069 h 1.6 
Re-188 16.98 h 17.001 ± 0.022 h <1 
Ir-192 74.02 d 73.810 ± 0.019 d <1 
Au-195 183 d 186.098 ± 0.047 d 1.7 
Au-198 2.696 d 2.69517 ± 0.00021 d <1 
Tl-201 3.044 d 3.0456 ± 0.0015 d <1 
Tl-202 12.23 d 12.466 ± 0.081 d <1 
Hg-203 46.60 d 46.619 ± 0.027 d <1 
Pb-203 52.05 h 51.923 ± 0.037 h <1 
Bi-207 13880 d 11523 ± 15 d 20 
Th-228 698.7 d 698.60 ± 0.36 d <1 
a100(absolute value of difference)/ NIST 
 
 
7.4. Total energy of emitted radiations 
 
Uncertainty in the total energy emitted by the various types of radiations accompanying 
radioactive decay translates directly to uncertainty in the computed tissue dose.  Revised 
information on the decay process (i.e., a change in the decay scheme) can have a 
substantial effect on the partitioning of the available energy.  For example, 80Sr decays by 
electron capture.  In ICRP Publication 38, 100% of the transitions were depicted as 
leading to the ground state of 80Rb (Figure 7.1, left).  Recent information (Endo et al., 
2005) indicates that transitions occur to four excited states in 80Rb as well as the ground 
state and that decay by positron emission is energetically possible (Figure 7.1, right).  
The identified gamma emissions from the excited states and associated radiations 
substantially increase the estimate of total energy emissions (Table 7.3).  
 
Other examples of potentially important updates in nuclear decay data are changes in the 
branching fraction for alpha decay in 202Pb, and the revision of the electron capture to 
positron ratio for 135Ce.  The main consideration regarding the total energy emission is 
the quality of the decay scheme information. 
 
 
Table 7.3. Energy of radiations emitted by Sr-80 
 Emitted Energy (MeV nt-1)a 
Radiation ICRP 38 JAERI – 1347 
γ-rays - 0.3278 
x-rays 0.0080 0.0073 
γ± - 0.1020 
β+ - 0.0357 
IC electrons - 0.0013 
Auger 0.0055 0.0049 
Total 0.0135 0.4789 
ant = nuclear transformation 
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ICRP Publication 38 
decay scheme for 80Sr  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Updated decay scheme for 80Sr (Endo et al., 2005) 
 
 
 
Figure 7.1.  Decay scheme for 80Sr given in ICRP Publication 38 (1983) compared with 
JAERI 1347 (Endo et al., 2005) 
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7.5. Radiations from spontaneous fission 
 
Spontaneous fission is a decay mode of some heavy nuclei where the nucleus breaks into 
two intermediate-mass fragments and several neutrons.  It has been observed only for 
nuclei with atomic numbers greater than 230.  The large amount of energy involved in 
this process is distributed among fission fragments and prompt neutrons and gamma 
emissions.  In addition, delayed beta and gamma emissions occur from the newly formed 
fission fragments.  EDISTR adopted the methods of Dillman and Jones (1975) for 
calculating the energies and intensities of spontaneous fission emissions. 
 
The energy of the fission fragments is an important issue for internally deposited 
radionuclides, because ~80% of the available energy is associated with the fragments.  It 
has been shown that total kinetic energy of the fragments as described by a simple 
Coulomb repulsion model agrees within about 5% with the experimental data. 
 
In EDISTR the Maxwellian distribution was used to calculate the average energy of 
prompt neutrons.  The widely used radiation transport code MCNP represents the neutron 
spectrum shape by the Watt spectrum as do some other Monte Carlo transport codes.  The 
total energy of the prompt neutron spectrum is proportional to the number of prompt 
neutrons emitted per fission. These data have been updated to some extent since the 
preparation of ICRP Publication 38, but changes are generally minor. For example, 
Dillman and Jones (1975) suggested values of 2.07, 2.24, 3.14 and 3.73 for 238U, 242Pu, 
248Cm, and 252Cf, compared with recent estimates of 2.01, 2.15, 3.11 and 3.765 
respectively (Wilson et al, 2002). 
 
Shortly after fissioning and the prompt emission of neutrons, the remaining energy of the 
fission fragments is released as prompt gamma rays. EDISTR assigned a gamma-ray 
energy value of 7.64 MeV per fission for all spontaneous fission nuclides.  A set of 
equations developed by Valentine (2001) yield estimates that are somewhat different 
from the EDISTR value but are in close agreement with updated experimental data.  
These equations indicate a total energy of prompt gamma ray emissions per fission of 
6.61, 6.54, 6.78 and 6.94 for 233U, 235U, 239Pu, and 252Cf, respectively, compared with the 
value of 7.64 assumed in EDISTR. 
 
After the fission fragments reach ground state or isomeric states, further energy is emitted 
by beta decay with accompanying gamma emissions.  Exact treatment of these emissions 
would require consideration of the yield of fission fragments and tracking the change in 
the composition of these products over time.  For an internal source, this would also 
entail consideration of the biokinetics of each individual member. For example, 
spontaneous fission of 252Cf yields over 700 radionuclides of about 50 elements.  Dillman 
and Jones (1975) developed equations for predicting the energy of delayed beta and 
gamma emissions based on the number of beta decays to reach a stable nuclide.  The 
empirical equations are based on experimental data on spontaneous fission of 236U.  The 
predictions of these equations are reasonably consistent with experimental data. 
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7.6. Conclusions 
 
For most common radionuclides the nuclear decay processes are sufficiently well 
understood that uncertainties in the energies and intensities of the emission 
accompanying nuclear decay are minor.  Considerable uncertainty often exists in the 
physical half-life of long-lived radionuclides, which can be important in issues regarding 
expected environmental behavior as in the case of 79Se.  Uncertainty in the electron 
capture to positron ratio can result in substantial uncertainty in the total energy emission 
for this decay mode.  Increased use of accelerators in production of isotopes for medical 
use and for neutron studies (e.g., spallation neutron sources) can result in production of 
radionuclides for which experimental data are weak or missing.   
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8. RECOMMENDATIONS FOR A COMPREHENSIVE STUDY 
 
This section describes a general approach for assessing and reducing potential errors in 
dose estimates for radionuclides.  The approach consists of a series of steps to be 
followed for each exposure case, where an exposure case is defined as a given 
combination of radionuclide, exposure mode, and (when pertinent) specified form of the 
radionuclide and level of knowledge of that form. A list of 50 radionuclides is proposed 
for consideration, based on their importance as indicated by past experience or the 
potential for elevated exposures in the future. Estimates of the time, funds, and other 
resources required to carry out a detailed assessment for this set of radionuclides are 
provided. 
 
8.1. Definitions and practical bounds for a comprehensive study 
 
8.1.1. Definitions of uncertainty and variability 
 
Publications addressing uncertainties in biokinetic and dosimetric quantities for 
radionuclides generally do not clearly define what is meant by “uncertainty”.  In many 
cases, it appears from the discussions and analytical methods that the reference may be to 
an unknown individual.  In the present pilot study and for purposes of the proposed 
comprehensive study, uncertainty refers to knowledge concerning a central value 
(usually, an arithmetic or geometric mean) for the population of interest.  The uncertainty 
in the central value of a quantity in the population should not be confused with the 
“variability” of that feature in the population.  Variability refers to quantitative 
differences between different members of a population under similar conditions (inter-
individual variability) or within an individual under different conditions (intra-individual 
variability). 
 
8.1.2. Potential error compared with uncertainty and variability 
 
The discussions and analyses in this report have emphasized the importance of evaluating 
the potential error associated with a dose estimator rather than simply focusing on 
uncertainty and variability, which are contributing factors to the potential error but often 
are not the only contributing factors.  The potential error in an application of a dose 
coefficient stems in part from limitations in the information needed to construct the 
biokinetic and dosimetric models used to develop the coefficient, but the additional 
problem arises in many cases that the models do not fully or accurately reflect available 
information.  The latter problem may reflect expansion of the database after the 
construction of the models but can also arise from poor modeling practices such as 
selective or uncritical use of data or inadequate review of the database.  One of the early 
steps in assessing the uncertainties in dose estimates should be to attempt to differentiate 
between fixable errors in the underlying models, stemming from incomplete or improper 
use of the database, and actual uncertainties in model estimates arising from inadequate 
data.  Where feasible, models should be modified or replaced to adequately reflect the 
full, critically reviewed database before an uncertainty assessment is initiated.   
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8.1.3. The need to avoid new dosimetric frontiers 
 
For the comprehensive study to be completed in a reasonable length of time at a 
reasonable cost, attention should be limited to the following topics:   
o potential errors in equivalent dose to tissues per unit intake or per unit external 
exposure to radionuclides; 
o the sensitivity of the effective dose to potential errors in equivalent doses to 
tissues. 
It is not feasible to address issues such as the appropriateness of the ICRP’s definition of 
tissue dose or effective dose as measures of radiogenic risk.   
 
8.1.4. Exposure modes to be addressed 
 
For a given radionuclide, the analysis should focus on potential errors for: 
o ingestion of a unit activity of the radionuclide; where necessary, different 
characterizations should be given for different forms of the radionuclide or 
different levels of knowledge of the form, e.g., 137Cs known to be in highly 
absorbable form, and 137Cs ingested in an unknown form 
o inhalation of a unit activity of different general forms (e.g., known to be highly 
soluble, known to be moderately soluble, or form unknown) 
o any other mode of uptake to blood that has been shown to be important for the 
radionuclide of interest, e.g.,  absorption of 3H or 131I through the skin or intake of 
239Pu or 241Am through wounds 
o external exposure to the radionuclide on the ground surface, based on the 
idealized exposure geometry (infinite extent) considered in FGR12 
o external exposure due to submersion in air, based on the idealized exposure 
geometry (infinite extent) considered in FGR12 
 
8.1.5. Radionuclides to be addressed 
 
ICRP documents provide dose coefficients for ingestion or inhalation of over 800 
radionuclides.  For the case of inhalation, different dose coefficients are provided for 
different absorption types and sometimes for different particle sizes.  Federal Guidance 
Report No. 12 tabulates thousands of dose coefficients covering a number of different 
external exposure scenarios. 
  
It is not feasible to provide careful uncertainty assessments for all of these thousands of 
cases.  The full uncertainty study should focus on radionuclides for which elevated 
exposures to human beings seem most likely on the basis of past experience and 
consideration of potential uses of radionuclides in the near future.  For example, the full 
study should address radionuclides frequently encountered in occupational settings, 
released in potentially significant quantities due to reactor operations or accidents (Table 
8.1), or mentioned frequently in the NRC’s database of reportable events, or 
radionuclides that may be dispersed due to terrorist events involving radiological 
dispersal devices or nuclear explosions. 
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Table 8.1. Primary radionuclides and exposure modes associated with the 
Chernobyl accident (Balonov, 1993) 
Internal exposurea,b External exposurea Exposed 
persons 
Time after 
accident (d) Inhalation  Ingestion Gamma Beta 
 
1-10 
 
131I, 133I , 
132Te, TUE 
 
–  
 
132Te, 131I, 
noble gases 
 
106Ru, 144Ce, 
132Te  
 
11-100 
 
TUE, 144Ce  
–  
95Zr, 106Ru, 
134Cs, 137Cs  
 
106Ru, 144Ce 
 
Plant staff, 
emergency 
workers, 
mitigators 
 
>100 
 
TUE, 144Ce  
 
– 
 
106Ru, 134Cs, 
137Cs 
 
106Ru, 144Ce, 
90Sr  
 
Evacuated 
population 
 
1-11 
 
131I, 133I , 
132Te, TUE 
 
131I , 132Te, 
137Cs, 134Cs  
 
132Te, 131I , 
noble gases 
 
106Ru, 144Ce, 
132Te  
 
<100 
 
131I, TUE 
 
131I, 137Cs, 
134Cs, 89Sr  
 
132Te, 131I, 134Cs 
137Cs 
 
106Ru, 132Te  
 
Rest of  
population 
 
>100 
 
TUE, 106Ru, 
144Ce  
 
137Cs, 134Cs, 
90Sr  
 
134Cs, 137Cs, 
106Ru  
– 
aShort-lived daughters not listed; e.g., 137Cs as a source of gamma radiation refers to its 
short-lived daughter 137mBa. 
bTUE = transuranic elements (mainly isotopes of plutonium, americium, curium) 
 
Based on these considerations, we have developed a list of 50 radionuclides to be 
addressed in a comprehensive study.  These have been divided into Group I, Group II, 
and Group III, to be addressed in the same order.  It is expected that the full list will be 
modified somewhat and the suggested order of treatment of radionuclides may be 
changed to address specific needs of funding agencies. 
 
Group I: 32P, 60Co, 63Ni, 85Sr, 89Sr, 90Sr, 134Cs, 137Cs, 125I, 131I, 192Ir, 238U, 238Pu, 241Am, 
252Cf 
 
Group II:  3H, 14C, 35S, 91Y, 99mTc, 103Pd, 103Ru, 106Ru, 109Cd, 147Pm, 210Po, 226Ra, 227Ac, 
239Pu, 240Pu, 241Pu, 242Pu 
 
Group III:  55Fe, 59Fe, 86Rb, 95Zr, 95Nb, 99Mo, 110mAg, 125Sb, 132Te, 140Ba, 140La, 141Ce, 
144Ce, 197Hg, 203Hg, 207Bi, 237Np, 239Np, 242Cm  
  
Group I includes several radionuclides that appear frequently in the NRC’s history of 
reportable events (137Cs > 241Am > 192Ir > 131I > 238U > 63Ni > 60Co > 125I > 90Sr > 32P), 
some other important isotopes of the same elements (e.g., 85Sr, 89Sr, 134Cs), and some 
radionuclides of concern with regard to potential use in radiological dispersal devices 
(238Pu and 252Cf, in addition to some radionuclides already included due to the frequency 
of occurrence in the NRC database – 60Co, 90Sr, 137Cs, 192Ir, and 241Am).  In this list, 238U 
represents natural uranium isotopes; the biokinetics, dosimetry, uncertainty, and 
variability are expected to be virtually the same for 238U as for 234U or 235U.  Five of the 
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radionuclides in Group I represent about 75% of the leaking source events (63Ni > 137Cs > 
241Am > 125I > 90Sr), and seven represent about 85% of the reported medical events (131I > 
192Ir > 137Cs = 60Co > 90Sr > 125I > 32P) listed in the NRC database.  Seven of the 
radionuclides, 60Co, 90Sr, 137Cs, 192Ir, 241Am, 252Cf, and 238Pu, are the radionuclides of 
greatest concern as components of dirty bombs according to some assessments because of 
their portability, dispersibility, and widespread use in commercial sources, as well as 
their potential hazards as internal or external emitters. 
 
Group II includes several other radionuclides that appear frequently in the NRC database 
of reportable events: 3H > 99mTc > 210Po > 35S > 109Cd > 14C > 147Pm > 226Ra > 103Pd.   
Other radionuclides are included in Group II because they are potentially important 
sources of dose following reactor accidents and are sometimes mentioned in the literature 
with regard to occupational exposure or exposure to fallout (e.g., 106Ru).  Actinium-227 is 
included mainly because fixable errors in its published dose coefficients have important 
implications with regard to transport regulations for radioactive material containing 
unknown radionuclides. 
  
Group III includes several other radionuclides that appear a number of times in the NRC 
database of reportable events.  This group also includes a few remaining radionuclides 
such as 95Zr, 95Nb, 132Te, and 144Ce, that have been addressed frequently in the literature, 
mainly because of their potential importance in occupational settings, releases following 
reactor accidents, or fallout. 
 
8.2. Proposed methods of assessment of potential error, uncertainty, and variability 
 
8.2.1.  Inhalation or ingestion of radionuclides 
 
Step 1:  Specify the case (radionuclide, intake mode, and form of the radionuclide or 
level of knowledge concerning the form)  
 
As discussed in Section 2, a number of papers and reports address “the uncertainty in a 
dose coefficient” for an internal emitter, but this is not a well defined concept. The level 
of confidence that can be placed in a dose coefficient for ingestion or inhalation may vary 
considerably from one application to another, depending on the form of the radionuclide 
and the level of knowledge concerning that form.  While one could assign either a 
minimal uncertainty or a worst-case uncertainty to an ingestion or inhalation dose 
coefficient, either approach could be misleading in many applications. 
 
A workable solution is to develop different uncertainty statements for different forms of 
radionuclides or different levels of knowledge of the form.  For example, an uncertainty 
statement could be provided for an ingestion dose coefficient for 137Cs under the 
assumption that the radionuclide is incorporated in food or ingested in soluble inorganic 
form, and an alternate uncertainty statement could be derived for arbitrary use of the dose 
coefficient, i.e., in the absence of knowledge of the form of 137Cs ingested. 
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The number of different cases to be considered for inhalation or ingestion of a 
radionuclide will vary from one radionuclide to another.  For inhalation of some 
radionuclides, it may be necessary to address several different forms or levels of 
knowledge concerning the form. 
 
Step 2:  Critically review the biokinetic and dosimetric database for the 
radionuclide and its physiological analogues. 
 
Usually, this is most efficiently done by element rather than by radionuclide.  For some 
radionuclides it may be necessary to address specific compounds; e.g., for 14C, it is useful 
to address CO2 separately from most other carbon compounds. 
 
Step 3: Evaluate current dose models for a radionuclide against the critically 
reviewed data. 
 
If current models are supported by the critically reviewed data, go to Step 4.  If 
inconsistencies between the models and database are judged to contribute substantially to 
potential errors in dose estimates, modify or replace the models insofar as feasible within 
the time constraints of the project.   
 
Several examples were given in Sections 3 and 5 in which comparison of critically 
reviewed data with current ICRP models revealed major problems in the models. For 
example, in Section 3.3.7 it is pointed out that a review of the database for inhaled 
mercury vapor revealed that the ICRP’s recommended half-time for mercury vapor 
deposited in the lungs (1.7 d) was based on misinterpretation of the original data, and 
revised parameter values were derived. Reassessment of the data indicates that the 
ICRP’s current model for inhaled mercury vapor may overestimate lung dose by an order 
of magnitude for inhalation of most mercury isotopes.  Of course, some uncertainty 
remains in the revised model for mercury vapor, but the potential error in applying the 
model has been reduced.  
 
Step 4:  Assess the sensitivity of dose estimates to uncertainties in model structures, 
parameter values, and assumptions of the underlying models 
 
The “underlying models” refer to current ICRP models if no improvements were 
indicated in Step 3 and to the modified models if improvements were made. 
 
The method commonly used to examine sensitivity of dose estimates to uncertainties in 
underlying data is parameter uncertainty analysis. This method was discussed in Sections 
3 and 5 in connection with various case studies.  The method can be instructive, but it is 
not well suited to most biokinetic models used in radiation protection.  These models 
generally are not process models, or not entirely process models, and many or all of their 
parameter values may not be observable quantities.  Moreover, an analysis of the 
sensitivity of dose estimates to gaps in knowledge must take into account that the model 
structure may be incomplete, incorrect, or misleading, and that model assumptions (e.g., 
regarding the biokinetics of radioactive progeny produced in vivo) that are not generally 
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treated in parameter uncertainty analyses may be important sources of uncertainty in dose 
estimates.  
 
An approach to analyzing sensitivity of dose to gaps in information that has stronger 
logical support is comparison of predictions of different but equally plausible models.  
This approach was illustrated in Sections 3-5. 
 
The approach of comparing equally plausible models was used by the authors and 
coworkers at EPA to assess uncertainty in each of the thousands of risk coefficients given 
in FGR13 (the full uncertainty analysis is not yet published).  For each radionuclide and 
exposure mode, up to 54 different models were compared. A difficulty with that analysis 
was that the number of cases to be considered was so large that it was difficult to ensure 
that the different models were indeed equally plausible and that the investigators had not 
overlooked modeling approaches that would produce a wider range of plausible dose or 
risk estimates.  It is for such reasons that we recommend that attention be restricted to 
about 50 radionuclides and a small number of exposure modes (see Section 8.2.5) in the 
full project proposed here. 
 
The specific quantities for which uncertainties are to be quantified should include 
estimates of the 50-y committed dose equivalent.  Also, it would be useful to quantify 
uncertainties in urinary excretion rates, because urinary data are commonly used in dose 
reconstructions. 
 
Finally, it may be prudent to avoid very specific quantitative statements of uncertainty 
and instead summarize uncertainty results in terms of relatively broad uncertainty 
categories.  These categories could represent a range of knowledge, e.g., well known, 
moderately well known, poorly known, and very poorly known. Such an approach was 
used in FGR13 (see Table 2.4 of that report).  Of course, documentation of the analysis 
should include quantitative results on which the assignment of exposure cases to 
uncertainty categories is based.  Such quantitative results are illustrated in Table 8.2 for 
ingestion or inhalation of 137Cs, either in soluble form or in an unknown form. 
 
Step 5.  Characterize variability 
 
Variability of dose from intake of a radionuclide should be characterized only insofar as 
relevant observations are available for the radionuclide of interest or for its established 
physiological analogues or governing physiological processes. For example, sufficient 
measurements on human subjects are available to characterize variation of biokinetics 
and dose from ingestion of soluble 137Cs or 90Sr with age, gender, and certain states of 
health.  Although direct observations on the variability in the biokinetics of 3H taken in as 
tritiated water are sparse, the behavior of 3H is known to be tied closely to water 
replacement in the body, and variability with age, gender, and certain states of health in 
water replacement is reasonably well understood. On the other hand, no particularly 
useful information is available on differences with age or gender in the biokinetics of 
inhaled 106Ru, and there are no known close physiological analogues of ruthenium.  
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Therefore, variability in the biokinetics or dose per unit intake of 106Ru might be 
characterized simply as “unknown”.  
 
 
 
Table 8.2. Central estimates and plausible ranges of 50-y-committed doses per unit 
intake of 137Cs (adult male) 
 
 
Intake 
mode 
 
 
 
Form 
 
 
 
Tissue 
 
Best 
estimate 
(Sv Bq-1) 
 
Lower 
bound 
(Sv Bq-1) 
 
Upper 
bound 
(Sv Bq-1) 
Ratio of 
upper to 
lower 
bound 
Ingestion 
 
 
 
 
Ingestion 
 
 
 
 
Inhalation 
 
 
 
 
Inhalation 
Soluble 
inorganic or 
incorporated 
in food  
 
Unknown form 
 
 
 
 
Soluble 
 
 
 
 
Unknown form 
Lung 
Colon 
Red Marrow 
Effective dose 
 
Lung 
Colon 
Red Marrow 
Effective dose 
 
Lung 
Colon 
Red Marrow 
Effective dose 
 
Lung 
Colon 
Red Marrow 
Effective dose 
8.0E-9 
1.8E-8 
1.5E-8 
1.1E-8 
 
8.0E-9 
1.8E-8 
1.5E-8 
1.1E-8 
 
2.7E-9 
6.2E-9 
5.2E-9 
3.9E-9 
 
2.7E-9 
6.2E-9 
5.2E-9 
3.9E-9 
6.0E-9 
9.0E-9 
8.0E-9 
8.0E-9 
 
0.6E-9 
9.0E-9 
0.8E-9 
1.5E-9 
 
2.0E-9 
2.0E-9 
2.0E-9 
2.0E-9 
 
2.0E-9 
2.0E-9 
2.0E-9 
2.0E-9 
1.8E-8 
2.7E-8 
2.4E-8 
2.4E-8 
 
1.8E-8 
3.6E-8 
2.4E-8 
2.4E-8 
 
1.4E-8 
7.0E-9 
7.0E-9 
7.0E-9 
 
4.0E-7 
8.0E-9 
1.2E-8 
5.0E-8 
3.0 
3.0 
3.0 
3.0 
 
30 
4.0 
30 
16 
 
7.0 
3.5 
3.5 
3.5 
 
200 
4.0 
6.0 
25 
 
 
As illustrated in Table 8.3, statistical analysis of reported biokinetic data for some 
frequently studied radionuclides will allow estimates of variation of certain biokinetic or 
dosimetric properties between subjects of the same age and gender.  Such information 
should be documented as part of this project as an indication of the status of knowledge 
of dose per unit intake for individuals or subgroups of the population.  
 
8.2.2.  External dose    
 
Characterization of the uncertainty in an external dose coefficient for a radionuclide, 
assuming an idealized exposure geometry as defined in FGR12, is essentially a 
propagation of errors associated with three sources of uncertainty:  the nuclear decay data 
for the radionuclide; the radiation field incident upon the body for the specified exposure 
geometry; and the dose rate to specific tissues due to a body surface source, taking body 
size into account.   
 
The uncertainties in nuclear decay data are negligible for most radionuclides; some 
exceptions are discussed in Section 7.  The error in the estimated radiation field incident 
upon the body depends on the energy of the radiations, and error levels have been 
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determined by comparison of FGR12 estimates with actual measurements and with other 
theoretical models.  Errors in estimated dose rates to tissues due to a body surface source 
arise in large part from the simplified representation of the human body as a 
mathematical phantom and generally increase with decreasing energy.  Comparisons with 
voxel phantoms provide an indication of energy-specific levels of error associated with 
these dose rates. 
 
 
Table 8.3. Variability of biokinetics of Sr in healthy young adult males, age ~22 ya 
 
Quantity 
 No. of  
subjects 
Geometric 
mean 
(%) 
Geometric 
S.D. 
 Observed 
maximum 
(%) 
Estimated 
98th 
percentile 
  Retention at 5 d (injection) 
  Retention, at 50 d (injection) 
  Retention at 200 d(injection) 
  Retention at 6 d (ingestion) 
  Retention at 20 d (ingestion) 
  Retention at 50 d (ingestion) 
  Urinary Sr on day 4 (injection) 
  Urinary Sr on day 4 (ingestion) 
  Fecal Sr on day 4 (injection) 
6 
7 
5 
8 
9 
8 
5 
9 
4 
65% 
25% 
4.3% 
14% 
9.3% 
5.0% 
1.7% 
0.41% 
0.52% 
1.1 
1.4 
1.4 
1.6 
1.7 
1.6 
1.2 
1.6 
1.4 
77% 
38% 
5.7% 
28% 
22% 
10% 
2.3% 
0.57% 
0.68% 
83% 
48% 
8.3% 
39% 
28% 
13% 
2.5% 
1.2% 
1.1% 
aBased on data of Likhtarev et al., 1975 
  
 
8.3. Estimates of resources required for a comprehensive project 
 
It is expected that the project as described in this section could be completed in three 
years at a level of effort of 1.4 man-years per year. Group I, Group II, and Group III 
radionuclides would be addressed during the first, second, and third years of the project, 
respectively.  Approximately $18K would be needed for library costs (ordering papers 
and reports) and equipment. The equipment would include two relatively high-speed 
desktop computers and software such as the latest version of Crystal Ball, to be used 
mainly for quality assurance of the software developed by the investigators. 
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